Processing 00000000.tx.1: The Peroxisome Proliferator-Activated Receptor-2 Pro12Ala Polymorphism Michael Stumvoll, and Hans Hring From the University Hospital, Department of Endocrinology, Metabolism and Pathobiochemistry, Eberhard-Karls-Universitt, Tbingen, Germany  ABSTRACT TOP ABSTRACT INTRODUCTION ASSOCIATION WITH TYPE 2... 

Phrase: "The Peroxisome Proliferator-Activated Receptor-2 Pro12Ala Polymorphism Michael Stumvoll,"

Phrase: "and"

Phrase: "Hans Hring From the University Hospital,"

Phrase: "Department of Endocrinology,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   858   C0587463:Endocrinology department [Health Care Related Organization]
   790   C1704729:Department [Organization]

Phrase: "Metabolism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0025519:Metabolism [Organism Function]
  1000   C0025520:metabolism [Functional Concept]

Phrase: "and"

Phrase: "Pathobiochemistry,"

Phrase: "Eberhard-Karls-Universitt,"

Phrase: "Tbingen,"

Phrase: "Germany  ABSTRACT TOP ABSTRACT INTRODUCTION ASSOCIATION WITH TYPE 2..."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   762   C3645563:Association type [Intellectual Product]
   742   C0004083:Association [Mental Process]
   742   C0439849:Association [Qualitative Concept]
   742   C0596306:Association [Phenomenon or Process]
   742   C0699792:association [Social Behavior]
Processing 00000000.tx.2: EFFECT ON INSULIN SENSITIVITY EFFECT ON INSULIN SECRETION EFFECT ON OBESITY CELLULAR MECHANISM SUMMARY AND CONCLUSIONS REFERENCES  Peroxisome proliferator-activated receptor (PPAR)- is a transcription factor with a key role in adipocyte differentiation. 

Phrase: "EFFECT ON INSULIN SENSITIVITY EFFECT"

Phrase: "ON INSULIN SECRETION EFFECT"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C1280500:Effect [Qualitative Concept]
   827   C2348382:Effect [Qualitative Concept]
   734   C1256369:insulin secretion [Cell Function]

Phrase: "ON OBESITY CELLULAR MECHANISM SUMMARY"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C1552616:summary [Intellectual Product]
   812   C1706244:Summary [Intellectual Product]

Phrase: "AND"

Phrase: "CONCLUSIONS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707478:Conclusions [Idea or Concept]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Peroxisome proliferator-activated receptor (PPAR)-"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
  1000   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   861   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C0752063:Peroxysome [Cell Component]
   812   C1879547:Activated [Activity]
   812   C2984308:Peroxisome [Functional Concept]
   779 E C1515877:Activate [Functional Concept]
   741 E C3546463:peroxisomal [Cell Component]

Phrase: "is"

Phrase: "a transcription factor with a key role"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   778   C0040648:TRANSCRIPTION FACTOR [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   774   C0050325:A-factor [Biologically Active Substance,Organic Chemical]
   774   C0960756:factor A [Organic Chemical]
   748   C0040649:Transcription [Genetic Function]
   748   C1521761:Factor [Functional Concept]
   748   C2827422:Factor [Conceptual Entity]

Phrase: "in adipocyte differentiation."
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C1159884:adipocyte differentiation [Cell Function]
   861   C0007589:Differentiation [Cell Function]
   861   C1511938:Differentiation [Clinical Attribute]
   861   C2945687:Differentiation [Functional Concept]
   789 E C0205615:Differentiated [Qualitative Concept]
Processing 00000000.tx.3: The Ala allele of the common Pro12Ala polymorphism in the isoform PPAR-2 is associated with reduced risk for type 2 diabetes. 

Phrase: "The Ala allele of the common Pro12Ala polymorphism"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0002085:Allele [Gene or Genome]

Phrase: "in the isoform PPAR-2"
Meta Candidates (Total=10; Excluded=2; Pruned=0; Remaining=8)
   901   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   901   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   827   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   799   C0597298:Isoform [Amino Acid, Peptide, or Protein]
   799   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   799   C0752063:Peroxysome [Cell Component]
   799   C1879547:Activated [Activity]
   799   C2984308:Peroxisome [Functional Concept]
   766 E C1515877:Activate [Functional Concept]
   727 E C3546463:peroxisomal [Cell Component]

Phrase: "is"

Phrase: "associated with reduced risk"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   833   C0332281:Associated with [Qualitative Concept]
           Associated
   770   C0035647:Risk [Qualitative Concept]
   770   C0392756:Reduced [Qualitative Concept]
   737 E C0750490:Associate [Idea or Concept]
   737 E C1706221:Associate [Professional or Occupational Group]

Phrase: "for type 2 diabetes."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0011860:Type 2 Diabetes [Disease or Syndrome]
   913   C1320657:type diabetes [Finding]
   901   C0441730:Type 2 [Classification]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]
Processing 00000000.tx.4: The effect on the individual is weak, but because of a prevalence of >75% of the high-risk Pro allele, the population-attributable risk is enormous. 

Phrase: "The effect on the individual"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1280500:Effect [Qualitative Concept]
   760   C2348382:Effect [Qualitative Concept]

Phrase: "is"

Phrase: "weak,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0004093:Weak [Sign or Symptom]
  1000   C1762617:Weak [Qualitative Concept]

Phrase: "but because of a prevalence of >75%"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0033105:Prevalence [Quantitative Concept]
   748   C0220900:prevalence [Quantitative Concept]
   748   C0233535:but [Mental or Behavioral Dysfunction]

Phrase: "of the high-risk Pro allele,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0002085:Allele [Gene or Genome]

Phrase: "the population-attributable risk"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
  1000   C1514229:Population Attributable Risk [Quantitative Concept]
   913   C0242444:population risk [Population Group]
   913   C2987720:Population risk [Quantitative Concept]
   901   C0814766:Attributable Risk [Qualitative Concept]
   827   C0032659:Population [Quantitative Concept]
   827   C0035647:Risk [Qualitative Concept]
   827   C0596130:Attributable [Mental Process]
   827   C1257890:Population [Population Group]

Phrase: "is"

Phrase: "enormous."
Processing 00000000.tx.5: The in vivo effects of the polymorphism are secondary to alterations in adipose tissue, where PPAR-2 is predominantly expressed. 

Phrase: "The in vivo effects of the polymorphism"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   748   C1280500:effects [Qualitative Concept]
   714 E C2348382:Effect [Qualitative Concept]

Phrase: "are"

Phrase: "secondary to alterations"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   882   C0175668:Secondary to [Temporal Concept]
           Secondary
   790   C0027627:secondary [Neoplastic Process]
   790   C0205436:Secondary [Quantitative Concept]

Phrase: "in adipose tissue,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0001527:Adipose tissue [Tissue]
   861   C0040300:Tissue [Tissue]
   861   C1547928:Tissue [Intellectual Product]
   789   C0028754:Adiposity [Disease or Syndrome]
   789   C1563743:adiposity [Organism Attribute]

Phrase: "where PPAR-2"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   901   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   901   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   827   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   799   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   799   C0752063:Peroxysome [Cell Component]
   799   C1879547:Activated [Activity]
   799   C2984308:Peroxisome [Functional Concept]
   766 E C1515877:Activate [Functional Concept]
   727 E C3546463:peroxisomal [Cell Component]

Phrase: "is"

Phrase: "predominantly"

Phrase: "expressed."
Processing 00000000.tx.6: Moderate reduction in transcriptional activity of PPAR- as a result of the polymorphism modulates production and release of adipose-derived factors. 

Phrase: "Moderate reduction in transcriptional activity of PPAR-"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   757   C2267000:Reduction Activity [Molecular Function]
   739   C0301630:Reduction [Natural Phenomenon or Process]
   739   C0392756:Reduction [Qualitative Concept]
   739   C0441610:Reduction [Therapeutic or Preventive Procedure]

Phrase: "as"

Phrase: "a result of the polymorphism"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C1274040:Result [Functional Concept]
   760   C1546471:Result [Idea or Concept]
   760   C2825142:Result [Finding]

Phrase: "modulates"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0443264:modulate [Spatial Concept]

Phrase: "production"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033268:production [Occupational Activity]

Phrase: "and"

Phrase: "release of adipose-derived factors."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   781   C0599947:release factor [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   760   C0030685:Release [Health Care Activity]
   760   C0391871:Release [Functional Concept]
   760   C0439180:% release [Quantitative Concept]
   760   C0680255:release [Health Care Activity]
   760   C1283071:Release [Functional Concept]
   760   C1963578:Release [Therapeutic or Preventive Procedure]
Processing 00000000.tx.7: Both decreased release of insulin-desensitizing free fatty acids, tumor necrosis factor-, and resistin and increased release of the insulin-sensitizing hormone adiponectin result in secondary improvement of insulin sensitivity of glucose uptake and suppression of glucose production. 

Phrase: "Both decreased release of insulin-desensitizing free fatty acids,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   742   C0030685:Release [Health Care Activity]
   742   C0391871:Release [Functional Concept]
   742   C0439180:% release [Quantitative Concept]
   742   C0680255:release [Health Care Activity]
   742   C1283071:Release [Functional Concept]
   742   C1963578:Release [Therapeutic or Preventive Procedure]

Phrase: "tumor necrosis factor-,"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
  1000   C0041368:tumor necrosis factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C1323304:tumor necrosis factor [Molecular Function]
  1000   C1456820:Tumour necrosis factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   901   C0333516:Tumor necrosis [Neoplastic Process]
   827   C0027540:Necrosis [Organ or Tissue Function]
   827   C0027651:Tumor [Neoplastic Process]
   827   C1334928:Necrosis [Finding]
   827   C1521761:Factor [Functional Concept]
   827   C1578706:Tumor [Intellectual Product]
   827   C2827422:Factor [Conceptual Entity]
   827   C3273930:Tumor [Finding]

Phrase: "and"

Phrase: "resistin"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0963992:resistin [Amino Acid, Peptide, or Protein,Hormone]
  1000   C1426906:RESISTIN [Gene or Genome]

Phrase: "and"

Phrase: "increased release of the insulin-sensitizing hormone adiponectin result"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   742   C0030685:Release [Health Care Activity]
   742   C0391871:Release [Functional Concept]
   742   C0439180:% release [Quantitative Concept]
   742   C0680255:release [Health Care Activity]
   742   C1283071:Release [Functional Concept]
   742   C1963578:Release [Therapeutic or Preventive Procedure]

Phrase: "in secondary improvement"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2986411:Improvement [Conceptual Entity]

Phrase: "of insulin sensitivity"
Meta Candidates (Total=15; Excluded=4; Pruned=0; Remaining=11)
  1000   C0920563:Insulin Sensitivity [Pathologic Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036667:Sensitivity [Quantitative Concept]
   861   C0312418:Sensitivity [Mental Process]
   861   C0427965:Sensitivity [Finding]
   861   C1511883:Sensitivity [Quantitative Concept]
   861   C1522640:Sensitivity [Qualitative Concept]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   861   C2346484:SENSITIVITY [Phenomenon or Process]
   861   C2349185:Sensitivity [Qualitative Concept]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   789 E C0332324:Sensitive [Functional Concept]
   789 E C1550474:sensitive [Idea or Concept]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "of glucose uptake"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C1159527:glucose uptake [Cell Function]
   861   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   861   C0243144:Uptake [Physiologic Function]
   861   C0347980:% uptake [Quantitative Concept]

Phrase: "and"

Phrase: "suppression of glucose production."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0221103:Suppression [Pathologic Function]
   770   C0301625:Suppression [Organism Function]
   770   C0439181:% suppression [Quantitative Concept]
   770   C0728721:suppression [Mental Process]
Processing 00000000.tx.8: The population effect of this polymorphism may be modulated by environmental or genetic factors such as obesity, ethnicity, ratio of unsaturated to saturated fatty acids, and genetic background. 

Phrase: "The population effect of this polymorphism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1280500:Effect [Qualitative Concept]
   753   C2348382:Effect [Qualitative Concept]

Phrase: "may"

Phrase: "be"

Phrase: "modulated by environmental"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0014406:Environmental [Spatial Concept]
   790   C0443264:Modulated [Spatial Concept]

Phrase: "or"

Phrase: "genetic factors such as obesity,"
Meta Candidates (Total=12; Excluded=7; Pruned=0; Remaining=5)
   781   C0299583:Obesity Factor [Amino Acid, Peptide, or Protein,Hormone]
   760   C0017296:GENETIC [Therapeutic or Preventive Procedure]
   760   C0314603:Genetic [Functional Concept]
   726   C1521761:Factor [Functional Concept]
   726   C2827422:Factor [Conceptual Entity]
   704 E C0005615:Birth [Organism Function]
   704 E C0035150:Reproduction [Organism Function]
   704 E C0079946:origin [Classification]
   704 E C0439659:Origin [Temporal Concept]
   704 E C1550512:origin [Intellectual Product]
   704 E C1550722:birth [Idea or Concept]
   704 E C3245487:birth [Intellectual Product]

Phrase: "ethnicity,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0015031:Ethnicity [Population Group]
  1000   C0243103:ethnicity [Qualitative Concept]
   928 E C0680174:ethnic [Finding]

Phrase: "ratio of unsaturated"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0456603:Ratio [Quantitative Concept]
   790   C1547037:Ratio [Intellectual Product]

Phrase: "to saturated fatty acids,"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0597423:Fatty Acids, Saturated [Biologically Active Substance,Food,Lipid]
   901   C0015684:Fatty Acids [Lipid]
   827   C0001128:Acids [Chemical]
   827   C0522534:Saturated [Phenomenon or Process]
   827   C1705188:SATURATED [Quantitative Concept]
   793 E C0202406:Acid [Laboratory Procedure]

Phrase: "and"

Phrase: "genetic background."
Meta Candidates (Total=17; Excluded=14; Pruned=0; Remaining=3)
   861   C0017296:GENETIC [Therapeutic or Preventive Procedure]
   861   C0314603:Genetic [Functional Concept]
   861   C1706907:Background [Conceptual Entity]
   805 E C0005615:Birth [Organism Function]
   805 E C0035150:Reproduction [Organism Function]
   805 E C0079946:origin [Classification]
   805 E C0439659:Origin [Temporal Concept]
   805 E C1550512:origin [Intellectual Product]
   805 E C1550722:birth [Idea or Concept]
   805 E C3245487:birth [Intellectual Product]
   777 E C0454729:Natal [Geographic Area]
   777 E C0559522:Genital [Body System]
   777 E C1546649:Genital [Intellectual Product]
   777 E C1550642:Genital [Body Substance]
   768 E C0205313:Original [Idea or Concept]
   768 E C2347409:Original [Occupational Activity]
   750 E C0598240:originality [Mental Process]
Processing 00000000.tx.9: Once diabetes has developed, the protective effect of the Ala allele may be lost, since increased vascular complications and more pronounced -cell dysfunction have been reported. 

Phrase: "Once diabetes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: "has"

Phrase: "developed"

Phrase: ","

Phrase: "the protective effect of the Ala allele"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C1280500:Effect [Qualitative Concept]
   748   C2348382:Effect [Qualitative Concept]

Phrase: "may"

Phrase: "be"

Phrase: "lost"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0745777:Lost [Functional Concept]

Phrase: ","

Phrase: "since"

Phrase: "increased vascular complications"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   827   C0009566:Complications [Pathologic Function]
   827   C1171258:complications [Pathologic Function]
   793 E C2362589:Complication [Idea or Concept]
   743 E C0231242:Complicated [Functional Concept]

Phrase: "and"

Phrase: "more"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205172:More [Functional Concept]

Phrase: "pronounced -"

Phrase: "cell dysfunction"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   861   C0031847:dysfunction [Functional Concept]
   861   C0277785:Dysfunction, NOS [Qualitative Concept]
   805 E C0231174:Malfunction [Functional Concept]
   805 E C1881681:MALFUNCTION [Phenomenon or Process]

Phrase: "have"

Phrase: "been"

Phrase: "reported."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]
Processing 00000000.tx.10: These observations, however, are currently unexplained. 

Phrase: "These observations,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0302523:observations [Research Activity]
  1000   C0700325:observations [Health Care Activity]
  1000   C3244290:observations [Functional Concept]
   966 E C1964257:Observation [Diagnostic Procedure]
   916 E C1518527:OBSERVATIONAL [Research Activity]

Phrase: "however,"

Phrase: "are"

Phrase: "currently unexplained."
Processing 00000000.tx.11: In conclusion, the Pro12Ala polymorphism in PPAR-2 represents the first genetic variant with a broad impact on the risk of common type 2 diabetes. 

Phrase: "In conclusion,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707478:Conclusion [Idea or Concept]

Phrase: "the Pro12Ala polymorphism in PPAR-2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   742   C0032529:Polymorphism [Genetic Function]
   742   C1882417:Polymorphism [Qualitative Concept]

Phrase: "represents"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882932:Represent [Activity]

Phrase: "the first genetic variant with a broad impact"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0205419:Variant [Qualitative Concept]

Phrase: "on the risk"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0035647:Risk [Qualitative Concept]

Phrase: "of common type 2 diabetes."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   923   C0011860:Type 2 Diabetes [Disease or Syndrome]
   875   C1320657:type diabetes [Finding]
   861   C0441730:Type 2 [Classification]
   812   C0011847:Diabetes [Disease or Syndrome]
   812   C0011849:Diabetes [Disease or Syndrome]
   812   C0332307:Type [Qualitative Concept]
   812   C1547052:*Type [Quantitative Concept]
Processing 00000000.tx.12: The precise understanding of its mechanism may lead to novel diagnostic, preventive, and therapeutic approaches for improving the management of type 2 diabetes.  

Phrase: "The precise understanding of its mechanism"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0162340:Understanding [Mental Process]

Phrase: "may"

Phrase: "lead to novel diagnostic, preventive,"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   760   C0011900:Diagnostic [Finding]
   760   C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   760   C0205314:Novel [Temporal Concept]
   760   C0348026:Diagnostic [Functional Concept]
   760   C0445202:preventive [Functional Concept]
   760   C0679622:novel [Intellectual Product]
   760   C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   760   C1456501:Preventive [Qualitative Concept]
   760   C1522538:Lead [Functional Concept]
   760   C2348269:Lead [Element, Ion, or Isotope]
   760   C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "and"

Phrase: "therapeutic approaches for improving"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0449445:Approaches [Spatial Concept]
   770   C1292724:Approaches [Functional Concept]

Phrase: "the management of type 2 diabetes."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0001554:Management [Occupational Activity]
   753   C0376636:management [Health Care Activity]
   753   C1273870:Management [Occupational Activity]
   753   C3273539:Management [Occupation or Discipline]
Processing 00000000.tx.13: INTRODUCTION TOP ABSTRACT INTRODUCTION ASSOCIATION WITH TYPE 2... 

Phrase: "INTRODUCTION TOP ABSTRACT INTRODUCTION ASSOCIATION WITH TYPE 2..."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   767   C3645563:Association type [Intellectual Product]
   744   C0004083:Association [Mental Process]
   744   C0439849:Association [Qualitative Concept]
   744   C0596306:Association [Phenomenon or Process]
   744   C0699792:association [Social Behavior]
Processing 00000000.tx.14: EFFECT ON INSULIN SENSITIVITY EFFECT ON INSULIN SECRETION EFFECT ON OBESITY CELLULAR MECHANISM SUMMARY AND CONCLUSIONS REFERENCES  Peroxisome proliferator-activated receptor (PPAR)- is a transcription factor that belongs to the same family of nuclear receptors as steroid and thyroid hormone receptors (1). 

Phrase: "EFFECT ON INSULIN SENSITIVITY EFFECT"

Phrase: "ON INSULIN SECRETION EFFECT"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C1280500:Effect [Qualitative Concept]
   827   C2348382:Effect [Qualitative Concept]
   734   C1256369:insulin secretion [Cell Function]

Phrase: "ON OBESITY CELLULAR MECHANISM SUMMARY"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C1552616:summary [Intellectual Product]
   812   C1706244:Summary [Intellectual Product]

Phrase: "AND"

Phrase: "CONCLUSIONS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707478:Conclusions [Idea or Concept]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Peroxisome proliferator-activated receptor"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
  1000   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   861   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C0752063:Peroxysome [Cell Component]
   812   C1879547:Activated [Activity]
   812   C2984308:Peroxisome [Functional Concept]
   779 E C1515877:Activate [Functional Concept]
   741 E C3546463:peroxisomal [Cell Component]

Phrase: "(PPAR"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
  1000   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   861   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C0752063:Peroxysome [Cell Component]
   812   C1879547:Activated [Activity]
   812   C2984308:Peroxisome [Functional Concept]
   779 E C1515877:Activate [Functional Concept]
   741 E C3546463:peroxisomal [Cell Component]

Phrase: ")"

Phrase: "-"

Phrase: "is"

Phrase: "a transcription factor"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0040648:TRANSCRIPTION FACTOR [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C0040649:Transcription [Genetic Function]
   861   C1521761:Factor [Functional Concept]
   861   C2827422:Factor [Conceptual Entity]

Phrase: "that"

Phrase: "belongs to the same family of nuclear receptors"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   770   C0206588:Receptors, Nuclear [Amino Acid, Peptide, or Protein,Receptor]
   767   C0028574:Nuclear Family [Family Group]
   744   C0015576:Family [Family Group]
   744   C0445247:Same [Qualitative Concept]
   744   C0521447:Nuclear [Spatial Concept]
   744   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   744   C1704727:Family [Conceptual Entity]

Phrase: "as steroid"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0038317:Steroid [Steroid]

Phrase: "and"

Phrase: "thyroid hormone receptors"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C0034843:Receptors, Thyroid Hormone [Amino Acid, Peptide, or Protein,Receptor]
   901   C0019929:hormone receptors [Amino Acid, Peptide, or Protein,Receptor]
   901   C0040135:Thyroid hormone [Amino Acid, Peptide, or Protein,Hormone]
   867 E C1367453:HORMONE RECEPTOR [Gene or Genome]
   827   C0019932:Hormone [Hormone]
   827   C0040132:Thyroid, NOS [Body Part, Organ, or Organ Component]
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   755 E C0458083:Hormonal [Qualitative Concept]

Phrase: "(1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: ")."
Processing 00000000.tx.15: It is activated by certain fatty acids, prostanoids, and thiazolidinediones, a novel class of insulin-sensitizing antidiabetic agents (24). 

Phrase: "It"

Phrase: "is"

Phrase: "activated by certain fatty acids,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   806   C0015684:Fatty Acids [Lipid]
   760   C0001128:Acids [Chemical]
   760   C1879547:Activated [Activity]
   726 E C0202406:Acid [Laboratory Procedure]
   726 E C1515877:Activate [Functional Concept]

Phrase: "prostanoids,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0033554:Prostanoids [Biologically Active Substance,Eicosanoid,Pharmacologic Substance]
   966 E C1623719:Prostanoid [Biologically Active Substance,Lipid]

Phrase: "and"

Phrase: "thiazolidinediones,"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C1257987:Thiazolidinediones [Organic Chemical,Pharmacologic Substance]
   966 E C0289779:thiazolidinedione [Organic Chemical,Pharmacologic Substance]
   966 E C3537039:Thiazolidinedione [Pharmacologic Substance]

Phrase: "a novel class of insulin-sensitizing antidiabetic agents"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   778   C1579433:Insulin-class Agent [Pharmacologic Substance]
   744   C0456387:Class [Intellectual Product]
   744   C1705943:Class [Classification]

Phrase: "(24"

Phrase: ")."
Processing 00000000.tx.16: Upon activation, it heterodimerizes with the retinoid X receptor and binds to specific PPAR-responsive elements of DNA to promote transcription of numerous target genes (5). 

Phrase: "Upon activation,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1879547:Activation [Activity]

Phrase: "it"

Phrase: "heterodimerizes with the retinoid X receptor"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   833   C0140283:Retinoid X Receptor [Amino Acid, Peptide, or Protein,Receptor]
   790   C1421546:X RECEPTOR [Gene or Genome]
   783   C0140278:Retinoid Receptor [Amino Acid, Peptide, or Protein,Receptor]
   753   C0035339:Retinoid [Biologically Active Substance,Organic Chemical,Pharmacologic Substance]
   753   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   753   C3536891:Retinoid [Pharmacologic Substance]

Phrase: "and"

Phrase: "binds to specific PPAR-responsive elements of DNA to"
Meta Candidates (Total=17; Excluded=2; Pruned=0; Remaining=15)
   790   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   790   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   753   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   751   C0058595:DNA receptor [Amino Acid, Peptide, or Protein,Receptor]
   736   C0012854:DNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   736   C0013879:Elements [Element, Ion, or Isotope]
   736   C0205342:Responsive [Functional Concept]
   736   C0205369:Specific [Qualitative Concept]
   736   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   736   C0752063:Peroxysome [Cell Component]
   736   C1145667:Bind [Activity]
   736   C1167622:bind [Molecular Function]
   736   C1552740:specific [Intellectual Product]
   736   C1879547:Activated [Activity]
   736   C2984308:Peroxisome [Functional Concept]
   703 E C1515877:Activate [Functional Concept]
   703 E C1705248:Element [Conceptual Entity]

Phrase: "promote"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033414:Promote [Activity]

Phrase: "transcription of numerous target genes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   797   C0040649:genes transcription [Genetic Function]
           Transcription

Phrase: "(5"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439084:>5 [Quantitative Concept]
  1000   C0728893:+5 [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.17: Although the isoform PPAR-1 is expressed in most tissues, PPAR-2 is specific for adipose tissue, where it plays a key role in regulating adipogenic differentiation (6). 

Phrase: "Although"

Phrase: "the isoform PPAR-1"
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
   901   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   901   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   885   C0296644:peroxisome receptor 1 [Amino Acid, Peptide, or Protein,Receptor]
   885   C1419151:PEROXISOME RECEPTOR 1 [Gene or Genome]
   827   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   799   C0597298:Isoform [Amino Acid, Peptide, or Protein]
   799   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   799   C0752063:Peroxysome [Cell Component]
   799   C1879547:Activated [Activity]
   799   C2984308:Peroxisome [Functional Concept]
   766 E C1515877:Activate [Functional Concept]
   727 E C3546463:peroxisomal [Cell Component]

Phrase: "is"

Phrase: "expressed in most tissues,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0040300:Tissues [Tissue]
   737 E C1547928:Tissue [Intellectual Product]

Phrase: "PPAR-2"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   937   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   937   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   840   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   804   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   804   C0752063:Peroxysome [Cell Component]
   804   C1879547:Activated [Activity]
   804   C2984308:Peroxisome [Functional Concept]
   771 E C1515877:Activate [Functional Concept]
   733 E C3546463:peroxisomal [Cell Component]

Phrase: "is"

Phrase: "specific for adipose tissue,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   819   C1955394:Tissue specific [Body Substance]
   770   C0205369:Specific [Qualitative Concept]
   770   C1552740:specific [Intellectual Product]

Phrase: "where"

Phrase: "it"

Phrase: "plays"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0032214:Play [Daily or Recreational Activity]
  1000   C0600138:Plays [Finding]

Phrase: "a key role in"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0035820:Role [Social Behavior]
   770   C1705810:Role [Conceptual Entity]

Phrase: "regulating"

Phrase: "adipogenic differentiation"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   861   C0007589:Differentiation [Cell Function]
   861   C1511938:Differentiation [Clinical Attribute]
   861   C2945687:Differentiation [Functional Concept]
   789 E C0205615:Differentiated [Qualitative Concept]

Phrase: "(6"

Phrase: ")."
Processing 00000000.tx.18: The PPAR- gene is located on chromosome 3 (7), and the specific isoforms are a result of alternative mRNA splicing. 

Phrase: "The PPAR- gene"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   840   C1335671:Receptor Gene [Gene or Genome]
   804   C0017337:Gene [Gene or Genome]
   771   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   771   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "is"

Phrase: "located on chromosome 3"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C0008666:Chromosome 3 [Cell Component]
   770   C0008633:Chromosome [Cell Component]

Phrase: "(7"

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "the specific isoforms"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0597298:Isoforms [Amino Acid, Peptide, or Protein]

Phrase: "are"

Phrase: "a result of alternative mRNA splicing."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C1274040:Result [Functional Concept]
   753   C1546471:Result [Idea or Concept]
   753   C2825142:Result [Finding]
Processing 00000000.tx.19: A number of genetic variants in the PPAR- gene have been identified. 

Phrase: "A number of genetic variants"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   843   C3172256:Number of birth [Finding]
   760   C0237753:*Number [Quantitative Concept]
   760   C0449788:Number [Quantitative Concept]

Phrase: "in the PPAR- gene"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   840   C1335671:Receptor Gene [Gene or Genome]
   804   C0017337:Gene [Gene or Genome]
   771   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   771   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "have"

Phrase: "been"

Phrase: "identified."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205396:Identified [Qualitative Concept]
  1000   C1550043:Identified [Finding]
  1000   C1551388:Identified [Functional Concept]
Processing 00000000.tx.20: These include a very rare gain-of-function mutation (Pro115Gln) associated with obesity but not insulin resistance (8), two loss-of-function mutations (Val290Met and Pro467Leu) reported in three individuals with severe insulin resistance but normal body weight (9), the silent CAC478CAT mutation (1012), and the highly prevalent Pro12Ala polymorphism in PPAR-2 (Fig. 1). 

Phrase: "These"

Phrase: "include"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0332257:include [Functional Concept]
  1000   C1552866:include [Idea or Concept]
  1000   C2700399:Include [Activity]

Phrase: "a very rare gain-of-function mutation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   799   C0026882:Mutation [Genetic Function]
   799   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "(Pro115Gln"

Phrase: ")"

Phrase: "associated with obesity"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   882   C0332281:Associated with [Qualitative Concept]
           Associated
   790   C0028754:Obesity [Disease or Syndrome]
   790   C1963185:Obesity [Finding]
   756 E C0750490:Associate [Idea or Concept]
   756 E C1706221:Associate [Professional or Occupational Group]

Phrase: "but"

Phrase: "not insulin resistance"
Meta Candidates (Total=12; Excluded=5; Pruned=0; Remaining=7)
   901   C0021655:Insulin Resistance [Pathologic Function]
   901   C2700570:INSULIN RESISTANCE [Gene or Genome]
   827   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C0237834:Resistance [Mental Process]
   827   C1514892:Resistance [Physiologic Function]
   827   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C1579433:Insulin [Pharmacologic Substance]
   771 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   755 E C0332325:Resistant [Functional Concept]
   755 E C1550464:resistent [Idea or Concept]
   755 E C2827757:RESISTANT [Laboratory or Test Result]
   743 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "(8"

Phrase: ")"

Phrase: ","

Phrase: "two loss-of-function mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   804   C0026882:Mutations [Genetic Function]
   771 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "(Val290Met"

Phrase: "and"

Phrase: "Pro467Leu"

Phrase: ")"

Phrase: "reported in three individuals"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   770   C0205449:Three [Quantitative Concept]
   770   C0684224:Reported [Intellectual Product]
   770   C0700287:Reported [Health Care Activity]
   770   C3496591:Reported [Clinical Attribute]
   737   C0027361:Individual [Population Group]
   737   C0237401:Individual [Human]
   737 E C3273238:Report [Intellectual Product]

Phrase: "with severe insulin resistance"
Meta Candidates (Total=12; Excluded=5; Pruned=0; Remaining=7)
   901   C0021655:Insulin Resistance [Pathologic Function]
   901   C2700570:INSULIN RESISTANCE [Gene or Genome]
   827   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C0237834:Resistance [Mental Process]
   827   C1514892:Resistance [Physiologic Function]
   827   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C1579433:Insulin [Pharmacologic Substance]
   771 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   755 E C0332325:Resistant [Functional Concept]
   755 E C1550464:resistent [Idea or Concept]
   755 E C2827757:RESISTANT [Laboratory or Test Result]
   743 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "but"

Phrase: "normal body weight"
Meta Candidates (Total=13; Excluded=1; Pruned=0; Remaining=12)
  1000   C0421272:Normal Body Weight [Clinical Attribute]
  1000   C1285592:Normal body weight [Clinical Attribute]
   913   C2712185:Normal weight [Finding]
   901   C0005910:Body Weight [Organism Attribute]
           weight
   901   C1305866:body weight [Diagnostic Procedure]
           weight
   827   C0043100:Weight [Quantitative Concept]
   827   C0242821:body [Human]
   827   C0460148:Body [Anatomical Structure]
   827   C1268086:Body [Anatomical Structure]
   827   C1705104:Weight [Idea or Concept]
   743 E C1995017:Bodies [Cell Component]

Phrase: "(9"

Phrase: ")"

Phrase: ","

Phrase: "the silent CAC478CAT mutation"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   913   C1519323:Silent Mutation [Genetic Function]
   827   C0026882:Mutation [Genetic Function]
   827   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "(1012"

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "the highly prevalent Pro12Ala polymorphism in PPAR-2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   738   C0032529:Polymorphism [Genetic Function]
   738   C1882417:Polymorphism [Qualitative Concept]

Phrase: "(Fig. 1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")."
Processing 00000000.tx.21: The latter is the result of a CCA-to-GCA missense mutation in codon 12 of exon B of the PPAR- gene. 

Phrase: "The latter"

Phrase: "is"

Phrase: "the result of a CCA-to-GCA missense mutation"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   742   C1274040:Result [Functional Concept]
   742   C1546471:Result [Idea or Concept]
   742   C2825142:Result [Finding]

Phrase: "in codon 12"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0009221:Codon [Nucleotide Sequence]
   861   C1095825:Codon [Plant]

Phrase: "of exon B"

Phrase: "of the PPAR- gene."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   840   C1335671:Receptor Gene [Gene or Genome]
   804   C0017337:Gene [Gene or Genome]
   771   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   771   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
Processing 00000000.tx.22: This exon encodes the NH2-terminal residue that defines the adipocyte-specific PPAR-2 isoform. 

Phrase: "This exon"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0015295:Exon [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "encodes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2700640:Encode [Activity]

Phrase: "the NH2-terminal residue"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C1709915:Residue [Conceptual Entity]
   827   C1882936:RESIDUE [Phenomenon or Process]
   755 E C1609982:Residual [Qualitative Concept]

Phrase: "that"

Phrase: "defines"

Phrase: "the adipocyte-specific PPAR-2 isoform."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   793   C0597298:Isoform [Amino Acid, Peptide, or Protein]
Processing 00000000.tx.23: The Pro12Ala polymorphism in PPAR-2, which is the focus of this review, was first identified in 1997 (13), and the rare allele frequencies are 12% in Caucasians, 10% in Native Americans, 8% in Samoans, 4% in Japanese, 3% in African-Americans, 2% in Nauruans, and 1% in Chinese (14, 15). 

Phrase: "The Pro12Ala polymorphism in PPAR-2,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   742   C0032529:Polymorphism [Genetic Function]
   742   C1882417:Polymorphism [Qualitative Concept]

Phrase: "which"

Phrase: "is"

Phrase: "the focus of this review,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0205234:Focus [Spatial Concept]
   760   C1285542:focus [Functional Concept]

Phrase: "was"

Phrase: "first"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205435:First [Quantitative Concept]
  1000   C1279901:First [Qualitative Concept]

Phrase: "identified in 1997"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0205396:Identified [Qualitative Concept]
   790   C1550043:Identified [Finding]
   790   C1551388:Identified [Functional Concept]

Phrase: "(13"

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "the rare allele frequencies"
Meta Candidates (Total=7; Excluded=5; Pruned=0; Remaining=2)
   901   C0017270:Frequencies, Allele [Quantitative Concept]
   827   C0439603:Frequencies [Temporal Concept]
   793 E C0376249:frequency [Quantitative Concept]
   793 E C0871396:Frequency [Quantitative Concept]
   793 E C1561548:Frequency [Qualitative Concept]
   793 E C1705502:Frequency [Quantitative Concept]
   743 E C0332183:Frequent [Temporal Concept]

Phrase: "are"

Phrase: "12% in Caucasians,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0007457:Caucasians [Population Group]
   790   C0043157:Caucasians [Population Group]

Phrase: "10% in Native Americans,"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   833   C0282204:Native Americans [Population Group]
   833   C1515945:Native Americans [Population Group]
   802 E C0886378:American native [Therapeutic or Preventive Procedure]
   770   C0302891:Native [Functional Concept]
   770   C0596070:americans [Population Group]

Phrase: "8% in Samoans,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1556103:Samoans [Population Group]

Phrase: "4% in Japanese,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1556094:Japanese [Population Group]

Phrase: "3% in African-Americans,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   833   C0085756:African Americans [Population Group]
   770   C0027567:African [Population Group]
   770   C0439086:<3 [Quantitative Concept]
   770   C0596070:americans [Population Group]
   770   C2827736:3+ [Quantitative Concept]
   770   C2981702:3+ [Classification]

Phrase: "2% in Nauruans,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0740116:+2 [Quantitative Concept]
   790   C2827735:2+ [Quantitative Concept]
   790   C2981700:2+ [Classification]

Phrase: "and"

Phrase: "1% in Chinese"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0008120:chinese [Language]
   790   C0152035:Chinese [Population Group]
   790   C2827734:1+ [Quantitative Concept]
   790   C2981698:1+ [Classification]

Phrase: "(14,"

Phrase: "15"

Phrase: ")."
Processing 00000000.tx.24: In Caucasians, the ethnic group with the highest frequency, this translates into a carrier prevalence of the polymorphism of almost 25%. 

Phrase: "In Caucasians,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0007457:Caucasians [Population Group]
  1000   C0043157:Caucasians [Population Group]

Phrase: "the ethnic group with the highest frequency,"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   778   C0015031:Ethnic group [Population Group]
           ETHNIC
   778   C1879937:Ethnic Group [Intellectual Product]
   748   C0441833:Group [Idea or Concept]
   748   C0680174:ethnic [Finding]
   748   C0687744:group [Population Group]
   748   C1257890:Group [Population Group]
   748   C1552516:Group [Health Care Related Organization]
   748   C1705428:Group [Conceptual Entity]
   748   C1705429:Group [Population Group]

Phrase: "this"

Phrase: "translates into a carrier prevalence of the polymorphism of almost 25%."
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   738   C0007294:Carrier [Finding]
   738   C0032529:Polymorphism [Genetic Function]
   738   C0033105:Prevalence [Quantitative Concept]
   738   C0040710:translate [Occupational Activity]
   738   C0220900:prevalence [Quantitative Concept]
   738   C0560175:Carrier [Finding]
   738   C1706209:Carrier [Medical Device]
   738   C1882417:Polymorphism [Qualitative Concept]
   738   C3273162:Carrier [Intellectual Product]
Processing 00000000.tx.25: View larger version (26K): [in this window] [in a new window]  FIG. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(26K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  FIG."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.26: 1. 

Phrase: "1."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]
Processing 00000000.tx.27: Organization of the PPAR- gene.   

Phrase: "Organization of the PPAR- gene."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   767   C1156085:peroxisome organisation [Cell Function]
   767   C1517495:Gene Organization [Gene or Genome]
   744   C0029237:Organisation [Physiologic Function]
   744   C0029246:Organization [Organization]
   744   C0220885:organization [Qualitative Concept]
   744   C1300196:Organization [Functional Concept]
   744   C1522486:Organization [Professional or Occupational Group]
Processing 00000000.tx.28: ASSOCIATION WITH TYPE 2 DIABETES TOP ABSTRACT INTRODUCTION ASSOCIATION WITH TYPE 2... 

Phrase: "ASSOCIATION WITH TYPE 2 DIABETES TOP ABSTRACT INTRODUCTION ASSOCIATION"

Phrase: "WITH TYPE 2..."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0441730:Type 2 [Classification]
   861   C0332307:Type [Qualitative Concept]
   861   C1547052:*Type [Quantitative Concept]
Processing 00000000.tx.29: EFFECT ON INSULIN SENSITIVITY EFFECT ON INSULIN SECRETION EFFECT ON OBESITY CELLULAR MECHANISM SUMMARY AND CONCLUSIONS REFERENCES  The pathogenesis of type 2 diabetes is characterized by failure of -cell function to compensate for decreased insulin sensitivity. 

Phrase: "EFFECT ON INSULIN SENSITIVITY EFFECT"

Phrase: "ON INSULIN SECRETION EFFECT"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C1280500:Effect [Qualitative Concept]
   827   C2348382:Effect [Qualitative Concept]
   734   C1256369:insulin secretion [Cell Function]

Phrase: "ON OBESITY CELLULAR MECHANISM SUMMARY"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C1552616:summary [Intellectual Product]
   812   C1706244:Summary [Intellectual Product]

Phrase: "AND"

Phrase: "CONCLUSIONS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707478:Conclusions [Idea or Concept]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "The pathogenesis of type 2 diabetes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0543483:pathogenesis [Functional Concept]
   753   C0699748:Pathogenesis [Pathologic Function]

Phrase: "is"

Phrase: "characterized by failure of -cell function to"
Meta Candidates (Total=13; Excluded=0; Pruned=0; Remaining=13)
   778   C0007613:Cell Function [Cell Function]
   748   C0007634:Cell [Cell]
   748   C0031843:function [Physiologic Function]
   748   C0231174:Failure [Functional Concept]
   748   C0542341:Function [Functional Concept]
   748   C0680095:failure [Individual Behavior]
   748   C0700205:FUNCTION [Classification]
   748   C1269647:Cell [Cell]
   748   C1704653:Cell [Medical Device]
   748   C1705273:Function [Intellectual Product]
   748   C1880022:Characterized [Activity]
   748   C1948049:Cell [Spatial Concept]
   738   C0679223:functional failure [Pathologic Function]

Phrase: "compensate for decreased insulin sensitivity."
Meta Candidates (Total=20; Excluded=2; Pruned=0; Remaining=18)
   806   C0920563:Insulin Sensitivity [Pathologic Function]
   797   C0020580:Decreased Sensitivity [Finding]
   797   C1880261:DECREASED SENSITIVITY [Phenomenon or Process]
   797   C2348085:DECREASED SENSITIVITY [Phenomenon or Process]
   760   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C0036667:Sensitivity [Quantitative Concept]
   760   C0205216:Decreased [Quantitative Concept]
   760   C0205432:compensate [Qualitative Concept]
   760   C0312418:Sensitivity [Mental Process]
   760   C0392756:Decreased [Qualitative Concept]
   760   C0427965:Sensitivity [Finding]
   760   C0442797:decreased [Qualitative Concept]
   760   C1511883:Sensitivity [Quantitative Concept]
   760   C1522640:Sensitivity [Qualitative Concept]
   760   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C1579433:Insulin [Pharmacologic Substance]
   760   C2346484:SENSITIVITY [Phenomenon or Process]
   760   C2349185:Sensitivity [Qualitative Concept]
   726 E C0547047:Decrease [Quantitative Concept]
   704 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
Processing 00000000.tx.30: The etiology is multifactorial, and twin studies clearly indicate a major role for involvement of genetic factors (16,17). 

Phrase: "The etiology"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0015127:aetiology [Functional Concept]
  1000   C1314792:Aetiology [Functional Concept]
  1000   C1524003:Etiology [Conceptual Entity]

Phrase: "is"

Phrase: "multifactorial,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1837655:Multifactorial [Finding]

Phrase: "and"

Phrase: "twin"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0041427:Twin [Family Group]
  1000   C0205173:Twin [Functional Concept]

Phrase: "studies"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557651:Study [Manufactured Object]
  1000   C0947630:studies [Laboratory Procedure]
  1000   C2603343:Study [Research Activity]

Phrase: "clearly"

Phrase: "indicate"

Phrase: "a major role for involvement of genetic factors"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0035820:Role [Social Behavior]
   744   C1705810:Role [Conceptual Entity]

Phrase: "(16,"

Phrase: "17"

Phrase: ")."
Processing 00000000.tx.31: Moreover, excess concordance rates in monozygotic versus dizygotic twins clearly suggest a contribution of genetic factors to both insulin resistance and -cell dysfunction (18). 

Phrase: "Moreover,"

Phrase: "excess concordance rates in monozygotic"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0680240:concordance [Social Behavior]
   726   C0871208:Rate [Activity]
   726   C1521828:Rate [Quantitative Concept]

Phrase: "versus"

Phrase: "dizygotic twins clearly"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   901   C0041429:Twins, Dizygotic [Family Group]
   901   C0220761:Dizygotic twins [Finding]
   827   C0041427:Twins [Family Group]
   793 E C0205173:Twin [Functional Concept]

Phrase: "suggest"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "a contribution of genetic factors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1880177:Contribution [Activity]

Phrase: "to both insulin resistance"
Meta Candidates (Total=12; Excluded=5; Pruned=0; Remaining=7)
  1000   C0021655:Insulin Resistance [Pathologic Function]
  1000   C2700570:INSULIN RESISTANCE [Gene or Genome]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0237834:Resistance [Mental Process]
   861   C1514892:Resistance [Physiologic Function]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   789 E C0332325:Resistant [Functional Concept]
   789 E C1550464:resistent [Idea or Concept]
   789 E C2827757:RESISTANT [Laboratory or Test Result]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "and -"

Phrase: "cell dysfunction"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   861   C0031847:dysfunction [Functional Concept]
   861   C0277785:Dysfunction, NOS [Qualitative Concept]
   805 E C0231174:Malfunction [Functional Concept]
   805 E C1881681:MALFUNCTION [Phenomenon or Process]

Phrase: "(18"

Phrase: ")."
Processing 00000000.tx.32: However, due to enormous heterogeneity and probably polygenicity, very few genetic variants have been identified to account for a substantial proportion of common type 2 diabetes. 

Phrase: "However,"

Phrase: "due to enormous heterogeneity"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0019409:Heterogeneity [Qualitative Concept]
   777 E C1512426:Heterogenous [Idea or Concept]

Phrase: "and"

Phrase: "probably polygenicity,"

Phrase: "very few genetic variants"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0205419:variants [Qualitative Concept]

Phrase: "have"

Phrase: "been"

Phrase: "identified"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205396:Identified [Qualitative Concept]
  1000   C1550043:Identified [Finding]
  1000   C1551388:Identified [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "account for a substantial proportion of common type 2 diabetes."
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
   782   C0011860:Type 2 Diabetes [Disease or Syndrome]
   760   C0441730:Type 2 [Classification]
   757   C1320657:Diabetes type [Finding]
   739   C0011847:Diabetes [Disease or Syndrome]
   739   C0011849:Diabetes [Disease or Syndrome]
   739   C0205214:Common [Quantitative Concept]
   739   C0332307:Type [Qualitative Concept]
   739   C1522138:Common [Functional Concept]
   739   C1547052:*Type [Quantitative Concept]
   739   C1551359:account [Idea or Concept]
   739   C1709707:Proportion [Quantitative Concept]
   739   C2741673:Account # [Clinical Attribute]
   739   C2981730:Account [Classification]
   739   C3245511:common [Intellectual Product]
Processing 00000000.tx.33: First evidence for an association between the Pro12Ala polymorphisms in PPAR-2 and type 2 diabetes came from Japanese-Americans, in which a frequency of the rare Ala allele of 9.3% in subjects with normal glucose tolerance versus only 2.2% in patients with type 2 diabetes was observed (11). 

Phrase: "First evidence for an association"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0332120:Evidence [Functional Concept]

Phrase: "between the Pro12Ala polymorphisms"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0032529:polymorphisms [Genetic Function]
   827 E C1882417:Polymorphism [Qualitative Concept]

Phrase: "in PPAR-2"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   937   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   937   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   840   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   804   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   804   C0752063:Peroxysome [Cell Component]
   804   C1879547:Activated [Activity]
   804   C2984308:Peroxisome [Functional Concept]
   771 E C1515877:Activate [Functional Concept]
   733 E C3546463:peroxisomal [Cell Component]

Phrase: "and"

Phrase: "type 2 diabetes"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0011860:Type 2 Diabetes [Disease or Syndrome]
   913   C1320657:type diabetes [Finding]
   901   C0441730:Type 2 [Classification]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]

Phrase: "came from Japanese-Americans,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   833   C0022343:Japanese Americans [Population Group]
   770   C0596070:americans [Population Group]
   770   C1556094:Japanese [Population Group]

Phrase: "in which"

Phrase: "a frequency of the rare Ala allele of 9.3%"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   757   C0017270:Allele Frequency [Quantitative Concept]
   739   C0376249:frequency [Quantitative Concept]
   739   C0439603:Frequency [Temporal Concept]
   739   C0871396:Frequency [Quantitative Concept]
   739   C1561548:Frequency [Qualitative Concept]
   739   C1705502:Frequency [Quantitative Concept]

Phrase: "in subjects"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   966   C0681850:Subject [Group]
   966   C1550501:{Subject} [Idea or Concept]
   966   C1706203:Subject [Idea or Concept]
   966   C2349001:Subject [Human]
   966   C2697811:Subject [Functional Concept]

Phrase: "with normal glucose tolerance"
Meta Candidates (Total=13; Excluded=2; Pruned=0; Remaining=11)
   901   C0178665:Glucose tolerance [Physiologic Function]
   901   C0860800:normal glucose [Finding]
   827   C0013220:Tolerance [Finding]
   827   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   827   C0020963:Tolerance [Pathologic Function]
   827   C0205307:Normal [Qualitative Concept]
   827   C0220929:tolerance [Mental Process]
   827   C0231197:Tolerance [Physiologic Function]
   827   C0439166:% normal [Quantitative Concept]
   827   C1704410:Tolerance [Qualitative Concept]
   827   C2347086:% Normal [Quantitative Concept]
   771 E C0680282:toleration [Social Behavior]
   755 E C0231198:Tolerant [Functional Concept]

Phrase: "versus"

Phrase: "only 2.2% in patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0030705:Patients [Patient or Disabled Group]
   760   C0205171:Only [Quantitative Concept]
   760   C1720467:Only [Intellectual Product]

Phrase: "with type 2 diabetes"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0011860:Type 2 Diabetes [Disease or Syndrome]
   913   C1320657:type diabetes [Finding]
   901   C0441730:Type 2 [Classification]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]

Phrase: "was"

Phrase: "observed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1441672:Observed [Functional Concept]

Phrase: "(11"

Phrase: ")."
Processing 00000000.tx.34: This type of association study, however, is frequently troubled by a lack of reproducibility. 

Phrase: "This type of association study,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   797   C0035171:Study Type [Research Activity]
   797   C2985227:Study Type [Research Activity]
   797   C3645563:Association type [Intellectual Product]
   760   C0332307:Type [Qualitative Concept]
   760   C1547052:*Type [Quantitative Concept]

Phrase: "however,"

Phrase: "is"

Phrase: "frequently"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332183:Frequently [Temporal Concept]

Phrase: "troubled by a lack of reproducibility."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0332268:lack [Qualitative Concept]
   753   C1514863:Reproducibility [Qualitative Concept]
Processing 00000000.tx.35: Nevertheless, in a study that used the powerful tool of transmission disequilibrium testing in 333 Scandinavian parent-offspring trios with abnormal glucose tolerance, only the Pro12Ala polymorphism remained significant among 16 variants with previously published evidence for association with type 2 diabetes (or related disorders) (19). 

Phrase: "Nevertheless,"

Phrase: "in a study"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0557651:Study [Manufactured Object]
  1000   C2603343:Study [Research Activity]

Phrase: "that"

Phrase: "used"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1273517:used [Finding]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the powerful tool of transmission disequilibrium testing"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0336791:Tool [Manufactured Object]
   748   C2827396:Tool [Manufactured Object]
   743   C0336794:Power tool [Manufactured Object]

Phrase: "in 333 Scandinavian parent-offspring trios"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   771   C1336674:TRIO [Gene or Genome]
   771   C1448979:TRIO [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "with abnormal glucose tolerance,"
Meta Candidates (Total=14; Excluded=2; Pruned=0; Remaining=12)
  1000   C0235401:Abnormal glucose tolerance [Finding]
   901   C0178665:Glucose tolerance [Physiologic Function]
   901   C0580546:Abnormal glucose [Finding]
   827   C0013220:Tolerance [Finding]
   827   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   827   C0020963:Tolerance [Pathologic Function]
   827   C0205161:Abnormal [Qualitative Concept]
   827   C0220929:tolerance [Mental Process]
   827   C0231197:Tolerance [Physiologic Function]
   827   C1704410:Tolerance [Qualitative Concept]
   827   C2347472:% Abnormal [Quantitative Concept]
   827   C2699333:ABNORMAL [Intellectual Product]
   771 E C0680282:toleration [Social Behavior]
   755 E C0231198:Tolerant [Functional Concept]

Phrase: "only"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205171:Only [Quantitative Concept]
  1000   C1720467:Only [Intellectual Product]

Phrase: "the Pro12Ala polymorphism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0032529:Polymorphism [Genetic Function]
   861   C1882417:Polymorphism [Qualitative Concept]

Phrase: "remained"

Phrase: "significant among 16 variants"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0237881:significant [Quantitative Concept]
   770   C0750502:Significant [Idea or Concept]
   770   C1546944:Significant [Qualitative Concept]

Phrase: "with previously published evidence"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0332120:Evidence [Functional Concept]

Phrase: "for association"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0004083:Association [Mental Process]
  1000   C0439849:Association [Qualitative Concept]
  1000   C0596306:Association [Phenomenon or Process]
  1000   C0699792:association [Social Behavior]

Phrase: "with type 2 diabetes"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0011860:Type 2 Diabetes [Disease or Syndrome]
   913   C1320657:type diabetes [Finding]
   901   C0441730:Type 2 [Classification]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]

Phrase: "("

Phrase: "or"

Phrase: "related disorders"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0012634:Disorders [Disease or Syndrome]

Phrase: ")"

Phrase: "(19"

Phrase: ")."
Processing 00000000.tx.36: This association of the Pro12Ala polymorphism with type 2 diabetes was recently replicated in two large population-based studies from Finland and Japan including well over 4,000 subjects (15,20). 

Phrase: "This association of the Pro12Ala polymorphism"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0004083:Association [Mental Process]
   753   C0439849:Association [Qualitative Concept]
   753   C0596306:Association [Phenomenon or Process]
   753   C0699792:association [Social Behavior]

Phrase: "with type 2 diabetes"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0011860:Type 2 Diabetes [Disease or Syndrome]
   913   C1320657:type diabetes [Finding]
   901   C0441730:Type 2 [Classification]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]

Phrase: "was"

Phrase: "recently"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332185:Recently [Temporal Concept]

Phrase: "replicated in two large population-based studies"
Meta Candidates (Total=18; Excluded=8; Pruned=0; Remaining=10)
   802   C1709599:Population Based Study [Research Activity]
   774   C0681876:population studies [Research Activity]
   757 E C2348561:Study Population [Population Group]
   748   C0032659:Population [Quantitative Concept]
   748   C0205173:replicated [Functional Concept]
   748   C0205448:Two [Quantitative Concept]
   748   C0549177:Large [Quantitative Concept]
   748   C0947630:studies [Laboratory Procedure]
   748   C1257890:Population [Population Group]
   748   C1527178:Based [Functional Concept]
   748   C1705938:Based [Idea or Concept]
   714 E C0002055:base [Inorganic Chemical]
   714 E C0178499:Base [Chemical Viewed Functionally]
   714 E C0205341:Replicate [Functional Concept]
   714 E C0557651:Study [Manufactured Object]
   714 E C1880279:Base [Biomedical or Dental Material]
   714 E C1883725:Replicate [Qualitative Concept]
   714 E C2603343:Study [Research Activity]

Phrase: "from Finland"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016132:Finland [Geographic Area]

Phrase: "and"

Phrase: "Japan"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022341:Japan [Geographic Area]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "well over 4,000 subjects"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   771   C0681850:Subject [Group]
   771   C1550501:{Subject} [Idea or Concept]
   771   C1706203:Subject [Idea or Concept]
   771   C2349001:Subject [Human]
   771   C2697811:Subject [Functional Concept]

Phrase: "(15,"

Phrase: "20"

Phrase: ")."
Processing 00000000.tx.37: Although the initial publication reported a 75% risk reduction for diabetes conferred by the Ala allele (11), of five subsequent studies (12,2124), only one (22) was able to reproduce a significant association. 

Phrase: "Although"

Phrase: "the initial publication"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0034036:Publication [Intellectual Product,Manufactured Object]
   861   C0034037:Publication [Occupational Activity]
   861   C1704324:Publication [Intellectual Product]

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "a 75% risk reduction for diabetes"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C1137094:Risk Reduction [Individual Behavior]
   753   C0301630:Reduction [Natural Phenomenon or Process]
   753   C0392756:Reduction [Qualitative Concept]
   753   C0441610:Reduction [Therapeutic or Preventive Procedure]

Phrase: "conferred by the Ala allele"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0002085:Allele [Gene or Genome]

Phrase: "(11"

Phrase: ")"

Phrase: ","

Phrase: "of five subsequent studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   827   C0947630:studies [Laboratory Procedure]
   793 E C0557651:Study [Manufactured Object]
   793 E C2603343:Study [Research Activity]

Phrase: "(12,"

Phrase: "2124"

Phrase: ")"

Phrase: ","

Phrase: "only one (22"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0205171:Only [Quantitative Concept]
   827   C0205447:One [Quantitative Concept]
   827   C1720467:Only [Intellectual Product]

Phrase: ")"

Phrase: "was"

Phrase: "able to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0085732:Able [Organism Attribute]
   861   C1299581:Able [Finding]

Phrase: "reproduce"

Phrase: "a significant association."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0004083:Association [Mental Process]
   861   C0439849:Association [Qualitative Concept]
   861   C0596306:Association [Phenomenon or Process]
   861   C0699792:association [Social Behavior]
Processing 00000000.tx.38: However, a meta-analysis including those five plus the aforementioned data set (19) demonstrated a significant risk reduction of 21% (19). 

Phrase: "However,"

Phrase: "a meta-analysis"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0282458:Meta-Analysis [Intellectual Product]
  1000   C0920317:Meta-Analysis [Research Activity]
   861   C0002778:Analysis [Laboratory Procedure]
   861   C0936012:Analysis [Research Activity]
   861   C1042496:Meta [Eukaryote]
   861   C1524024:analysis [Functional Concept]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "those five plus the aforementioned data set"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   778   C0150098:Data Set [Intellectual Product]
   778   C1706233:Dataset [Intellectual Product]
   748   C0036849:Set [Mental Process]
   748   C0205451:Five [Quantitative Concept]
   748   C0332287:Plus [Qualitative Concept]
   748   C1442518:Set [Functional Concept]
   748   C1511726:Data [Idea or Concept]
   748   C1705195:Set [Conceptual Entity]
   748   C3245479:data [Medical Device]

Phrase: "(19"

Phrase: ")"

Phrase: "demonstrated"

Phrase: "a significant risk reduction of 21%"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C1137094:Risk Reduction [Individual Behavior]
   753   C0301630:Reduction [Natural Phenomenon or Process]
   753   C0392756:Reduction [Qualitative Concept]
   753   C0441610:Reduction [Therapeutic or Preventive Procedure]

Phrase: "(19"

Phrase: ")."
Processing 00000000.tx.39: The resulting population-attributable risk was estimated as 25% (11). 

Phrase: "The resulting population-attributable risk"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   923   C1514229:Population Attributable Risk [Quantitative Concept]
   875   C0242444:population risk [Population Group]
   875   C2987720:Population risk [Quantitative Concept]
   861   C0814766:Attributable Risk [Qualitative Concept]
   812   C0032659:Population [Quantitative Concept]
   812   C0035647:Risk [Qualitative Concept]
   812   C0596130:Attributable [Mental Process]
   812   C1257890:Population [Population Group]

Phrase: "was"

Phrase: "estimated as 25%"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0750572:Estimated [Quantitative Concept]

Phrase: "(11"

Phrase: ")."
Processing 00000000.tx.40: In other words, if the entire population carried the Ala allele, the prevalence for type 2 diabetes would be 25% lower. 

Phrase: "In other words,"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   966   C1705313:Word [Idea or Concept]
   928 E C0439824:Verbal [Qualitative Concept]
   900 E C0871946:verb [Intellectual Product]

Phrase: "if"

Phrase: "the entire population"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0032659:Population [Quantitative Concept]
   861   C1257890:Population [Population Group]

Phrase: "carried"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0206243:carried [Activity]
  1000   C0699809:carried [Finding]

Phrase: "the Ala allele,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0002085:Allele [Gene or Genome]

Phrase: "the prevalence for type 2 diabetes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0033105:Prevalence [Quantitative Concept]
   753   C0220900:prevalence [Quantitative Concept]

Phrase: "would"

Phrase: "be"

Phrase: "25% lower."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0441994:Lower [Spatial Concept]
   861   C1548802:Lower [Body Location or Region]
   861   C2003888:Lower [Activity]
Processing 00000000.tx.41: In contrast, mutations responsible for monogenic mature-onset diabetes of the young, though having a major effect on the individuals glucose homeostasis, are so rare that they hardly affect a populations risk of type 2 diabetes (25). 

Phrase: "In contrast,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1979874:Contrast [Qualitative Concept]

Phrase: "mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0026882:Mutations [Genetic Function]
   966 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "responsible for monogenic mature-onset diabetes of the young,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   742   C1273518:Responsible [Finding]
   704   C0342276:Maturity-onset diabetes of the young [Disease or Syndrome]
   704   C2984262:Maturity onset diabetes of the young [Functional Concept]

Phrase: "though"

Phrase: "having"

Phrase: "a major effect on the individuals glucose homeostasis,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   767   C1158774:glucose effect [Genetic Function]
   744   C1280500:Effect [Qualitative Concept]
   744   C2348382:Effect [Qualitative Concept]

Phrase: "are"

Phrase: "so rare"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0521114:Rare [Temporal Concept]
   861   C0522498:Rare [Qualitative Concept]
   861   C1514917:RARE [Gene or Genome]

Phrase: "that"

Phrase: "they hardly"

Phrase: "affect"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001721:Affect [Mental Process]

Phrase: "a populations"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0032659:Population [Quantitative Concept]
  1000   C1257890:Population [Population Group]

Phrase: "risk of type 2 diabetes"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   862   C0011860:Type 2 Diabetes [Disease or Syndrome]
   806   C0441730:Type 2 [Classification]
   797   C1171304:diabetes risk [Quantitative Concept]
   797   C1320657:Diabetes type [Finding]
   760   C0011847:Diabetes [Disease or Syndrome]
   760   C0011849:Diabetes [Disease or Syndrome]
   760   C0035647:Risk [Qualitative Concept]
   760   C0332307:Type [Qualitative Concept]
   760   C1547052:*Type [Quantitative Concept]

Phrase: "(25"

Phrase: ")."
Processing 00000000.tx.42: This underlines the importance of alleles with weak individual effect but high population prevalence, such as the (so-called) wild-type Pro allele of PPAR-2 (75% prevalence in Caucasians), and clearly indicates the prominent role of PPAR- among candidate genes for common type 2 diabetes. 

Phrase: "This underlines"

Phrase: "the importance of alleles"

Phrase: "with weak individual effect"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1280500:Effect [Qualitative Concept]
   827   C2348382:Effect [Qualitative Concept]

Phrase: "but"

Phrase: "high population prevalence,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   913   C1512456:High Prevalence [Quantitative Concept]
   827   C0033105:Prevalence [Quantitative Concept]
   827   C0220900:prevalence [Quantitative Concept]

Phrase: "such as the (so-called"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0037640:SO [Geographic Area]
   827   C0679006:Call [Mental Process]
   827   C1947967:Call [Functional Concept]

Phrase: ")"

Phrase: "wild-type Pro allele of PPAR-2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   739   C0002085:Allele [Gene or Genome]

Phrase: "(75% prevalence in Caucasians"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0033105:Prevalence [Quantitative Concept]
   770   C0220900:prevalence [Quantitative Concept]

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "clearly"

Phrase: "indicates"

Phrase: "the prominent role of PPAR-"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0035820:Role [Social Behavior]
   744   C1705810:Role [Conceptual Entity]

Phrase: "among candidate genes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1332838:Candidate Genes [Gene or Genome]
   861   C0017337:Genes [Gene or Genome]

Phrase: "for common type 2 diabetes."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   923   C0011860:Type 2 Diabetes [Disease or Syndrome]
   875   C1320657:type diabetes [Finding]
   861   C0441730:Type 2 [Classification]
   812   C0011847:Diabetes [Disease or Syndrome]
   812   C0011849:Diabetes [Disease or Syndrome]
   812   C0332307:Type [Qualitative Concept]
   812   C1547052:*Type [Quantitative Concept]
Processing 00000000.tx.43: To make diagnostic, preventive, or therapeutic use of a polymorphism, it is necessary to understand how and in which metabolic, genetic, or environmental context the genotype influences the phenotype. 

Phrase: "To"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "make"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1881534:Make [Functional Concept]

Phrase: "diagnostic, preventive,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0445202:preventive [Functional Concept]
   861   C1456501:Preventive [Qualitative Concept]

Phrase: "or"

Phrase: "therapeutic use of a polymorphism,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   806   C0039795:therapeutic use [Therapeutic or Preventive Procedure]
   806   C1524063:Use of [Functional Concept]
   760   C0039796:Therapeutic [Therapeutic or Preventive Procedure]
   760   C0042153:use [Functional Concept]
   760   C0302350:Therapeutic [Functional Concept]
   760   C0457083:Use [Functional Concept]
   760   C1947944:Use [Intellectual Product]

Phrase: "it"

Phrase: "is"

Phrase: "necessary to"

Phrase: "understand"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0162340:Understand [Mental Process]

Phrase: "how"

Phrase: "and in which metabolic, genetic,"
Meta Candidates (Total=13; Excluded=7; Pruned=0; Remaining=6)
   760   C0017296:GENETIC [Therapeutic or Preventive Procedure]
   760   C0311400:Metabolic [Functional Concept]
   760   C0314603:Genetic [Functional Concept]
   760   C1515981:And [Idea or Concept]
   760   C1524026:Metabolic [Cell Function]
   760   C2707259:Metabolic [Clinical Attribute]
   704 E C0005615:Birth [Organism Function]
   704 E C0035150:Reproduction [Organism Function]
   704 E C0079946:origin [Classification]
   704 E C0439659:Origin [Temporal Concept]
   704 E C1550512:origin [Intellectual Product]
   704 E C1550722:birth [Idea or Concept]
   704 E C3245487:birth [Intellectual Product]

Phrase: "or"

Phrase: "environmental context"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0683581:environmental context [Functional Concept]
   861   C0449255:Context [Finding]
   861   C0542559:Context [Functional Concept]

Phrase: "the genotype"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017431:Genotype [Organism Attribute]

Phrase: "influences"

Phrase: "the phenotype."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0031437:Phenotype [Organism Attribute]
  1000   C1285572:Phenotype [Laboratory Procedure]
Processing 00000000.tx.44: A number of recent studies on metabolic pathways, diabetic and nondiabetic subphenotypes, and gene-environment and gene-gene interaction effects have provided some useful information regarding the potential mechanism by which the Pro12Ala polymorphism reduces the risk for type 2 diabetes. 

Phrase: "A number of recent studies"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0237753:*Number [Quantitative Concept]
   760   C0449788:Number [Quantitative Concept]

Phrase: "on metabolic pathways,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C1291081:Metabolic Pathways [Functional Concept]
   861   C0311400:Metabolic [Functional Concept]
   861   C1524026:Metabolic [Cell Function]
   861   C1704259:Pathways [Molecular Function]
   861   C1705987:Pathways [Conceptual Entity]
   861   C2707259:Metabolic [Clinical Attribute]

Phrase: "diabetic"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0241863:DIABETIC [Finding]

Phrase: "and"

Phrase: "nondiabetic subphenotypes,"

Phrase: "and"

Phrase: "gene-environment"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0014406:Environment [Spatial Concept]

Phrase: "and"

Phrase: "gene-gene interaction effects"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   875   C0596610:gene interaction [Genetic Function]
   812   C1280500:effects [Qualitative Concept]
   812   C1704675:Interaction [Functional Concept]
   779 E C2348382:Effect [Qualitative Concept]

Phrase: "have"

Phrase: "provided"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1999230:Provided [Activity]

Phrase: "some useful information"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C1533716:Information [Idea or Concept]
   789 E C3242430:informational [Idea or Concept]

Phrase: "regarding"

Phrase: "the potential mechanism by which"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0441712:Mechanism [Functional Concept]
   760   C1706376:Mechanism [Manufactured Object]

Phrase: "the Pro12Ala polymorphism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0032529:Polymorphism [Genetic Function]
   861   C1882417:Polymorphism [Qualitative Concept]

Phrase: "reduces"

Phrase: "the risk for type 2 diabetes."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   783   C1171304:diabetes risk [Quantitative Concept]
   753   C0035647:Risk [Qualitative Concept]
Processing 00000000.tx.45: Generally, a genetic variant that affects the risk for type 2 diabetes must influence insulin sensitivity, insulin secretion, or susceptibility for obesity.  

Phrase: "Generally,"

Phrase: "a genetic variant"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0205419:Variant [Qualitative Concept]

Phrase: "that"

Phrase: "affects"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001721:Affect [Mental Process]

Phrase: "the risk for type 2 diabetes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   783   C1171304:diabetes risk [Quantitative Concept]
   753   C0035647:Risk [Qualitative Concept]

Phrase: "must"

Phrase: "influence"

Phrase: "insulin sensitivity,"
Meta Candidates (Total=15; Excluded=4; Pruned=0; Remaining=11)
  1000   C0920563:Insulin Sensitivity [Pathologic Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036667:Sensitivity [Quantitative Concept]
   861   C0312418:Sensitivity [Mental Process]
   861   C0427965:Sensitivity [Finding]
   861   C1511883:Sensitivity [Quantitative Concept]
   861   C1522640:Sensitivity [Qualitative Concept]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   861   C2346484:SENSITIVITY [Phenomenon or Process]
   861   C2349185:Sensitivity [Qualitative Concept]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   789 E C0332324:Sensitive [Functional Concept]
   789 E C1550474:sensitive [Idea or Concept]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "insulin secretion,"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C1256369:insulin secretion [Cell Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036536:secretion [Biologic Function]
   861   C0036537:Secretion [Body Substance]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "or"

Phrase: "susceptibility for obesity."
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   790   C0012655:Susceptibility [Clinical Attribute]
   790   C0220898:Susceptibility [Organism Attribute]
   790   C1264642:Susceptibility [Functional Concept]
   790   C1547045:*Susceptibility [Quantitative Concept]
   718 E C0231204:Susceptible [Functional Concept]
   718 E C2827758:SUSCEPTIBLE [Laboratory or Test Result]
Processing 00000000.tx.46: EFFECT ON INSULIN SENSITIVITY TOP ABSTRACT INTRODUCTION ASSOCIATION WITH TYPE 2... 

Phrase: "EFFECT ON INSULIN SENSITIVITY TOP ABSTRACT INTRODUCTION ASSOCIATION"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C1280500:Effect [Qualitative Concept]
   744   C2348382:Effect [Qualitative Concept]

Phrase: "WITH TYPE 2..."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0441730:Type 2 [Classification]
   861   C0332307:Type [Qualitative Concept]
   861   C1547052:*Type [Quantitative Concept]
Processing 00000000.tx.47: EFFECT ON INSULIN SENSITIVITY EFFECT ON INSULIN SECRETION EFFECT ON OBESITY CELLULAR MECHANISM SUMMARY AND CONCLUSIONS REFERENCES  In the original article, significantly greater insulin sensitivity was reported in nondiabetic Ala carriers (11). 

Phrase: "EFFECT ON INSULIN SENSITIVITY EFFECT"

Phrase: "ON INSULIN SECRETION EFFECT"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C1280500:Effect [Qualitative Concept]
   827   C2348382:Effect [Qualitative Concept]
   734   C1256369:insulin secretion [Cell Function]

Phrase: "ON OBESITY CELLULAR MECHANISM SUMMARY"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C1552616:summary [Intellectual Product]
   812   C1706244:Summary [Intellectual Product]

Phrase: "AND"

Phrase: "CONCLUSIONS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707478:Conclusions [Idea or Concept]

Phrase: "REFERENCES  In the original article,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0205313:Original [Idea or Concept]
   760   C1514811:Reference [Idea or Concept]
   760   C1706462:Reference [Conceptual Entity]
   760   C1706852:Article [Intellectual Product]
   760   C2347409:Original [Occupational Activity]

Phrase: "significantly greater insulin sensitivity"
Meta Candidates (Total=15; Excluded=4; Pruned=0; Remaining=11)
   861   C0920563:Insulin Sensitivity [Pathologic Function]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0036667:Sensitivity [Quantitative Concept]
   812   C0312418:Sensitivity [Mental Process]
   812   C0427965:Sensitivity [Finding]
   812   C1511883:Sensitivity [Quantitative Concept]
   812   C1522640:Sensitivity [Qualitative Concept]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   812   C2346484:SENSITIVITY [Phenomenon or Process]
   812   C2349185:Sensitivity [Qualitative Concept]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   741 E C0332324:Sensitive [Functional Concept]
   741 E C1550474:sensitive [Idea or Concept]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "was"

Phrase: "reported in nondiabetic Ala carriers"
Meta Candidates (Total=8; Excluded=4; Pruned=0; Remaining=4)
   760   C0007294:carriers [Finding]
   760   C0684224:Reported [Intellectual Product]
   760   C0700287:Reported [Health Care Activity]
   760   C3496591:Reported [Clinical Attribute]
   726 E C0560175:Carrier [Finding]
   726 E C1706209:Carrier [Medical Device]
   726 E C3273162:Carrier [Intellectual Product]
   726 E C3273238:Report [Intellectual Product]

Phrase: "(11"

Phrase: ")."
Processing 00000000.tx.48: However, Ala carriers also had a lower BMI, and after adjustment the difference in insulin sensitivity was no longer significant. 

Phrase: "However,"

Phrase: "Ala carriers also"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   827   C0007294:carriers [Finding]
   793 E C0560175:Carrier [Finding]
   793 E C1706209:Carrier [Medical Device]
   793 E C3273162:Carrier [Intellectual Product]

Phrase: "had"

Phrase: "a lower BMI,"

Phrase: "and after adjustment"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0376209:Adjustment [Individual Behavior]
   790   C0456081:Adjustment [Functional Concept]
   790   C0683269:adjustment [Individual Behavior]
   790   C1515981:And [Idea or Concept]

Phrase: "the difference in insulin sensitivity"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1705241:*Difference [Quantitative Concept]
   760   C1705242:Difference [Qualitative Concept]

Phrase: "was"

Phrase: "no longer significant."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0237881:significant [Quantitative Concept]
   861   C0750502:Significant [Idea or Concept]
   861   C1546944:Significant [Qualitative Concept]
Processing 00000000.tx.49: It therefore remained unclear what the primary result of the polymorphism was. 

Phrase: "It therefore"

Phrase: "remained"

Phrase: "unclear"

Phrase: "what the primary result of the polymorphism"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C1274040:Result [Functional Concept]
   748   C1546471:Result [Idea or Concept]
   748   C2825142:Result [Finding]

Phrase: "was."
Processing 00000000.tx.50: In one small study, the confounding influence of BMI (and other relevant variables) on insulin sensitivity was eliminated by pair-matching carriers of the polymorphism with wild-type control subjects (26). 

Phrase: "In one small study,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557651:Study [Manufactured Object]
   827   C2603343:Study [Research Activity]

Phrase: "the confounding influence of BMI ("

Phrase: "and"

Phrase: "other relevant variables"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439828:variables [Qualitative Concept]

Phrase: ")"

Phrase: "on insulin sensitivity"
Meta Candidates (Total=15; Excluded=4; Pruned=0; Remaining=11)
  1000   C0920563:Insulin Sensitivity [Pathologic Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036667:Sensitivity [Quantitative Concept]
   861   C0312418:Sensitivity [Mental Process]
   861   C0427965:Sensitivity [Finding]
   861   C1511883:Sensitivity [Quantitative Concept]
   861   C1522640:Sensitivity [Qualitative Concept]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   861   C2346484:SENSITIVITY [Phenomenon or Process]
   861   C2349185:Sensitivity [Qualitative Concept]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   789 E C0332324:Sensitive [Functional Concept]
   789 E C1550474:sensitive [Idea or Concept]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "was"

Phrase: "eliminated by pair-matching carriers of the polymorphism"
Meta Candidates (Total=10; Excluded=3; Pruned=0; Remaining=7)
   744   C0007294:carriers [Finding]
   744   C0032529:Polymorphism [Genetic Function]
   744   C0150103:MATCHING [Research Activity]
   744   C0849355:Eliminated [Qualitative Concept]
   744   C1708943:Matching [Qualitative Concept]
   744   C1709450:Pair [Qualitative Concept]
   744   C1882417:Polymorphism [Qualitative Concept]
   711 E C0560175:Carrier [Finding]
   711 E C1706209:Carrier [Medical Device]
   711 E C3273162:Carrier [Intellectual Product]

Phrase: "with wild-type control subjects"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   812   C0243148:control [Qualitative Concept]
   812   C1550141:Control [Substance]
   812   C1882979:Control [Conceptual Entity]
   812   C2587213:Control [Functional Concept]
   812   C3274648:Control [Qualitative Concept]
   779   C0681850:Subject [Group]
   779   C1550501:{Subject} [Idea or Concept]
   779   C1706203:Subject [Idea or Concept]
   779   C2349001:Subject [Human]
   779   C2697811:Subject [Functional Concept]

Phrase: "(26"

Phrase: ")."
Processing 00000000.tx.51: Glucose infusion rates during euglycemic-hyperinsulinemic clamp (the gold standard technique for measuring insulin sensitivity in humans) per se were not different; 

Phrase: "Glucose infusion rates during euglycemic-hyperinsulinemic clamp"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   774   C0079318:Glucose Clamp [Research Device]
   762   C2964135:Infusion Rate [Temporal Concept]
   748   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   748   C0574032:Infusion [Therapeutic or Preventive Procedure]
   748   C1827465:Infusion [Functional Concept]
   714   C0871208:Rate [Activity]
   714   C1521828:Rate [Quantitative Concept]

Phrase: "("

Phrase: "the gold standard technique for measuring insulin sensitivity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0449851:Technique [Functional Concept]

Phrase: "in humans"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0086418:Humans [Human]

Phrase: ")"

Phrase: "per se"

Phrase: "were"

Phrase: "not different"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C1705242:Different [Qualitative Concept]
   789 E C1705241:*Difference [Quantitative Concept]
   761 E C0443199:Differential [Qualitative Concept]

Phrase: ";"
Processing 00000000.tx.52: however, expressing them per unit insulin revealed a significantly greater insulin sensitivity index (26). 

Phrase: "however,"

Phrase: "expressing"

Phrase: "them per unit insulin"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   770   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   770   C0439148:Unit [Quantitative Concept]
   770   C1519795:Unit [Quantitative Concept]
   770   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   770   C1579433:Insulin [Pharmacologic Substance]
   770   C1704753:Unit [Manufactured Object]
   770   C1880519:Unit [Quantitative Concept]
   715 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]

Phrase: "revealed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0443289:Revealed [Qualitative Concept]

Phrase: "a significantly greater insulin sensitivity index"
Meta Candidates (Total=18; Excluded=4; Pruned=0; Remaining=14)
   840   C0920563:Insulin Sensitivity [Pathologic Function]
   804   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   804   C0036667:Sensitivity [Quantitative Concept]
   804   C0312418:Sensitivity [Mental Process]
   804   C0427965:Sensitivity [Finding]
   804   C0918012:Index [Intellectual Product]
   804   C1511883:Sensitivity [Quantitative Concept]
   804   C1522640:Sensitivity [Qualitative Concept]
   804   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   804   C1552854:index [Idea or Concept]
   804   C1579433:Insulin [Pharmacologic Substance]
   804   C1637833:% index [Quantitative Concept]
   804   C2346484:SENSITIVITY [Phenomenon or Process]
   804   C2349185:Sensitivity [Qualitative Concept]
   748 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   733 E C0332324:Sensitive [Functional Concept]
   733 E C1550474:sensitive [Idea or Concept]
   721 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "(26"

Phrase: ")."
Processing 00000000.tx.53: In the largest study so far addressing this issue, a 7% greater insulin sensitivity was observed in 616 normal glucose-tolerant Swedish 70-year-old men carrying the Ala allele (27). 

Phrase: "In the largest"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0443228:Largest [Quantitative Concept]
   966 E C0549177:Large [Quantitative Concept]

Phrase: "study"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0557651:Study [Manufactured Object]
  1000   C2603343:Study [Research Activity]

Phrase: "so far"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0037640:SO [Geographic Area]
   861   C0205108:far [Spatial Concept]

Phrase: "addressing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0376649:Address [Intellectual Product]
   966   C1442065:Address [Spatial Concept]

Phrase: "this issue,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0033213:Issue [Finding]
  1000   C1706387:Issue [Intellectual Product]

Phrase: "a 7% greater insulin sensitivity"
Meta Candidates (Total=15; Excluded=4; Pruned=0; Remaining=11)
   861   C0920563:Insulin Sensitivity [Pathologic Function]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0036667:Sensitivity [Quantitative Concept]
   812   C0312418:Sensitivity [Mental Process]
   812   C0427965:Sensitivity [Finding]
   812   C1511883:Sensitivity [Quantitative Concept]
   812   C1522640:Sensitivity [Qualitative Concept]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   812   C2346484:SENSITIVITY [Phenomenon or Process]
   812   C2349185:Sensitivity [Qualitative Concept]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   741 E C0332324:Sensitive [Functional Concept]
   741 E C1550474:sensitive [Idea or Concept]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "was"

Phrase: "observed in 616 normal glucose-tolerant Swedish 70-year-old men"
Meta Candidates (Total=14; Excluded=2; Pruned=0; Remaining=12)
   756   C0860800:normal glucose [Finding]
   738   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   738   C0025266:Men [Population Group]
   738   C0205307:Normal [Qualitative Concept]
   738   C0231198:Tolerant [Functional Concept]
   738   C0439166:% normal [Quantitative Concept]
   738   C0439234:year [Temporal Concept]
   738   C0439508:/year [Temporal Concept]
   738   C0580836:Old [Temporal Concept]
   738   C1441672:Observed [Functional Concept]
   738   C1710263:Swedish [Population Group]
   738   C2347086:% Normal [Quantitative Concept]
   704 E C0024554:MAN [Finding]
   704 E C0086418:Man [Human]

Phrase: "carrying"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0206243:Carrying [Activity]
   966 E C0699809:carry [Finding]

Phrase: "the Ala allele"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0002085:Allele [Gene or Genome]

Phrase: "(27"

Phrase: ")."
Processing 00000000.tx.54: In the same article, a 6% difference in the same direction using the minimal model estimate for insulin sensitivity was reported for 364 young Danes; 

Phrase: "In the same article,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1706852:Article [Intellectual Product]

Phrase: "a 6% difference in the same direction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C1705241:*Difference [Quantitative Concept]
   748   C1705242:Difference [Qualitative Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the minimal model estimate for insulin sensitivity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0750572:Estimate [Quantitative Concept]

Phrase: "was"

Phrase: "reported for 364 young Danes"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   760   C0332239:Young [Temporal Concept]
   760   C0337800:Danes [Population Group]
   760   C0684224:Reported [Intellectual Product]
   760   C0700287:Reported [Health Care Activity]
   760   C3496591:Reported [Clinical Attribute]
   726 E C3273238:Report [Intellectual Product]

Phrase: ";"
Processing 00000000.tx.55: however, it failed to reach statistical difference. 

Phrase: "however,"

Phrase: "it"

Phrase: "failed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0231175:Failed [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "reach"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2584321:Reach [Organism Function]

Phrase: "statistical difference."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C1705241:*Difference [Quantitative Concept]
   861   C1705242:Difference [Qualitative Concept]
   789 E C0443199:Differential [Qualitative Concept]
Processing 00000000.tx.56: A power calculation based on these data revealed a required sample size of 2,000 to achieve significance. 

Phrase: "A power calculation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1441506:Calculation [Activity]

Phrase: "based on these data"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   802   C0242356:data base [Intellectual Product]
   802   C0993637:Data Base [Intellectual Product]
   770   C1511726:Data [Idea or Concept]
   770   C1527178:Based [Functional Concept]
   770   C1705938:Based [Idea or Concept]
   770   C3245479:data [Medical Device]
   737 E C0002055:base [Inorganic Chemical]
   737 E C0178499:Base [Chemical Viewed Functionally]
   737 E C1880279:Base [Biomedical or Dental Material]

Phrase: "revealed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0443289:Revealed [Qualitative Concept]

Phrase: "a required sample size of 2,000 to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0242618:Sample Size [Quantitative Concept]
   744   C0456389:size [Spatial Concept]

Phrase: "achieve"

Phrase: "significance."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0237881:Significance [Quantitative Concept]
  1000   C0750502:Significance [Idea or Concept]
   928 E C1546944:Significant [Qualitative Concept]
Processing 00000000.tx.57: In a Chinese/ Japanese sib-pair study, which by design controlled relatively well for genetic background and childhood environment, a greater estimated insulin sensitivity (homeostasis model analysis) was observed in carriers of the Ala allele (28). 

Phrase: "In a Chinese/ Japanese sib-pair study,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   804   C0557651:Study [Manufactured Object]
   804   C2603343:Study [Research Activity]

Phrase: "which by design"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C1707689:Design [Activity]
   790   C2983265:DESIGN [Intellectual Product]

Phrase: "controlled"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
  1000   C2587213:Controlled [Functional Concept]
   966 E C0243148:control [Qualitative Concept]
   966 E C1550141:Control [Substance]
   966 E C1882979:Control [Conceptual Entity]
   966 E C3274648:Control [Qualitative Concept]

Phrase: "relatively well for genetic background"
Meta Candidates (Total=12; Excluded=7; Pruned=0; Remaining=5)
   760   C0017296:GENETIC [Therapeutic or Preventive Procedure]
   760   C0205170:Well [Qualitative Concept]
   760   C0314603:Genetic [Functional Concept]
   760   C1706907:Background [Conceptual Entity]
   760   C3146287:Well [Manufactured Object]
   704 E C0005615:Birth [Organism Function]
   704 E C0035150:Reproduction [Organism Function]
   704 E C0079946:origin [Classification]
   704 E C0439659:Origin [Temporal Concept]
   704 E C1550512:origin [Intellectual Product]
   704 E C1550722:birth [Idea or Concept]
   704 E C3245487:birth [Intellectual Product]

Phrase: "and"

Phrase: "childhood environment,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0014406:Environment [Spatial Concept]

Phrase: "a greater estimated insulin sensitivity"
Meta Candidates (Total=15; Excluded=4; Pruned=0; Remaining=11)
   861   C0920563:Insulin Sensitivity [Pathologic Function]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0036667:Sensitivity [Quantitative Concept]
   812   C0312418:Sensitivity [Mental Process]
   812   C0427965:Sensitivity [Finding]
   812   C1511883:Sensitivity [Quantitative Concept]
   812   C1522640:Sensitivity [Qualitative Concept]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   812   C2346484:SENSITIVITY [Phenomenon or Process]
   812   C2349185:Sensitivity [Qualitative Concept]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   741 E C0332324:Sensitive [Functional Concept]
   741 E C1550474:sensitive [Idea or Concept]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "(homeostasis model analysis"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0002778:Analysis [Laboratory Procedure]
   827   C0936012:Analysis [Research Activity]
   827   C1524024:analysis [Functional Concept]

Phrase: ")"

Phrase: "was"

Phrase: "observed in carriers of the Ala allele"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   748   C0002085:Allele [Gene or Genome]
   748   C0007294:carriers [Finding]
   748   C1441672:Observed [Functional Concept]
   714 E C0560175:Carrier [Finding]
   714 E C1706209:Carrier [Medical Device]
   714 E C3273162:Carrier [Intellectual Product]

Phrase: "(28"

Phrase: ")."
Processing 00000000.tx.58: Interestingly, a more pronounced effect of the Pro12Ala polymorphism on insulin sensitivity was observed before the background of the common Gly972Arg polymorphism in insulin receptor substrate-1 (29). 

Phrase: "Interestingly,"

Phrase: "a more pronounced effect of the Pro12Ala polymorphism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C1280500:Effect [Qualitative Concept]
   744   C2348382:Effect [Qualitative Concept]

Phrase: "on insulin sensitivity"
Meta Candidates (Total=15; Excluded=4; Pruned=0; Remaining=11)
  1000   C0920563:Insulin Sensitivity [Pathologic Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036667:Sensitivity [Quantitative Concept]
   861   C0312418:Sensitivity [Mental Process]
   861   C0427965:Sensitivity [Finding]
   861   C1511883:Sensitivity [Quantitative Concept]
   861   C1522640:Sensitivity [Qualitative Concept]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   861   C2346484:SENSITIVITY [Phenomenon or Process]
   861   C2349185:Sensitivity [Qualitative Concept]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   789 E C0332324:Sensitive [Functional Concept]
   789 E C1550474:sensitive [Idea or Concept]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "was"

Phrase: "observed before the background of the common Gly972Arg polymorphism"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   742   C0032529:Polymorphism [Genetic Function]
   742   C0205214:Common [Quantitative Concept]
   742   C1441672:Observed [Functional Concept]
   742   C1522138:Common [Functional Concept]
   742   C1706907:Background [Conceptual Entity]
   742   C1882417:Polymorphism [Qualitative Concept]
   742   C3245511:common [Intellectual Product]

Phrase: "in insulin receptor substrate-1"
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
  1000   C0123658:Insulin Receptor Substrate-1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
  1000   C1334140:INSULIN RECEPTOR SUBSTRATE 1 [Gene or Genome]
   861   C0034818:Insulin Receptor [Amino Acid, Peptide, or Protein,Enzyme,Receptor]
   861   C1334133:INSULIN RECEPTOR [Gene or Genome]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   812   C1710236:Substrate [Manufactured Object]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "(29"

Phrase: ")."
Processing 00000000.tx.59: Taken together, these studies provide substantial evidence that the Pro12Ala polymorphism improves insulin sensitivity in humans. 

Phrase: "Taken"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1883727:Taken [Conceptual Entity]
   966 E C1515187:Take [Health Care Activity]

Phrase: "together,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883357:Together [Qualitative Concept]

Phrase: "these studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0947630:studies [Laboratory Procedure]
   966 E C0557651:Study [Manufactured Object]
   966 E C2603343:Study [Research Activity]

Phrase: "provide"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1999230:Provide [Activity]

Phrase: "substantial evidence"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0332120:Evidence [Functional Concept]

Phrase: "that"

Phrase: "the Pro12Ala polymorphism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0032529:Polymorphism [Genetic Function]
   861   C1882417:Polymorphism [Qualitative Concept]

Phrase: "improves"

Phrase: "insulin sensitivity in humans."
Meta Candidates (Total=13; Excluded=1; Pruned=0; Remaining=12)
   833   C0920563:Insulin Sensitivity [Pathologic Function]
   802   C0795635:Human insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   770   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   770   C0036667:Sensitivity [Quantitative Concept]
   770   C0312418:Sensitivity [Mental Process]
   770   C0427965:Sensitivity [Finding]
   770   C1511883:Sensitivity [Quantitative Concept]
   770   C1522640:Sensitivity [Qualitative Concept]
   770   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   770   C1579433:Insulin [Pharmacologic Substance]
   770   C2346484:SENSITIVITY [Phenomenon or Process]
   770   C2349185:Sensitivity [Qualitative Concept]
   715 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
Processing 00000000.tx.60: In subgroups with obesity, the difference in insulin sensitivity was more pronounced (22,30,31), suggesting an interaction of the polymorphism with factors originating from adipose tissue. 

Phrase: "In subgroups"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1079230:subgroups [Virus]
   966 E C1515021:Subgroup [Classification]

Phrase: "with obesity,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0028754:Obesity [Disease or Syndrome]
  1000   C1963185:Obesity [Finding]

Phrase: "the difference in insulin sensitivity"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1705241:*Difference [Quantitative Concept]
   760   C1705242:Difference [Qualitative Concept]

Phrase: "was"

Phrase: "more"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205172:More [Functional Concept]

Phrase: "pronounced"

Phrase: "(22,"

Phrase: "30,"

Phrase: "31"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450355:31 [Intellectual Product]

Phrase: ")"

Phrase: ","

Phrase: "suggesting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "an interaction of the polymorphism"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1704675:Interaction [Functional Concept]

Phrase: "with factors"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C1521761:Factor [Functional Concept]
   966   C2827422:Factor [Conceptual Entity]

Phrase: "originating from adipose tissue."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   833   C0001527:Adipose tissue [Tissue]
   770   C0040300:Tissue [Tissue]
   770   C1547928:Tissue [Intellectual Product]
Processing 00000000.tx.61: In healthy, lean, and normal glucose tolerant subjects, greater insulin sensitivity of glucose disposal was tightly coupled to greater insulin sensitivity of lipolysis, as measured by isotope dilution (32). 

Phrase: "In healthy, lean,"

Phrase: "and"

Phrase: "normal glucose tolerant subjects,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   779   C0681850:Subject [Group]
   779   C1550501:{Subject} [Idea or Concept]
   779   C1706203:Subject [Idea or Concept]
   779   C2349001:Subject [Human]
   779   C2697811:Subject [Functional Concept]

Phrase: "greater insulin sensitivity of glucose disposal"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   790   C0920563:Insulin Sensitivity [Pathologic Function]
   783   C1719133:Glucose/Insulin [Quantitative Concept]
   753   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   753   C0036667:Sensitivity [Quantitative Concept]
   753   C0312418:Sensitivity [Mental Process]
   753   C0427965:Sensitivity [Finding]
   753   C1511883:Sensitivity [Quantitative Concept]
   753   C1522640:Sensitivity [Qualitative Concept]
   753   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   753   C1579433:Insulin [Pharmacologic Substance]
   753   C2346484:SENSITIVITY [Phenomenon or Process]
   753   C2349185:Sensitivity [Qualitative Concept]

Phrase: "was"

Phrase: "tightly"

Phrase: "coupled to greater insulin sensitivity of lipolysis,"
Meta Candidates (Total=18; Excluded=2; Pruned=0; Remaining=16)
   778   C0920563:Insulin Sensitivity [Pathologic Function]
   748   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   748   C0023796:Lipolysis [Organism Function]
   748   C0036667:Sensitivity [Quantitative Concept]
   748   C0312418:Sensitivity [Mental Process]
   748   C0427965:Sensitivity [Finding]
   748   C0443228:greater [Quantitative Concept]
   748   C1511883:Sensitivity [Quantitative Concept]
   748   C1522640:Sensitivity [Qualitative Concept]
   748   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   748   C1579433:Insulin [Pharmacologic Substance]
   748   C1704243:Greater [Quantitative Concept]
   748   C1948027:Coupled [Functional Concept]
   748   C2346484:SENSITIVITY [Phenomenon or Process]
   748   C2349185:Sensitivity [Qualitative Concept]
   738   C0332324:Sensitive to [Functional Concept]
   714 E C0010222:couple [Family Group]
   714 E C0549177:Great [Quantitative Concept]

Phrase: "as"

Phrase: "measured by isotope dilution"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   770   C0022262:Isotope [Element, Ion, or Isotope]
   770   C0079240:Dilution [Laboratory Procedure]
   770   C0444706:Measured [Qualitative Concept]
   770   C1948037:Dilution [Functional Concept]
   770   C3541902:MEASURED [Diagnostic Procedure]
   737 E C0079809:Measure [Quantitative Concept]
   737 E C0242485:Measure [Functional Concept]

Phrase: "(32"

Phrase: ")."
Processing 00000000.tx.62: This finding was in principle confirmed in a larger cohort from the same laboratory by demonstrating significantly lower free fatty acid (FFA) concentrations during insulin stimulation (33). 

Phrase: "This finding"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0037088:Finding [Sign or Symptom]
  1000   C0243095:Finding [Finding]
  1000   C2825141:Finding [Finding]

Phrase: "was"

Phrase: "in principle"

Phrase: "confirmed in a larger cohort"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   760   C0443228:larger [Quantitative Concept]
   760   C0521093:confirmed [Qualitative Concept]
   760   C0549177:Larger [Quantitative Concept]
   760   C0599755:Cohort [Population Group]
   760   C0750484:Confirmed [Idea or Concept]
   760   C1704243:Larger [Quantitative Concept]
   726 E C1456348:Confirm [Qualitative Concept]

Phrase: "from the same laboratory"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0022877:Laboratory [Manufactured Object,Organization]
   861   C3244292:laboratory [Functional Concept]

Phrase: "by"

Phrase: "demonstrating"

Phrase: "significantly"

Phrase: "lower"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0441994:Lower [Spatial Concept]
  1000   C1548802:Lower [Body Location or Region]
  1000   C2003888:Lower [Activity]

Phrase: "free fatty acid (FFA) concentrations during insulin stimulation"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   748   C0086045:Concentrations [Mental Process]
   714 E C1446561:Concentration [Quantitative Concept]

Phrase: "(33"

Phrase: ")."
Processing 00000000.tx.63: Based on these results, it appears possible that alterations in transcriptional activity of the Ala variant in adipocytes (where PPAR-2 is expressed) primarily enhance insulins action on suppression of lipolysis, resulting in a decreased release of FFAs. 

Phrase: "Based on these results,"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   770   C1527178:Based [Functional Concept]
   770   C1705938:Based [Idea or Concept]
   737 E C0002055:base [Inorganic Chemical]
   737 E C0178499:Base [Chemical Viewed Functionally]
   737   C1274040:Result [Functional Concept]
   737   C1546471:Result [Idea or Concept]
   737 E C1880279:Base [Biomedical or Dental Material]
   737   C2825142:Result [Finding]

Phrase: "it"

Phrase: "appears"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0700364:APPEAR [Qualitative Concept]

Phrase: "possible"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0332149:Possible [Qualitative Concept]
  1000   C1705910:Possible [Qualitative Concept]
  1000   C2362652:Possible [Qualitative Concept]

Phrase: "that alterations in transcriptional activity of the Ala variant"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   745   C0184517:Activity alteration [Finding]
   708   C1515926:Alteration [Idea or Concept]

Phrase: "in adipocytes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0206131:Adipocytes [Cell]

Phrase: "(where PPAR-2"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   901   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   901   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   827   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   799   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   799   C0752063:Peroxysome [Cell Component]
   799   C1879547:Activated [Activity]
   799   C2984308:Peroxisome [Functional Concept]
   766 E C1515877:Activate [Functional Concept]
   727 E C3546463:peroxisomal [Cell Component]

Phrase: "is"

Phrase: "expressed"

Phrase: ")"

Phrase: "primarily"

Phrase: "enhance"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2349975:Enhance [Activity]

Phrase: "insulins action on suppression of lipolysis,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0441472:Action [Functional Concept]
   753   C3266814:Action [Activity]

Phrase: "resulting in a decreased release of FFAs."
Meta Candidates (Total=17; Excluded=4; Pruned=0; Remaining=13)
   778   C0332294:Resulting in [Functional Concept]
   748   C0015688:ffas [Lipid]
   748   C0030685:Release [Health Care Activity]
   748   C0205216:Decreased [Quantitative Concept]
   748   C0391871:Release [Functional Concept]
   748   C0392756:Decreased [Qualitative Concept]
   748   C0439180:% release [Quantitative Concept]
   748   C0442797:decreased [Qualitative Concept]
   748   C0678226:resulting [Functional Concept]
   748   C0680255:release [Health Care Activity]
   748   C1283071:Release [Functional Concept]
   748   C1708011:FFAS [Intellectual Product]
   748   C1963578:Release [Therapeutic or Preventive Procedure]
   714 E C0547047:Decrease [Quantitative Concept]
   714 E C1274040:Result [Functional Concept]
   714 E C1546471:Result [Idea or Concept]
   714 E C2825142:Result [Finding]
Processing 00000000.tx.64: Secondarily, reduced availability of FFAs would then permit muscle to utilize more glucose and liver to suppress glucose production more efficiently upon insulin stimulation (34). 

Phrase: "Secondarily,"

Phrase: "reduced availability of FFAs"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C0470187:Availability of [Functional Concept]
           Availability

Phrase: "would"

Phrase: "then"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883708:Then [Temporal Concept]

Phrase: "permit"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0023636:Permit [Regulation or Law]
  1000   C0329040:Permit [Fish]

Phrase: "muscle to"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0026845:Muscle [Tissue]
   789 E C0442025:Muscular [Spatial Concept]

Phrase: "utilize"

Phrase: "more glucose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "and"

Phrase: "liver to"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   861   C0023884:Liver [Body Part, Organ, or Organ Component]
   861   C0736268:LIVER [Body Part, Organ, or Organ Component]
   861   C1278929:Liver [Body Part, Organ, or Organ Component]
   861   C2346688:LIVER [Food]
   805 E C0205054:Hepatic [Body Location or Region]

Phrase: "suppress"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1260953:suppress [Functional Concept]

Phrase: "glucose production more efficiently upon insulin stimulation"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   774   C1719133:Glucose/Insulin [Quantitative Concept]
   748   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   748   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   748   C0033268:production [Occupational Activity]
   748   C1292856:Stimulation [Therapeutic or Preventive Procedure]
   748   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   748   C1579433:Insulin [Pharmacologic Substance]
   748   C1948023:Stimulation [Natural Phenomenon or Process]

Phrase: "(34"

Phrase: ")."
Processing 00000000.tx.65: The metabolic studies in humans were not designed to distinguish between insulin-sensitizing effects on peripheral glucose disposal and suppression of glucose production. 

Phrase: "The metabolic studies in humans"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   806   C0280606:Metabolic Studies [Diagnostic Procedure]
   806   C0412467:Metabolic studies [Diagnostic Procedure]
   797   C0178693:humans studies [Research Activity]
   760   C0947630:studies [Laboratory Procedure]
   726 E C0557651:Study [Manufactured Object]
   726 E C2603343:Study [Research Activity]

Phrase: "were"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "designed"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C1707689:Design [Activity]
   966   C2983265:DESIGN [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "distinguish between insulin-sensitizing effects"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   760   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C1280500:effects [Qualitative Concept]
   760   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C1579433:Insulin [Pharmacologic Substance]
   726 E C2348382:Effect [Qualitative Concept]
   704 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]

Phrase: "on peripheral glucose disposal"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1707797:Disposal [Activity]

Phrase: "and"

Phrase: "suppression of glucose production."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0221103:Suppression [Pathologic Function]
   770   C0301625:Suppression [Organism Function]
   770   C0439181:% suppression [Quantitative Concept]
   770   C0728721:suppression [Mental Process]
Processing 00000000.tx.66: Studies are therefore required that specifically address the question of whether this polymorphism affects glucose production and insulin clearance, two processes clearly influenced by FFA availability.  

Phrase: "Studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0947630:studies [Laboratory Procedure]
   966 E C0557651:Study [Manufactured Object]
   966 E C2603343:Study [Research Activity]

Phrase: "are"

Phrase: "therefore"

Phrase: "required"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514873:Required [Functional Concept]

Phrase: "that specifically"

Phrase: "address"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0376649:Address [Intellectual Product]
  1000   C1442065:Address [Spatial Concept]

Phrase: "the question of"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1522634:Question [Intellectual Product]

Phrase: "whether"

Phrase: "this polymorphism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0032529:Polymorphism [Genetic Function]
  1000   C1882417:Polymorphism [Qualitative Concept]

Phrase: "affects"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001721:Affect [Mental Process]

Phrase: "glucose production"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0033268:production [Occupational Activity]

Phrase: "and"

Phrase: "insulin clearance,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0449297:Clearance [Qualitative Concept]
   861   C1382187:Clearance [Clinical Attribute]
   861   C2825073:Clearance [Natural Phenomenon or Process]

Phrase: "two processes clearly"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   793   C1184743:Process [Body Part, Organ, or Organ Component]
   793   C1522240:Process [Phenomenon or Process]

Phrase: "influenced by FFA availability."
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   833   C0015688:free fatty acid [Lipid]
   833   C2698488:Free Fatty Acid [Laboratory Procedure]
   790   C0015684:Fatty acid [Lipid]
   753   C0001128:Acid [Chemical]
   753   C0202406:Acid [Laboratory Procedure]
   753   C0332296:free [Functional Concept]
   753   C0470187:Availability [Functional Concept]
   753   C1880497:Free [Qualitative Concept]
   753   C1996904:Free [Qualitative Concept]
Processing 00000000.tx.67: EFFECT ON INSULIN SECRETION TOP ABSTRACT INTRODUCTION ASSOCIATION WITH TYPE 2... 

Phrase: "EFFECT ON INSULIN SECRETION TOP ABSTRACT INTRODUCTION ASSOCIATION"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C1280500:Effect [Qualitative Concept]
   744   C2348382:Effect [Qualitative Concept]

Phrase: "WITH TYPE 2..."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0441730:Type 2 [Classification]
   861   C0332307:Type [Qualitative Concept]
   861   C1547052:*Type [Quantitative Concept]
Processing 00000000.tx.68: EFFECT ON INSULIN SENSITIVITY EFFECT ON INSULIN SECRETION EFFECT ON OBESITY CELLULAR MECHANISM SUMMARY AND CONCLUSIONS REFERENCES  Currently, strong evidence for a direct effect of the Pro12Ala polymorphism on insulin secretion is lacking. 

Phrase: "EFFECT ON INSULIN SENSITIVITY EFFECT"

Phrase: "ON INSULIN SECRETION EFFECT"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C1280500:Effect [Qualitative Concept]
   827   C2348382:Effect [Qualitative Concept]
   734   C1256369:insulin secretion [Cell Function]

Phrase: "ON OBESITY CELLULAR MECHANISM SUMMARY"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C1552616:summary [Intellectual Product]
   812   C1706244:Summary [Intellectual Product]

Phrase: "AND"

Phrase: "CONCLUSIONS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707478:Conclusions [Idea or Concept]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Currently,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0521116:Currently [Temporal Concept]

Phrase: "strong evidence for a direct effect of the Pro12Ala polymorphism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   757   C0332120:Evidence of [Functional Concept]
           Evidence

Phrase: "on insulin secretion"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C1256369:insulin secretion [Cell Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036536:secretion [Biologic Function]
   861   C0036537:Secretion [Body Substance]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "is"

Phrase: "lacking."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332268:Lacking [Qualitative Concept]
Processing 00000000.tx.69: However, in Japanese subjects with manifest type 2 diabetes, a lower -cell function index (homeostasis model analysis) was reported in carriers of the Ala allele (15). 

Phrase: "However,"

Phrase: "in Japanese subjects"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   827   C0681850:Subject [Group]
   827   C1550501:{Subject} [Idea or Concept]
   827   C1706203:Subject [Idea or Concept]
   827   C2349001:Subject [Human]
   827   C2697811:Subject [Functional Concept]

Phrase: "with manifest type 2 diabetes,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   923   C0011860:Type 2 Diabetes [Disease or Syndrome]
   875   C1320657:type diabetes [Finding]
   861   C0441730:Type 2 [Classification]
   812   C0011847:Diabetes [Disease or Syndrome]
   812   C0011849:Diabetes [Disease or Syndrome]
   812   C0332307:Type [Qualitative Concept]
   812   C1547052:*Type [Quantitative Concept]

Phrase: "a lower -cell function index"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0918012:Index [Intellectual Product]
   812   C1552854:index [Idea or Concept]
   812   C1637833:% index [Quantitative Concept]

Phrase: "(homeostasis model analysis"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0002778:Analysis [Laboratory Procedure]
   827   C0936012:Analysis [Research Activity]
   827   C1524024:analysis [Functional Concept]

Phrase: ")"

Phrase: "was"

Phrase: "reported in carriers of the Ala allele"
Meta Candidates (Total=9; Excluded=4; Pruned=0; Remaining=5)
   748   C0002085:Allele [Gene or Genome]
   748   C0007294:carriers [Finding]
   748   C0684224:Reported [Intellectual Product]
   748   C0700287:Reported [Health Care Activity]
   748   C3496591:Reported [Clinical Attribute]
   714 E C0560175:Carrier [Finding]
   714 E C1706209:Carrier [Medical Device]
   714 E C3273162:Carrier [Intellectual Product]
   714 E C3273238:Report [Intellectual Product]

Phrase: "(15"

Phrase: ")."
Processing 00000000.tx.70: Interestingly, lipid infusion designed to elevate plasma FFA concentrations fourfold resulted in a decrease in insulin secretion during hyperglycemic clamp in carriers of the Ala allele, but an increase in control subjects with two Pro alleles (35). 

Phrase: "Interestingly,"

Phrase: "lipid infusion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0574032:Infusion [Therapeutic or Preventive Procedure]
   861   C1827465:Infusion [Functional Concept]

Phrase: "designed"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C1707689:Design [Activity]
   966   C2983265:DESIGN [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "elevate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205250:elevate [Qualitative Concept]

Phrase: "plasma FFA concentrations"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   881   C0683150:plasma concentration [Quantitative Concept]
   804   C0086045:Concentrations [Mental Process]
   771 E C1446561:Concentration [Quantitative Concept]
   721 E C1880165:Concentrated [Biomedical or Dental Material]
   717   C0015688:free fatty acid [Lipid]
   717   C2698488:Free Fatty Acid [Laboratory Procedure]

Phrase: "fourfold"

Phrase: "resulted in a decrease"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0392756:Decrease [Qualitative Concept]
   770   C0547047:Decrease [Quantitative Concept]
   737   C1274040:Result [Functional Concept]
   737   C1546471:Result [Idea or Concept]
   737   C2825142:Result [Finding]

Phrase: "in insulin secretion"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C1256369:insulin secretion [Cell Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036536:secretion [Biologic Function]
   861   C0036537:Secretion [Body Substance]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "during hyperglycemic clamp"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0175721:Clamp [Medical Device]
   861   C1705942:Clamp [Manufactured Object]
   861   C1883710:Clamp [Functional Concept]

Phrase: "in carriers"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0007294:carriers [Finding]
   966 E C0560175:Carrier [Finding]
   966 E C1706209:Carrier [Medical Device]
   966 E C3273162:Carrier [Intellectual Product]

Phrase: "of the Ala allele,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0002085:Allele [Gene or Genome]

Phrase: "but"

Phrase: "an increase in control subjects"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0442805:Increase [Functional Concept]

Phrase: "with two Pro alleles"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0002085:Alleles [Gene or Genome]

Phrase: "(35"

Phrase: ")."
Processing 00000000.tx.71: These findings might provide a partial explanation for the above observation that -cell function deteriorates more in Ala carriers once diabetes has developed (15). 

Phrase: "These findings"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C2607943:findings [Functional Concept]
  1000   C2926606:Findings [Clinical Attribute]
  1000   C3539655:Findings [Intellectual Product]
   966 E C0037088:Finding [Sign or Symptom]
   966 E C0243095:Finding [Finding]
   966 E C2825141:Finding [Finding]

Phrase: "might"

Phrase: "provide"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1999230:Provide [Activity]

Phrase: "a partial explanation for the above observation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0681841:Explanation [Intellectual Product]

Phrase: "that -cell function"
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
  1000   C0007613:Cell Function [Cell Function]
   861   C0007634:Cell [Cell]
   861   C0031843:function [Physiologic Function]
   861   C0542341:Function [Functional Concept]
   861   C0700205:FUNCTION [Classification]
   861   C1269647:Cell [Cell]
   861   C1704653:Cell [Medical Device]
   861   C1705273:Function [Intellectual Product]
   861   C1948049:Cell [Spatial Concept]
   789 E C0205245:Functional [Functional Concept]
   789 E C2700217:Functional [Conceptual Entity]

Phrase: "deteriorates"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0184513:deteriorate [Finding]

Phrase: "more in Ala carriers once diabetes"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   753   C0007294:carriers [Finding]
   753   C0011847:Diabetes [Disease or Syndrome]
   753   C0011849:Diabetes [Disease or Syndrome]
   753   C0205172:More [Functional Concept]
   719 E C0560175:Carrier [Finding]
   719 E C1706209:Carrier [Medical Device]
   719 E C3273162:Carrier [Intellectual Product]

Phrase: "has"

Phrase: "developed"

Phrase: "(15"

Phrase: ")."
Processing 00000000.tx.72: Conceivably, superimposition of secondary mechanismssuch as chronic exposure to elevated FFAs and/or hyperglycemia, which are characteristic for overt type 2 diabetesalters (or even reverses) the effect of the genetic variant. 

Phrase: "Conceivably,"

Phrase: "superimposition of secondary mechanismssuch"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0429562:Superimposition [Finding]

Phrase: "as chronic exposure"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205191:chronic [Temporal Concept]
   861   C0274281:Exposure, NOS [Injury or Poisoning]
   861   C0332157:Exposure [Clinical Attribute]

Phrase: "to elevated FFAs"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0015688:ffas [Lipid]
   861   C1708011:FFAS [Intellectual Product]

Phrase: "and/or"

Phrase: "hyperglycemia,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0020456:Hyperglycaemia [Disease or Syndrome]

Phrase: "which"

Phrase: "are"

Phrase: "characteristic for overt type 2 diabetesalters"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   783   C3645613:Characteristic type [Intellectual Product]
   753   C1521970:Characteristic [Qualitative Concept]

Phrase: "("

Phrase: "or"

Phrase: "even"

Phrase: "reverses"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1555029:Reverse [Idea or Concept]

Phrase: ")"

Phrase: "the effect of the genetic variant."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1280500:Effect [Qualitative Concept]
   753   C2348382:Effect [Qualitative Concept]
Processing 00000000.tx.73: Expression of PPAR-, though not specifically of the isoform PPAR-, in -cells has been demonstrated (36). 

Phrase: "Expression of PPAR-,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   783   C0597360:receptor expression [Genetic Function]
   753   C0185117:Expression [Therapeutic or Preventive Procedure]
   716   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   716   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "though"

Phrase: "not specifically of the isoform PPAR-,"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   818   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   818   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   764   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   742   C0597298:Isoform [Amino Acid, Peptide, or Protein]
   742   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   742   C0752063:Peroxysome [Cell Component]
   742   C1518422:Not [Functional Concept]
   742   C1879547:Activated [Activity]
   742   C2984308:Peroxisome [Functional Concept]
   708 E C1515877:Activate [Functional Concept]

Phrase: "in -cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "has"

Phrase: "been"

Phrase: "demonstrated"

Phrase: "(36"

Phrase: ")."
Processing 00000000.tx.74: However, whether any of the above effects on -cell function were direct or secondary remains open and requires further and more detailed studies in, for example, heterozygous PPAR- knockout animals or humans homozygous for the Ala allele.  

Phrase: "However,"

Phrase: "whether"

Phrase: "any of the above effects on -cell function"
Meta Candidates (Total=13; Excluded=1; Pruned=0; Remaining=12)
   770   C0007613:Cell Function [Cell Function]
   744   C0007634:Cell [Cell]
   744   C0031843:function [Physiologic Function]
   744   C0542341:Function [Functional Concept]
   744   C0700205:FUNCTION [Classification]
   744   C1269647:Cell [Cell]
   744   C1280500:effects [Qualitative Concept]
   744   C1552551:Any [Qualitative Concept]
   744   C1704653:Cell [Medical Device]
   744   C1705273:Function [Intellectual Product]
   744   C1948049:Cell [Spatial Concept]
   744   C3272371:ANY [Intellectual Product]
   711 E C2348382:Effect [Qualitative Concept]

Phrase: "were"

Phrase: "direct"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439851:Direct [Qualitative Concept]
  1000   C1947931:Direct [Qualitative Concept]

Phrase: "or"

Phrase: "secondary remains"

Phrase: "open"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0175566:Open [Spatial Concept]

Phrase: "and"

Phrase: "requires"

Phrase: "further"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1517331:Further [Spatial Concept]
   966 E C0205108:far [Spatial Concept]

Phrase: "and"

Phrase: "more detailed studies in,"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   770   C0947630:studies [Laboratory Procedure]
   737 E C0557651:Study [Manufactured Object]
   737 E C2603343:Study [Research Activity]

Phrase: "for example,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707959:Example [Conceptual Entity]

Phrase: "heterozygous PPAR- knockout animals"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   801   C1171353:knockout animal [Animal]
   795   C0003062:Animals [Animal]
   710   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   710   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "or"

Phrase: "humans"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0086418:Humans [Human]

Phrase: "homozygous for the Ala allele."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0019904:Homozygous [Organism Attribute]
Processing 00000000.tx.75: EFFECT ON OBESITY TOP ABSTRACT INTRODUCTION ASSOCIATION WITH TYPE 2... 

Phrase: "EFFECT ON OBESITY TOP ABSTRACT INTRODUCTION ASSOCIATION"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C1280500:Effect [Qualitative Concept]
   748   C2348382:Effect [Qualitative Concept]

Phrase: "WITH TYPE 2..."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0441730:Type 2 [Classification]
   861   C0332307:Type [Qualitative Concept]
   861   C1547052:*Type [Quantitative Concept]
Processing 00000000.tx.76: EFFECT ON INSULIN SENSITIVITY EFFECT ON INSULIN SECRETION EFFECT ON OBESITY CELLULAR MECHANISM SUMMARY AND CONCLUSIONS REFERENCES  Because PPAR- plays a key role in adipocyte differentiation and body fat mass is a strong determinant of insulin sensitivity and type 2 diabetes, the influence of the Pro12Ala polymorphism on susceptibility for obesity has been of major interest. 

Phrase: "EFFECT ON INSULIN SENSITIVITY EFFECT"

Phrase: "ON INSULIN SECRETION EFFECT"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C1280500:Effect [Qualitative Concept]
   827   C2348382:Effect [Qualitative Concept]
   734   C1256369:insulin secretion [Cell Function]

Phrase: "ON OBESITY CELLULAR MECHANISM SUMMARY"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C1552616:summary [Intellectual Product]
   812   C1706244:Summary [Intellectual Product]

Phrase: "AND"

Phrase: "CONCLUSIONS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707478:Conclusions [Idea or Concept]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Because"

Phrase: "PPAR-"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
  1000   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   861   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C0752063:Peroxysome [Cell Component]
   812   C1879547:Activated [Activity]
   812   C2984308:Peroxisome [Functional Concept]
   779 E C1515877:Activate [Functional Concept]
   741 E C3546463:peroxisomal [Cell Component]

Phrase: "plays"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0032214:Play [Daily or Recreational Activity]
  1000   C0600138:Plays [Finding]

Phrase: "a key role in adipocyte differentiation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0035820:Role [Social Behavior]
   753   C1705810:Role [Conceptual Entity]

Phrase: "and"

Phrase: "body fat mass"
Meta Candidates (Total=13; Excluded=1; Pruned=0; Remaining=12)
  1000   C3656665:Body fat mass [Organism Attribute]
   913   C0518010:body mass [Finding]
   901   C0001527:Body Fat [Tissue]
   901   C0015665:body fat [Body Part, Organ, or Organ Component]
   901   C0344335:Body Fat [Clinical Attribute]
   827   C0242821:body [Human]
   827   C0424612:FAT [Organism Attribute]
   827   C0460148:Body [Anatomical Structure]
   827   C0577559:Mass [Finding]
   827   C1268086:Body [Anatomical Structure]
   827   C1306372:*Mass [Quantitative Concept]
   827   C3152252:Mass [Quantitative Concept]
   743 E C1995017:Bodies [Cell Component]

Phrase: "is"

Phrase: "a strong determinant of insulin sensitivity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1521761:Determinant [Functional Concept]

Phrase: "and"

Phrase: "type 2 diabetes,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0011860:Type 2 Diabetes [Disease or Syndrome]
   913   C1320657:type diabetes [Finding]
   901   C0441730:Type 2 [Classification]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]

Phrase: "the influence of the Pro12Ala polymorphism"

Phrase: "on susceptibility"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
  1000   C0012655:Susceptibility [Clinical Attribute]
  1000   C0220898:Susceptibility [Organism Attribute]
  1000   C1264642:Susceptibility [Functional Concept]
  1000   C1547045:*Susceptibility [Quantitative Concept]
   928 E C0231204:Susceptible [Functional Concept]
   928 E C2827758:SUSCEPTIBLE [Laboratory or Test Result]

Phrase: "for obesity"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0028754:Obesity [Disease or Syndrome]
  1000   C1963185:Obesity [Finding]

Phrase: "has"

Phrase: "been of major interest."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0205164:Major [Qualitative Concept]
   770   C0543488:Interest [Mental Process]
Processing 00000000.tx.77: In Pima Indians, suggestive linkage (logarithm of odds = 2.0) with percentage body fat was reported for the 3p24.2-p22 locus, which is close to the region harboring the PPAR- gene (3p25-p24.2) (37). 

Phrase: "In Pima Indians,"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   966   C1551488:Pima Indian [Population Group]
           Pima
   861   C1524069:Indians [Population Group]
   805 E C0032831:Potassium Iodide [Inorganic Chemical,Pharmacologic Substance]

Phrase: "suggestive linkage"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0023745:linkage [Molecular Function]

Phrase: "(logarithm of odds"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C2986775:Logarithm [Occupational Activity]

Phrase: "= 2.0"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0740116:+2 [Quantitative Concept]
   861   C2827735:2+ [Quantitative Concept]
   861   C2981700:2+ [Classification]

Phrase: ")"

Phrase: "with percentage body fat"
Meta Candidates (Total=12; Excluded=1; Pruned=0; Remaining=11)
  1000   C0518026:percentage body fat [Finding]
   901   C0001527:Body Fat [Tissue]
   901   C0015665:body fat [Body Part, Organ, or Organ Component]
   901   C0344335:Body Fat [Clinical Attribute]
   827   C0242821:body [Human]
   827   C0424612:FAT [Organism Attribute]
   827   C0439165:Percentage [Quantitative Concept]
   827   C0460148:Body [Anatomical Structure]
   827   C1268086:Body [Anatomical Structure]
   827   C1549488:Percentage [Idea or Concept]
   827   C1561533:Percentage [Idea or Concept]
   743 E C1995017:Bodies [Cell Component]

Phrase: "was"

Phrase: "reported for the 3p24.2-p22 locus,"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   748   C0684224:Reported [Intellectual Product]
   748   C0700287:Reported [Health Care Activity]
   748   C1521291:3p24 [Cell Component]
   748   C1538631:p22 [Gene or Genome]
   748   C1708726:Locus [Gene or Genome]
   748   C1825005:p22 [Gene or Genome]
   748   C1846989:p22 [Gene or Genome]
   748   C3496591:Reported [Clinical Attribute]
   714 E C3273238:Report [Intellectual Product]

Phrase: "which"

Phrase: "is"

Phrase: "close to the region"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0587267:Close [Functional Concept]

Phrase: "harboring"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0475311:Harbor [Manufactured Object]

Phrase: "the PPAR- gene"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   840   C1335671:Receptor Gene [Gene or Genome]
   804   C0017337:Gene [Gene or Genome]
   771   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   771   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "(3p25-p24.2"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0054970:p24 [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C1521294:3p25 [Cell Component]
   827   C1846989:p24 [Gene or Genome]
   827   C3539699:P24 [Gene or Genome]

Phrase: ")"

Phrase: "(37"

Phrase: ")."
Processing 00000000.tx.78: Cross-sectional studies with small to moderate sample sizes yielded inconsistent results by demonstrating either no difference (21,23,28,38, 39) or a modestly greater BMI in carriers of the Ala allele (10, 40,41). 

Phrase: "Cross-sectional studies with small to"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   833   C0010362:Cross-Sectional Studies [Research Activity]
   754   C0552389:cross sections [Spatial Concept]
   753   C0205155:Sectional [Spatial Concept]
   753   C0947630:studies [Laboratory Procedure]
   753   C2828360:Cross [Conceptual Entity]
   731   C1515004:Study Section [Professional or Occupational Group]
   719 E C0557651:Study [Manufactured Object]
   719 E C2603343:Study [Research Activity]

Phrase: "moderate"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0205081:Moderate [Qualitative Concept]
  1000   C1881878:Moderate [Qualitative Concept]
   944 E C1553901:Mitigate [Idea or Concept]

Phrase: "sample"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0370003:Sample [Substance]
  1000   C2347026:Sample [Conceptual Entity]

Phrase: "sizes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0456389:SIZES [Spatial Concept]

Phrase: "yielded inconsistent results by demonstrating either"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   719   C1274040:Result [Functional Concept]
   719   C1546471:Result [Idea or Concept]
   719   C2825142:Result [Finding]

Phrase: "no difference"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1705241:*Difference [Quantitative Concept]
  1000   C1705242:Difference [Qualitative Concept]
   928 E C0443199:Differential [Qualitative Concept]

Phrase: "(21,"

Phrase: "23,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450348:23 [Quantitative Concept]

Phrase: "28,"

Phrase: "38,"

Phrase: "39"

Phrase: ")"

Phrase: "or"

Phrase: "a modestly greater BMI in carriers of the Ala allele"

Phrase: "(10,"

Phrase: "40,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439509:/40 [Temporal Concept]

Phrase: "41"

Phrase: ")."
Processing 00000000.tx.79: Two sufficiently large studies (>1,000 nondiabetic subjects) found a lower BMI in Finns (11) and no difference in Japanese (15). 

Phrase: "Two sufficiently large studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   812   C0947630:studies [Laboratory Procedure]
   779 E C0557651:Study [Manufactured Object]
   779 E C2603343:Study [Research Activity]

Phrase: "("

Phrase: ">1,000 nondiabetic subjects"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   779   C0681850:Subject [Group]
   779   C1550501:{Subject} [Idea or Concept]
   779   C1706203:Subject [Idea or Concept]
   779   C2349001:Subject [Human]
   779   C2697811:Subject [Functional Concept]

Phrase: ")"

Phrase: "found"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0150312:Found [Quantitative Concept]
   966 E C0243095:Find [Finding]

Phrase: "a lower BMI in Finns"

Phrase: "(11"

Phrase: ")"

Phrase: "and"

Phrase: "no difference in Japanese"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1705241:*Difference [Quantitative Concept]
   770   C1705242:Difference [Qualitative Concept]

Phrase: "(15"

Phrase: ")."
Processing 00000000.tx.80: On the other hand, longitudinal studies in selected populations with relatively small sample sizes consistently suggested greater weight gain in association with the Ala allele (20,42, 43). 

Phrase: "On the"

Phrase: "other hand,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0018563:Hand [Body Part, Organ, or Organ Component]
  1000   C1281583:Hand [Body Part, Organ, or Organ Component]
  1000   C1552914:hand [Quantitative Concept]
   944 E C0024763:Manual [Intellectual Product,Manufactured Object]
   944 E C0175674:Manual [Functional Concept]

Phrase: "longitudinal studies in selected populations"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   806   C0023981:Longitudinal Studies [Research Activity]
   797   C0681876:population studies [Research Activity]
   781 E C2348561:Study Population [Population Group]
   760   C0205127:Longitudinal [Spatial Concept]
   760   C0947630:studies [Laboratory Procedure]
   726 E C0557651:Study [Manufactured Object]
   726 E C2603343:Study [Research Activity]

Phrase: "with relatively small sample"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0370003:Sample [Substance]
   827   C2347026:Sample [Conceptual Entity]

Phrase: "sizes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0456389:SIZES [Spatial Concept]

Phrase: "consistently"

Phrase: "suggested"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "greater weight gain in association"
Meta Candidates (Total=15; Excluded=8; Pruned=0; Remaining=7)
   806   C0043094:Weight Gain [Finding]
   806   C2911647:Weight gain [Finding]
   765 E C0231246:weight gaining [Sign or Symptom]
   760   C0005910:weight [Organism Attribute]
   760   C0043100:Weight [Quantitative Concept]
   760   C1305866:weight [Diagnostic Procedure]
   760   C1517378:Gain [Quantitative Concept]
   760   C1705104:Weight [Idea or Concept]
   704 E C0205217:Increased [Quantitative Concept]
   704 E C0439661:Acquired [Temporal Concept]
   704 E C0442805:Increase [Functional Concept]
   704 E C0442808:Increasing [Functional Concept]
   704 E C1301820:Obtain [Functional Concept]
   704 E C1706701:Acquire [Activity]
   704 E C3245488:acquired [Intellectual Product]

Phrase: "with the Ala allele"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0002085:Allele [Gene or Genome]

Phrase: "(20,"

Phrase: "42,"

Phrase: "43"

Phrase: ")."
Processing 00000000.tx.81: Thus, although cross-sectional evidence convincingly argues against susceptibility of obesity conferred by the Ala allele, the issue remains somewhat unclear. 

Phrase: "Thus,"

Phrase: "although"

Phrase: "cross-sectional evidence convincingly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0332120:Evidence [Functional Concept]

Phrase: "argues against susceptibility of obesity"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   760   C0012655:Susceptibility [Clinical Attribute]
   760   C0028754:Obesity [Disease or Syndrome]
   760   C0220898:Susceptibility [Organism Attribute]
   760   C1264642:Susceptibility [Functional Concept]
   760   C1547045:*Susceptibility [Quantitative Concept]
   760   C1963185:Obesity [Finding]

Phrase: "conferred by the Ala allele,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0002085:Allele [Gene or Genome]

Phrase: "the issue"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0033213:Issue [Finding]
  1000   C1706387:Issue [Intellectual Product]

Phrase: "remains"

Phrase: "somewhat unclear."
Processing 00000000.tx.82: In particular, the interpretation of the longitudinal analysis is complicated by the fact that greater insulin sensitivity per se predicts future weight gain (44). 

Phrase: "In particular,"

Phrase: "the interpretation of the longitudinal analysis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0459471:Interpretation [Intellectual Product]
   753   C3173575:Interpretation [Clinical Attribute]

Phrase: "is"

Phrase: "complicated by the fact"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0231242:Complicated [Functional Concept]

Phrase: "that greater insulin sensitivity"
Meta Candidates (Total=15; Excluded=4; Pruned=0; Remaining=11)
   901   C0920563:Insulin Sensitivity [Pathologic Function]
   827   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C0036667:Sensitivity [Quantitative Concept]
   827   C0312418:Sensitivity [Mental Process]
   827   C0427965:Sensitivity [Finding]
   827   C1511883:Sensitivity [Quantitative Concept]
   827   C1522640:Sensitivity [Qualitative Concept]
   827   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C1579433:Insulin [Pharmacologic Substance]
   827   C2346484:SENSITIVITY [Phenomenon or Process]
   827   C2349185:Sensitivity [Qualitative Concept]
   771 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   755 E C0332324:Sensitive [Functional Concept]
   755 E C1550474:sensitive [Idea or Concept]
   743 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "per se"

Phrase: "predicts"

Phrase: "future weight gain"
Meta Candidates (Total=15; Excluded=8; Pruned=0; Remaining=7)
   901   C0043094:Weight Gain [Finding]
   901   C2911647:Weight gain [Finding]
   859 E C0231246:weight gaining [Sign or Symptom]
   827   C0005910:weight [Organism Attribute]
   827   C0043100:Weight [Quantitative Concept]
   827   C1305866:weight [Diagnostic Procedure]
   827   C1517378:Gain [Quantitative Concept]
   827   C1705104:Weight [Idea or Concept]
   771 E C0205217:Increased [Quantitative Concept]
   771 E C0439661:Acquired [Temporal Concept]
   771 E C0442805:Increase [Functional Concept]
   771 E C0442808:Increasing [Functional Concept]
   771 E C1301820:Obtain [Functional Concept]
   771 E C1706701:Acquire [Activity]
   771 E C3245488:acquired [Intellectual Product]

Phrase: "(44"

Phrase: ")."
Processing 00000000.tx.83: Weight gain may be related to the greater insulin sensitivity particular of lipolysis (33), which would result in overproportionate retention of FFAs in stored triglycerides during physiological insulin stimulation (e.g., postprandially). 

Phrase: "Weight gain"
Meta Candidates (Total=15; Excluded=8; Pruned=0; Remaining=7)
  1000   C0043094:Weight Gain [Finding]
  1000   C2911647:Weight gain [Finding]
   958 E C0231246:weight gaining [Sign or Symptom]
   861   C0005910:weight [Organism Attribute]
   861   C0043100:Weight [Quantitative Concept]
   861   C1305866:weight [Diagnostic Procedure]
   861   C1517378:Gain [Quantitative Concept]
   861   C1705104:Weight [Idea or Concept]
   805 E C0205217:Increased [Quantitative Concept]
   805 E C0439661:Acquired [Temporal Concept]
   805 E C0442805:Increase [Functional Concept]
   805 E C0442808:Increasing [Functional Concept]
   805 E C1301820:Obtain [Functional Concept]
   805 E C1706701:Acquire [Activity]
   805 E C3245488:acquired [Intellectual Product]

Phrase: "may"

Phrase: "be"

Phrase: "related to the greater insulin sensitivity"
Meta Candidates (Total=18; Excluded=2; Pruned=0; Remaining=16)
   790   C0920563:Insulin Sensitivity [Pathologic Function]
   753   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   753   C0036667:Sensitivity [Quantitative Concept]
   753   C0312418:Sensitivity [Mental Process]
   753   C0427965:Sensitivity [Finding]
   753   C0439849:Related [Qualitative Concept]
   753   C0443228:greater [Quantitative Concept]
   753   C0445223:Related [Finding]
   753   C1511883:Sensitivity [Quantitative Concept]
   753   C1522640:Sensitivity [Qualitative Concept]
   753   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   753   C1579433:Insulin [Pharmacologic Substance]
   753   C1704243:Greater [Quantitative Concept]
   753   C2346484:SENSITIVITY [Phenomenon or Process]
   753   C2349185:Sensitivity [Qualitative Concept]
   748   C0332324:Sensitive to [Functional Concept]
   719 E C0163712:Relate [Organic Chemical]
   719 E C0549177:Great [Quantitative Concept]

Phrase: "particular of lipolysis"

Phrase: "(33"

Phrase: ")"

Phrase: ","

Phrase: "which"

Phrase: "would"

Phrase: "result in overproportionate retention of FFAs"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   753   C0015688:ffas [Lipid]
   753   C0035280:Retention [Mental Process]
   753   C0333117:Retention [Functional Concept]
   753   C1274040:Result [Functional Concept]
   753   C1546471:Result [Idea or Concept]
   753   C1708011:FFAS [Intellectual Product]
   753   C1753315:retention [Cell Function]
   753   C2825142:Result [Finding]

Phrase: "in stored triglycerides"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0041004:Triglycerides [Biologically Active Substance,Lipid]

Phrase: "during physiological insulin stimulation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1292856:Stimulation [Therapeutic or Preventive Procedure]
   827   C1948023:Stimulation [Natural Phenomenon or Process]

Phrase: "("

Phrase: "e.g."

Phrase: ","

Phrase: "postprandially"

Phrase: ")."
Processing 00000000.tx.84: In this scenario, obesity would be a consequence of increased insulin sensitivity and not directly of the Ala allele. 

Phrase: "In this scenario,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0683579:scenario [Functional Concept]

Phrase: "obesity"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0028754:Obesity [Disease or Syndrome]
  1000   C1963185:Obesity [Finding]

Phrase: "would"

Phrase: "be"

Phrase: "a consequence of increased insulin sensitivity"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0686907:Consequence of [Functional Concept]
           Consequence

Phrase: "and"

Phrase: "not directly of the Ala allele."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0002085:Allele [Gene or Genome]
   753   C1518422:Not [Functional Concept]
   753   C1947931:Directly [Qualitative Concept]
Processing 00000000.tx.85: It may be of note in this context that under a high-fat diet, heterozygous PPAR--deficient mice (an animal model for reduced PPAR- activity) were protected from the development of insulin resistance caused by adipocyte hypertrophy, compared with wild-type littermates (45). 

Phrase: "It"

Phrase: "may"

Phrase: "be of note"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C1316572:Note [Clinical Attribute]
   790   C1317574:Note [Intellectual Product]
   790   C1369612:Note [Clinical Attribute]
   790   C2987476:Be [Conceptual Entity]

Phrase: "in this context"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0449255:Context [Finding]
  1000   C0542559:Context [Functional Concept]

Phrase: "that under a high-fat diet,"
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
   833   C0521974:Diet, High-Fat [Therapeutic or Preventive Procedure]
   790   C0301585:Fat diet [Therapeutic or Preventive Procedure]
   753   C0012155:Diet [Food]
   753   C0205250:High [Qualitative Concept]
   753   C0424612:FAT [Organism Attribute]
   753   C1299351:High [Qualitative Concept]
   753   C1442959:Diet [Organism Function]
   753   C1519433:DIET [Therapeutic or Preventive Procedure]
   753   C2700149:HIGH [Intellectual Product]
   753   C2983588:DIET [Food]
   748 E C0012171:Dietary Fat [Food]
   748 E C1527016:Dietary Fat [Research Activity]

Phrase: "heterozygous PPAR"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   937   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   937   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   840   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   804   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   804   C0752063:Peroxysome [Cell Component]
   804   C1879547:Activated [Activity]
   804   C2984308:Peroxisome [Functional Concept]
   771 E C1515877:Activate [Functional Concept]
   733 E C3546463:peroxisomal [Cell Component]

Phrase: "--"

Phrase: "deficient mice"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0025914:Mice [Mammal]
   861   C0025929:mice [Mammal]
   861   C0026809:Mice [Mammal]

Phrase: "("

Phrase: "an animal model for reduced PPAR- activity"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0599779:Animal Model [Animal]
   739   C0003062:Animal [Animal]
   739   C3161035:Model [Intellectual Product]

Phrase: ")"

Phrase: "were"

Phrase: "protected from the development of insulin resistance"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   778   C0021655:Insulin Resistance [Pathologic Function]
   778   C2700570:INSULIN RESISTANCE [Gene or Genome]
   748   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   748   C0237834:Resistance [Mental Process]
   748   C0243107:development [Physiologic Function]
   748   C0678723:Development [Organism Function]
   748   C1514892:Resistance [Physiologic Function]
   748   C1527148:Development [Functional Concept]
   748   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   748   C1579433:Insulin [Pharmacologic Substance]

Phrase: "caused by adipocyte hypertrophy,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0020564:Hypertrophy [Pathologic Function]
   770   C0206131:Adipocyte [Cell]
   737   C0015127:cause [Functional Concept]
   737   C1524003:Cause [Conceptual Entity]

Phrase: "compared with wild-type littermates"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   806   C1883559:Wild Type [Organism Attribute]
   760   C0332307:Type [Qualitative Concept]
   760   C0445392:Wild [Intellectual Product]
   760   C1547052:*Type [Quantitative Concept]
   760   C1707455:Compared [Activity]

Phrase: "(45"

Phrase: ")."
Processing 00000000.tx.86: Clearly, any effect of this polymorphism on measures of obesity would be extremely subtle, and its demonstration would be crucially dependent on subject selection and interaction with ethnic background and other genetic or environmental factors. 

Phrase: "Clearly,"

Phrase: "any effect of this polymorphism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1280500:Effect [Qualitative Concept]
   760   C2348382:Effect [Qualitative Concept]

Phrase: "on measures"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0079809:Measures [Quantitative Concept]
  1000   C1879489:Measures [Functional Concept]
   966 E C0242485:Measure [Functional Concept]

Phrase: "of obesity"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0028754:Obesity [Disease or Syndrome]
  1000   C1963185:Obesity [Finding]

Phrase: "would"

Phrase: "be"

Phrase: "extremely subtle,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   789   C1710238:Subtlety [Clinical Attribute]

Phrase: "and"

Phrase: "its demonstration"

Phrase: "would"

Phrase: "be"

Phrase: "crucially dependent on subject selection"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0851827:Dependent [Qualitative Concept]
   760   C1701901:Dependent [Qualitative Concept]
   760   C3244310:dependent [Functional Concept]

Phrase: "and"

Phrase: "interaction with ethnic background"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1704675:Interaction [Functional Concept]

Phrase: "and"

Phrase: "other genetic"
Meta Candidates (Total=16; Excluded=14; Pruned=0; Remaining=2)
  1000   C0017296:GENETIC [Therapeutic or Preventive Procedure]
  1000   C0314603:Genetic [Functional Concept]
   944 E C0005615:Birth [Organism Function]
   944 E C0035150:Reproduction [Organism Function]
   944 E C0079946:origin [Classification]
   944 E C0439659:Origin [Temporal Concept]
   944 E C1550512:origin [Intellectual Product]
   944 E C1550722:birth [Idea or Concept]
   944 E C3245487:birth [Intellectual Product]
   916 E C0454729:Natal [Geographic Area]
   916 E C0559522:Genital [Body System]
   916 E C1546649:Genital [Intellectual Product]
   916 E C1550642:Genital [Body Substance]
   907 E C0205313:Original [Idea or Concept]
   907 E C2347409:Original [Occupational Activity]
   888 E C0598240:originality [Mental Process]

Phrase: "or"

Phrase: "environmental factors."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C1516998:Environmental Factors [Functional Concept]
   983 E C0686732:Environmental Factor [Qualitative Concept]
   827   C1521761:Factor [Functional Concept]
   827   C2827422:Factor [Conceptual Entity]
Processing 00000000.tx.87: For example, an interaction effect of the Pro12Ala polymorphism with the Trp64Arg polymorphism in the 3-adrenergic receptor (which by itself probably does not influence body weight [ 46]) has been reported (47). 

Phrase: "For example,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707959:Example [Conceptual Entity]

Phrase: "an interaction effect of the Pro12Ala polymorphism"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C1280500:Effect [Qualitative Concept]
   748   C1704675:Interaction [Functional Concept]
   748   C2348382:Effect [Qualitative Concept]

Phrase: "with the Trp64Arg polymorphism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0032529:Polymorphism [Genetic Function]
   861   C1882417:Polymorphism [Qualitative Concept]

Phrase: "in the 3-adrenergic receptor"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0034783:Adrenergic Receptor [Amino Acid, Peptide, or Protein,Receptor]
   827   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   827   C0599756:adrenergic [Functional Concept]

Phrase: "("

Phrase: "which by itself probably"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0750492:Probably [Idea or Concept]

Phrase: "does"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "influence"

Phrase: "body weight"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
  1000   C0005910:Body Weight [Organism Attribute]
           weight
  1000   C1305866:body weight [Diagnostic Procedure]
           weight
   861   C0043100:Weight [Quantitative Concept]
   861   C0242821:body [Human]
   861   C0460148:Body [Anatomical Structure]
   861   C1268086:Body [Anatomical Structure]
   861   C1705104:Weight [Idea or Concept]
   777 E C1995017:Bodies [Cell Component]

Phrase: "[ 46"

Phrase: "]"

Phrase: ")"

Phrase: "has"

Phrase: "been"

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "(47"

Phrase: ")."
Processing 00000000.tx.88: Moreover, a greater BMI was observed in Ala carriers when the dietary polyunsaturated fat-to-saturated fat ratio was low, suggesting gene-nutrient interaction via the PPAR- locus (48).  

Phrase: "Moreover,"

Phrase: "a greater BMI"

Phrase: "was"

Phrase: "observed in Ala carriers"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   770   C0007294:carriers [Finding]
   770   C1441672:Observed [Functional Concept]
   737 E C0560175:Carrier [Finding]
   737 E C1706209:Carrier [Medical Device]
   737 E C3273162:Carrier [Intellectual Product]

Phrase: "when"

Phrase: "the dietary polyunsaturated fat-to-saturated fat ratio"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   795   C0456603:Ratio [Quantitative Concept]
   795   C1547037:Ratio [Intellectual Product]

Phrase: "was"

Phrase: "low,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205251:low [Qualitative Concept]
  1000   C1299352:Low [Qualitative Concept]
  1000   C1550472:low [Idea or Concept]

Phrase: "suggesting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "gene-nutrient interaction via the PPAR- locus"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0242784:nutrient interaction [Natural Phenomenon or Process]
   757   C0596610:gene interaction [Genetic Function]
   739   C1704675:Interaction [Functional Concept]

Phrase: "(48"

Phrase: ")."
Processing 00000000.tx.89: CELLULAR MECHANISM TOP ABSTRACT INTRODUCTION ASSOCIATION WITH TYPE 2... 

Phrase: "CELLULAR MECHANISM TOP ABSTRACT INTRODUCTION ASSOCIATION WITH TYPE 2..."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   762   C3645563:Association type [Intellectual Product]
   742   C0004083:Association [Mental Process]
   742   C0439849:Association [Qualitative Concept]
   742   C0596306:Association [Phenomenon or Process]
   742   C0699792:association [Social Behavior]
Processing 00000000.tx.90: EFFECT ON INSULIN SENSITIVITY EFFECT ON INSULIN SECRETION EFFECT ON OBESITY CELLULAR MECHANISM SUMMARY AND CONCLUSIONS REFERENCES  PPAR- is a master transcriptional regulator involved in the expression of probably hundreds of genes (1). 

Phrase: "EFFECT ON INSULIN SENSITIVITY EFFECT"

Phrase: "ON INSULIN SECRETION EFFECT"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C1280500:Effect [Qualitative Concept]
   827   C2348382:Effect [Qualitative Concept]
   734   C1256369:insulin secretion [Cell Function]

Phrase: "ON OBESITY CELLULAR MECHANISM SUMMARY"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C1552616:summary [Intellectual Product]
   812   C1706244:Summary [Intellectual Product]

Phrase: "AND"

Phrase: "CONCLUSIONS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707478:Conclusions [Idea or Concept]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "PPAR-"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
  1000   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   861   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C0752063:Peroxysome [Cell Component]
   812   C1879547:Activated [Activity]
   812   C2984308:Peroxisome [Functional Concept]
   779 E C1515877:Activate [Functional Concept]
   741 E C3546463:peroxisomal [Cell Component]

Phrase: "is"

Phrase: "a master transcriptional regulator"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0040649:Transcriptional [Genetic Function]
   827   C0182953:REGULATOR [Medical Device]
   827   C1704734:Regulator [Medical Device]
   827   C1704735:Regulator [Conceptual Entity]

Phrase: "involved in the expression of probably hundreds of genes"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   745   C0017262:Gene Expression [Genetic Function]
   742   C0017337:Genes [Gene or Genome]
   742   C0185117:Expression [Therapeutic or Preventive Procedure]
   742   C0750492:Probably [Idea or Concept]
   742   C1314939:Involved [Functional Concept]

Phrase: "(1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: ")."
Processing 00000000.tx.91: Two studies have directly examined the transcriptional activity of the Ala variant of PPAR- in comparison to the Pro variant in experimental cell models (11,49). 

Phrase: "Two studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0947630:studies [Laboratory Procedure]
   827 E C0557651:Study [Manufactured Object]
   827 E C2603343:Study [Research Activity]

Phrase: "have"

Phrase: "directly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1947931:Directly [Qualitative Concept]

Phrase: "examined"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332128:Examined [Finding]

Phrase: "the transcriptional activity of the Ala variant of PPAR-"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   804   C2266880:Peroxisome Proliferator-activated Receptor Activity [Molecular Function]
   751   C1152633:receptor activity [Molecular Function]
   736   C0205177:Activity [Functional Concept]
   736   C0439167:% activity [Quantitative Concept]
   736   C0441655:Activity [Activity]
   736   C1561536:*Activity [Idea or Concept]

Phrase: "in comparison to the Pro variant"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0205419:Variant [Qualitative Concept]

Phrase: "in experimental cell models"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   913   C0086272:Models, Experimental [Intellectual Product]
   827   C3161035:Models [Intellectual Product]

Phrase: "(11,"

Phrase: "49"

Phrase: ")."
Processing 00000000.tx.92: Reduced binding of the Ala variant to the PPAR--responsive DNA elements was observed in transient transfection assays (11,49). 

Phrase: "Reduced"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0392756:Reduced [Qualitative Concept]

Phrase: "binding of the Ala variant"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0243122:binding [Functional Concept]
   760   C1145667:Binding [Activity]
   760   C1167622:Binding [Molecular Function]

Phrase: "to the PPAR"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
  1000   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   861   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C0752063:Peroxysome [Cell Component]
   812   C1879547:Activated [Activity]
   812   C2984308:Peroxisome [Functional Concept]
   779 E C1515877:Activate [Functional Concept]
   741 E C3546463:peroxisomal [Cell Component]

Phrase: "--"

Phrase: "responsive DNA elements"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0013879:Elements [Element, Ion, or Isotope]
   793 E C1705248:Element [Conceptual Entity]

Phrase: "was"

Phrase: "observed in transient transfection assays"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   760   C0040669:Transfection [Genetic Function,Molecular Biology Research Technique]
   760   C0040704:Transient [Population Group]
   760   C0205374:Transient [Temporal Concept]
   760   C1441672:Observed [Functional Concept]
   726   C0005507:Assay [Laboratory Procedure]
   726   C0243073:assay [Qualitative Concept]
   726   C1510438:Assay [Laboratory Procedure]

Phrase: "(11,"

Phrase: "49"

Phrase: ")."
Processing 00000000.tx.93: Moreover, reduced transcription of specific genes (lipoprotein lipase and acyl-CoA oxidase) was reported for cells overexpressing the Ala variant compared with cells overexpressing the wild-type protein (11). 

Phrase: "Moreover,"

Phrase: "reduced transcription of specific genes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   797   C0040649:genes transcription [Genetic Function]
           Transcription

Phrase: "(lipoprotein lipase"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0023816:LIPOPROTEIN LIPASE [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1416902:LIPOPROTEIN LIPASE [Gene or Genome]
   861   C0023764:Lipase [Amino Acid, Peptide, or Protein,Enzyme,Pharmacologic Substance]
   861   C0023820:Lipoprotein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "and"

Phrase: "acyl-CoA oxidase"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0050690:acyl-CoA oxidase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1412128:ACYL-CoA OXIDASE [Gene or Genome]
  1000   C2984960:Acyl CoA Oxidase [Laboratory Procedure]
   901   C0001374:Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]
   827   C0242417:Oxidase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: ")"

Phrase: "was"

Phrase: "reported for cells"
Meta Candidates (Total=9; Excluded=4; Pruned=0; Remaining=5)
   790   C0007634:Cells [Cell]
   790   C0684224:Reported [Intellectual Product]
   790   C0700287:Reported [Health Care Activity]
   790   C3282337:Cells [Cell]
   790   C3496591:Reported [Clinical Attribute]
   756 E C1269647:Cell [Cell]
   756 E C1704653:Cell [Medical Device]
   756 E C1948049:Cell [Spatial Concept]
   756 E C3273238:Report [Intellectual Product]

Phrase: "overexpressing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1514559:overexpress [Genetic Function]

Phrase: "the Ala variant"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0205419:Variant [Qualitative Concept]

Phrase: "compared with cells"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   790   C0007634:Cells [Cell]
   790   C1707455:Compared [Activity]
   790   C3282337:Cells [Cell]
   756 E C1269647:Cell [Cell]
   756 E C1704653:Cell [Medical Device]
   756 E C1948049:Cell [Spatial Concept]

Phrase: "overexpressing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1514559:overexpress [Genetic Function]

Phrase: "the wild-type protein"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   734   C1883559:Wild Type [Organism Attribute]

Phrase: "(11"

Phrase: ")."
Processing 00000000.tx.94: These studies clearly indicate reduced transcriptional activity of PPAR- as a result of the Pro-to-Ala exchange. 

Phrase: "These studies clearly"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0947630:studies [Laboratory Procedure]
   827 E C0557651:Study [Manufactured Object]
   827 E C2603343:Study [Research Activity]

Phrase: "indicate"

Phrase: "reduced transcriptional activity of PPAR-"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   855   C2266880:Peroxisome Proliferator-activated Receptor Activity [Molecular Function]
   767   C0086439:Reduced Activity [Sign or Symptom]
   767   C1152633:receptor activity [Molecular Function]
   744   C0205177:Activity [Functional Concept]
   744   C0439167:% activity [Quantitative Concept]
   744   C0441655:Activity [Activity]
   744   C1561536:*Activity [Idea or Concept]

Phrase: "as"

Phrase: "a result of the Pro-to-Ala exchange."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   744   C1274040:Result [Functional Concept]
   744   C1546471:Result [Idea or Concept]
   744   C2825142:Result [Finding]
Processing 00000000.tx.95: Because PPAR-2 is exclusively expressed in fat cells, any metabolic effects of the polymorphism, including those on glucose homeostasis, are likely to be secondary to alterations in adipose tissue. 

Phrase: "Because"

Phrase: "PPAR-2"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   937   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   937   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   840   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   804   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   804   C0752063:Peroxysome [Cell Component]
   804   C1879547:Activated [Activity]
   804   C2984308:Peroxisome [Functional Concept]
   771 E C1515877:Activate [Functional Concept]
   733 E C3546463:peroxisomal [Cell Component]

Phrase: "is"

Phrase: "exclusively"

Phrase: "expressed in fat cells,"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   833   C0206131:Fat Cells [Cell]
   770   C0007634:Cells [Cell]
   770   C0424612:FAT [Organism Attribute]
   770   C3282337:Cells [Cell]
   737 E C1269647:Cell [Cell]
   737 E C1704653:Cell [Medical Device]
   737 E C1948049:Cell [Spatial Concept]

Phrase: "any metabolic effects of the polymorphism,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   790   C2945675:metabolic effects [Physiologic Function]
   753   C1280500:effects [Qualitative Concept]
   719 E C2348382:Effect [Qualitative Concept]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "those on glucose homeostasis,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   833   C1326961:glucose homeostasis [Physiologic Function]
   770   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   770   C0019868:Homeostasis [Biologic Function]

Phrase: "are"

Phrase: "likely to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0332148:Likely [Qualitative Concept]
   861   C0750492:Likely [Idea or Concept]

Phrase: "be"

Phrase: "secondary to alterations"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   882   C0175668:Secondary to [Temporal Concept]
           Secondary
   790   C0027627:secondary [Neoplastic Process]
   790   C0205436:Secondary [Quantitative Concept]

Phrase: "in adipose tissue."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0001527:Adipose tissue [Tissue]
   861   C0040300:Tissue [Tissue]
   861   C1547928:Tissue [Intellectual Product]
   789   C0028754:Adiposity [Disease or Syndrome]
   789   C1563743:adiposity [Organism Attribute]
Processing 00000000.tx.96: There is evidence from humans that the Pro12Ala polymorphism promotes the suppression of FFA release by insulin (32,33). 

Phrase: "There"

Phrase: "is"

Phrase: "evidence from humans"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0332120:Evidence [Functional Concept]

Phrase: "that"

Phrase: "the Pro12Ala polymorphism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0032529:Polymorphism [Genetic Function]
   861   C1882417:Polymorphism [Qualitative Concept]

Phrase: "promotes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033414:Promote [Activity]

Phrase: "the suppression of FFA release"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0221103:Suppression [Pathologic Function]
   748   C0301625:Suppression [Organism Function]
   748   C0439181:% suppression [Quantitative Concept]
   748   C0728721:suppression [Mental Process]

Phrase: "by insulin"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1579433:Insulin [Pharmacologic Substance]
   944 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   916 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "(32,"

Phrase: "33"

Phrase: ")."
Processing 00000000.tx.97: It is unclear, however, which genes are specifically affected by the transcriptional changes conferred by the polymorphism. 

Phrase: "It"

Phrase: "is"

Phrase: "unclear, however,"

Phrase: "which genes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017337:Genes [Gene or Genome]

Phrase: "are"

Phrase: "specifically"

Phrase: "affected by the transcriptional changes"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   760   C0040649:Transcriptional [Genetic Function]
   760   C0392747:changes [Functional Concept]
   760   C0392760:Affected [Functional Concept]
   760   C0443172:changes [Quantitative Concept]
   760   C1314939:Affected [Functional Concept]
   726 E C0001721:Affect [Mental Process]
   726 E C1705241:Change [Quantitative Concept]

Phrase: "conferred by the polymorphism."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0032529:Polymorphism [Genetic Function]
   770   C1882417:Polymorphism [Qualitative Concept]
Processing 00000000.tx.98: Conceivably, the proportion of large versus small adipocytes is involved. 

Phrase: "Conceivably,"

Phrase: "the proportion of large"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1709707:Proportion [Quantitative Concept]

Phrase: "versus"

Phrase: "small adipocytes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0206131:Adipocytes [Cell]

Phrase: "is"

Phrase: "involved."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1314939:Involved [Functional Concept]
Processing 00000000.tx.99: Activators of PPAR- have been shown to promote differentiation of preadipocytes to small adipocytes (50), and in small adipocytes lipolysis is more insulin sensitive than in large adipocytes (51). 

Phrase: "Activators of PPAR-"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   716   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   716   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "have"

Phrase: "been"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "promote"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033414:Promote [Activity]

Phrase: "differentiation of preadipocytes"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   790   C0007589:Differentiation [Cell Function]
   790   C1511938:Differentiation [Clinical Attribute]
   790   C2945687:Differentiation [Functional Concept]
   718 E C0205615:Differentiated [Qualitative Concept]

Phrase: "to small adipocytes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0206131:Adipocytes [Cell]

Phrase: "(50"

Phrase: ")"

Phrase: ","

Phrase: "and in small adipocytes lipolysis"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0023796:Lipolysis [Organism Function]
   760   C0206131:Adipocytes [Cell]
   760   C0700321:Small [Quantitative Concept]
   760   C1515981:And [Idea or Concept]

Phrase: "is"

Phrase: "more insulin sensitive than"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   770   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   770   C0332324:Sensitive [Functional Concept]
   770   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   770   C1550474:sensitive [Idea or Concept]
   770   C1579433:Insulin [Pharmacologic Substance]
   750   C0920563:Insulin Sensitivity [Pathologic Function]
   715 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]

Phrase: "in large adipocytes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0206131:Adipocytes [Cell]

Phrase: "(51"

Phrase: ")."
Processing 00000000.tx.100: In addition, alterations in fat distribution (more subcutaneous and less visceral [52]) as a result of the polymorphism could mediate effects on lipolysis. 

Phrase: "In addition,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1883712:Addition [Functional Concept]
   928 E C1524062:Additional [Functional Concept]

Phrase: "alterations in fat distribution"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   737   C1515926:Alteration [Idea or Concept]

Phrase: "(more subcutaneous"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0443315:subcutaneous [Spatial Concept]

Phrase: "and"

Phrase: "less visceral"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0442045:Visceral [Spatial Concept]

Phrase: "[52"

Phrase: "]"

Phrase: ")"

Phrase: "as a result"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1274040:Result [Functional Concept]
  1000   C1546471:Result [Idea or Concept]
  1000   C2825142:Result [Finding]

Phrase: "of the polymorphism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0032529:Polymorphism [Genetic Function]
  1000   C1882417:Polymorphism [Qualitative Concept]

Phrase: "could"

Phrase: "mediate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0086597:Mediate [Social Behavior]

Phrase: "effects on lipolysis."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   790   C1280500:effects [Qualitative Concept]
   756 E C2348382:Effect [Qualitative Concept]
Processing 00000000.tx.101: In humans, PPAR- expression in visceral adipose tissue relative to subcutaneous adipose tissue is increased in obese subjects (53). 

Phrase: "In humans,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0086418:Humans [Human]

Phrase: "PPAR- expression in visceral adipose tissue"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   764   C0597360:receptor expression [Genetic Function]
   742   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "relative to subcutaneous adipose tissue"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0080103:Relative [Family Group]
   760   C0205345:Relative [Qualitative Concept]
   760   C1547039:*Relative [Quantitative Concept]

Phrase: "is"

Phrase: "increased in obese subjects"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   770   C0028754:Obese [Disease or Syndrome]
   770   C0205217:Increased [Quantitative Concept]
   770   C0442805:Increased [Functional Concept]
   737   C0681850:Subject [Group]
   737   C1550501:{Subject} [Idea or Concept]
   737   C1706203:Subject [Idea or Concept]
   737   C2349001:Subject [Human]
   737   C2697811:Subject [Functional Concept]

Phrase: "(53"

Phrase: ")."
Processing 00000000.tx.102: Because visceral adipose tissue is metabolically more harmful (54), the Ala allele would be expected to have an even greater impact in obese subjects, as in fact was shown to be the case (30). 

Phrase: "Because"

Phrase: "visceral adipose tissue"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C1563740:Visceral Adipose Tissue [Tissue]
   901   C0001527:Adipose tissue [Tissue]
   827   C0040300:Tissue [Tissue]
   827   C0442045:Visceral [Spatial Concept]
   827   C1547928:Tissue [Intellectual Product]
   755   C0028754:Adiposity [Disease or Syndrome]
   755   C1563743:adiposity [Organism Attribute]

Phrase: "is"

Phrase: "metabolically more harmful"

Phrase: "(54"

Phrase: ")"

Phrase: ","

Phrase: "the Ala allele"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0002085:Allele [Gene or Genome]

Phrase: "would"

Phrase: "be"

Phrase: "expected"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1517001:Expected [Idea or Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "have"

Phrase: "an even greater impact in obese subjects,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1825598:IMPACT [Gene or Genome]

Phrase: "as in fact"

Phrase: "was"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "the case"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0868928:Case [Functional Concept]
  1000   C1706255:CASE [Medical Device]
  1000   C1706256:Case [Conceptual Entity]

Phrase: "(30"

Phrase: ")."
Processing 00000000.tx.103: Interestingly, heterozygous PPAR--deficient transgenic mice had smaller adipocytes and greater insulin sensitivity than wild-type mice (45). 

Phrase: "Interestingly,"

Phrase: "heterozygous PPAR"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   937   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   937   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   840   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   804   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   804   C0752063:Peroxysome [Cell Component]
   804   C1879547:Activated [Activity]
   804   C2984308:Peroxisome [Functional Concept]
   771 E C1515877:Activate [Functional Concept]
   733 E C3546463:peroxisomal [Cell Component]

Phrase: "--"

Phrase: "deficient transgenic mice"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C0025936:Mice, Transgenic [Mammal]
   827   C0003069:Transgenic [Animal]
   827   C0025914:Mice [Mammal]
   827   C0025929:mice [Mammal]
   827   C0026809:Mice [Mammal]

Phrase: "had"

Phrase: "smaller adipocytes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0206131:Adipocytes [Cell]

Phrase: "and"

Phrase: "greater insulin sensitivity than wild-type mice"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   778   C0920563:Insulin Sensitivity [Pathologic Function]
   774   C0457592:Insulin type [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   748   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   748   C0036667:Sensitivity [Quantitative Concept]
   748   C0312418:Sensitivity [Mental Process]
   748   C0427965:Sensitivity [Finding]
   748   C1511883:Sensitivity [Quantitative Concept]
   748   C1522640:Sensitivity [Qualitative Concept]
   748   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   748   C1579433:Insulin [Pharmacologic Substance]
   748   C2346484:SENSITIVITY [Phenomenon or Process]
   748   C2349185:Sensitivity [Qualitative Concept]

Phrase: "(45"

Phrase: ")."
Processing 00000000.tx.104: These mice were also characterized by greater insulin sensitivity of both glucose disposal and suppression of glucose production (45,55). 

Phrase: "These mice"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0025914:Mice [Mammal]
  1000   C0025929:mice [Mammal]
  1000   C0026809:Mice [Mammal]

Phrase: "were"

Phrase: "also"

Phrase: "characterized by greater insulin sensitivity of both glucose disposal"
Meta Candidates (Total=18; Excluded=1; Pruned=0; Remaining=17)
   764   C0920563:Insulin Sensitivity [Pathologic Function]
   762   C1719133:Glucose/Insulin [Quantitative Concept]
   742   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   742   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   742   C0036667:Sensitivity [Quantitative Concept]
   742   C0312418:Sensitivity [Mental Process]
   742   C0427965:Sensitivity [Finding]
   742   C0443228:greater [Quantitative Concept]
   742   C1511883:Sensitivity [Quantitative Concept]
   742   C1522640:Sensitivity [Qualitative Concept]
   742   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   742   C1579433:Insulin [Pharmacologic Substance]
   742   C1704243:Greater [Quantitative Concept]
   742   C1707797:Disposal [Activity]
   742   C1880022:Characterized [Activity]
   742   C2346484:SENSITIVITY [Phenomenon or Process]
   742   C2349185:Sensitivity [Qualitative Concept]
   708 E C0549177:Great [Quantitative Concept]

Phrase: "and"

Phrase: "suppression of glucose production"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0221103:Suppression [Pathologic Function]
   770   C0301625:Suppression [Organism Function]
   770   C0439181:% suppression [Quantitative Concept]
   770   C0728721:suppression [Mental Process]

Phrase: "(45,"

Phrase: "55"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450382:55 [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.105: In these studies, insulin suppression of FFA release was not determined but would represent a prime candidate for mediating the insulin effects on glucose homeostasis. 

Phrase: "In these studies,"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0947630:studies [Laboratory Procedure]
   966 E C0557651:Study [Manufactured Object]
   966 E C2603343:Study [Research Activity]

Phrase: "insulin suppression of FFA release"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0221103:Suppression [Pathologic Function]
   748   C0301625:Suppression [Organism Function]
   748   C0439181:% suppression [Quantitative Concept]
   748   C0728721:suppression [Mental Process]

Phrase: "was"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "determined"

Phrase: "but"

Phrase: "would"

Phrase: "represent"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882932:Represent [Activity]

Phrase: "a prime candidate for"

Phrase: "mediating"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0086597:Mediating [Social Behavior]

Phrase: "the insulin effects on glucose homeostasis."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   767   C1158774:glucose effect [Genetic Function]
   753   C1280500:effects [Qualitative Concept]
   719 E C2348382:Effect [Qualitative Concept]
Processing 00000000.tx.106: In addition to fatty acids, adipose tissues release a number of peptide hormones that influence insulin sensitivity. 

Phrase: "In addition to fatty acids,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0015684:Fatty Acids [Lipid]
   861   C0001128:Acids [Chemical]
   827 E C0202406:Acid [Laboratory Procedure]

Phrase: "adipose tissues"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0001527:Adipose tissues [Tissue]
   861   C0040300:Tissues [Tissue]
   827 E C1547928:Tissue [Intellectual Product]
   789   C0028754:Adiposity [Disease or Syndrome]
   789   C1563743:adiposity [Organism Attribute]

Phrase: "release"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0030685:Release [Health Care Activity]
  1000   C0391871:Release [Functional Concept]
  1000   C0439180:% release [Quantitative Concept]
  1000   C0680255:release [Health Care Activity]
  1000   C1283071:Release [Functional Concept]
  1000   C1963578:Release [Therapeutic or Preventive Procedure]

Phrase: "a number of peptide hormones"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0237753:*Number [Quantitative Concept]
   760   C0449788:Number [Quantitative Concept]

Phrase: "that"

Phrase: "influence"

Phrase: "insulin sensitivity."
Meta Candidates (Total=15; Excluded=4; Pruned=0; Remaining=11)
  1000   C0920563:Insulin Sensitivity [Pathologic Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036667:Sensitivity [Quantitative Concept]
   861   C0312418:Sensitivity [Mental Process]
   861   C0427965:Sensitivity [Finding]
   861   C1511883:Sensitivity [Quantitative Concept]
   861   C1522640:Sensitivity [Qualitative Concept]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   861   C2346484:SENSITIVITY [Phenomenon or Process]
   861   C2349185:Sensitivity [Qualitative Concept]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   789 E C0332324:Sensitive [Functional Concept]
   789 E C1550474:sensitive [Idea or Concept]
   777 E C3537244:Insulins [Pharmacologic Substance]
Processing 00000000.tx.107: These include the cytokine tumor necrosis factor- (TNF-) (56), resistin (57), and adiponectin (apM-1) (58). 

Phrase: "These"

Phrase: "include"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0332257:include [Functional Concept]
  1000   C1552866:include [Idea or Concept]
  1000   C2700399:Include [Activity]

Phrase: "the cytokine tumor necrosis factor-"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   923   C0041368:tumor necrosis factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   923   C1323304:tumor necrosis factor [Molecular Function]
   923   C1456820:Tumour necrosis factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0333516:Tumor necrosis [Neoplastic Process]
   812   C0027540:Necrosis [Organ or Tissue Function]
   812   C0027651:Tumor [Neoplastic Process]
   812   C1334928:Necrosis [Finding]
   812   C1521761:Factor [Functional Concept]
   812   C1578706:Tumor [Intellectual Product]
   812   C2827422:Factor [Conceptual Entity]
   812   C3273930:Tumor [Finding]

Phrase: "(56"

Phrase: ")"

Phrase: ","

Phrase: "resistin"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0963992:resistin [Amino Acid, Peptide, or Protein,Hormone]
  1000   C1426906:RESISTIN [Gene or Genome]

Phrase: "(57"

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "adiponectin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0389071:Adiponectin [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "(apM-1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0389071:apM-1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
  1000   C2986675:APM-1 [Gene or Genome]
   861   C1510837:APM [Hazardous or Poisonous Substance]

Phrase: ")"

Phrase: "(58"

Phrase: ")."
Processing 00000000.tx.108: Although the insulin desensitizing evidence for TNF- and resistin is weak for humans, adiponectin concentrations were clearly shown to be positively correlated with insulin sensitivity, even after adjusting for body fat (59), to decrease with deteriorating glucose tolerance (59), and to increase after weight reduction (60). 

Phrase: "Although"

Phrase: "the insulin desensitizing evidence for TNF-"
Meta Candidates (Total=16; Excluded=1; Pruned=0; Remaining=15)
   800   C0041368:tumor necrosis factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   800   C1323304:tumor necrosis factor [Molecular Function]
   800   C1456820:Tumour necrosis factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   770   C0333516:Tumor necrosis [Neoplastic Process]
   744   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C0027540:Necrosis [Organ or Tissue Function]
   744   C0027651:Tumor [Neoplastic Process]
   744   C0332120:Evidence [Functional Concept]
   744   C1334928:Necrosis [Finding]
   744   C1521761:Factor [Functional Concept]
   744   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C1578706:Tumor [Intellectual Product]
   744   C1579433:Insulin [Pharmacologic Substance]
   744   C2827422:Factor [Conceptual Entity]
   744   C3273930:Tumor [Finding]
   731 E C1300818:Necrotic tumor [Neoplastic Process]

Phrase: "and"

Phrase: "resistin"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0963992:resistin [Amino Acid, Peptide, or Protein,Hormone]
  1000   C1426906:RESISTIN [Gene or Genome]

Phrase: "is"

Phrase: "weak for humans,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0004093:Weak [Sign or Symptom]
   790   C1762617:Weak [Qualitative Concept]

Phrase: "adiponectin concentrations"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0086045:Concentrations [Mental Process]
   827 E C1446561:Concentration [Quantitative Concept]
   777 E C1880165:Concentrated [Biomedical or Dental Material]

Phrase: "were"

Phrase: "clearly"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "positively"

Phrase: "correlated with insulin sensitivity,"
Meta Candidates (Total=13; Excluded=1; Pruned=0; Remaining=12)
   833   C0920563:Insulin Sensitivity [Pathologic Function]
   770   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   770   C0036667:Sensitivity [Quantitative Concept]
   770   C0312418:Sensitivity [Mental Process]
   770   C0427965:Sensitivity [Finding]
   770   C1511883:Sensitivity [Quantitative Concept]
   770   C1522640:Sensitivity [Qualitative Concept]
   770   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   770   C1579433:Insulin [Pharmacologic Substance]
   770   C1707520:Correlated [Qualitative Concept]
   770   C2346484:SENSITIVITY [Phenomenon or Process]
   770   C2349185:Sensitivity [Qualitative Concept]
   715 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]

Phrase: "even after adjusting"

Phrase: "for body fat"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
  1000   C0001527:Body Fat [Tissue]
  1000   C0015665:body fat [Body Part, Organ, or Organ Component]
  1000   C0344335:Body Fat [Clinical Attribute]
   861   C0242821:body [Human]
   861   C0424612:FAT [Organism Attribute]
   861   C0460148:Body [Anatomical Structure]
   861   C1268086:Body [Anatomical Structure]
   777 E C1995017:Bodies [Cell Component]

Phrase: "(59"

Phrase: ")"

Phrase: ","

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "decrease with deteriorating glucose tolerance"
Meta Candidates (Total=11; Excluded=1; Pruned=0; Remaining=10)
   806   C0178665:Glucose tolerance [Physiologic Function]
   760   C0013220:Tolerance [Finding]
   760   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   760   C0020963:Tolerance [Pathologic Function]
   760   C0184513:deteriorating [Finding]
   760   C0220929:tolerance [Mental Process]
   760   C0231197:Tolerance [Physiologic Function]
   760   C0392756:Decrease [Qualitative Concept]
   760   C0547047:Decrease [Quantitative Concept]
   760   C1704410:Tolerance [Qualitative Concept]
   704 E C0680282:toleration [Social Behavior]

Phrase: "(59"

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "increase after weight reduction"
Meta Candidates (Total=13; Excluded=3; Pruned=0; Remaining=10)
   833   C0043096:Weight Reduction [Finding]
   819   C0043094:WEIGHT INCREASE [Finding]
   791 E C0231246:gaining weight [Sign or Symptom]
   791 E C2911647:Weight gain [Finding]
   770   C0005910:weight [Organism Attribute]
   770   C0043100:Weight [Quantitative Concept]
   770   C0301630:Reduction [Natural Phenomenon or Process]
   770   C0392756:Reduction [Qualitative Concept]
   770   C0441610:Reduction [Therapeutic or Preventive Procedure]
   770   C0442805:Increase [Functional Concept]
   770   C1305866:weight [Diagnostic Procedure]
   770   C1705104:Weight [Idea or Concept]
   715 E C1517378:Gain [Quantitative Concept]

Phrase: "(60"

Phrase: ")."
Processing 00000000.tx.109: Moreover, intravenous administration of recombinant adiponectin to rodent models of insulin resistance restored normal insulin sensitivity (61). 

Phrase: "Moreover,"

Phrase: "intravenous administration of recombinant adiponectin"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   806   C0013125:intravenous administration [Spatial Concept]
   806   C0021440:intravenous administration [Therapeutic or Preventive Procedure]
   760   C0001554:Administration [Occupational Activity]
   760   C1533734:Administration [Therapeutic or Preventive Procedure]

Phrase: "to rodent"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0035804:Rodent [Mammal]

Phrase: "models of insulin resistance"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   833   C0021655:Insulin Resistance [Pathologic Function]
   833   C2700570:INSULIN RESISTANCE [Gene or Genome]
   770   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   770   C0237834:Resistance [Mental Process]
   770   C1514892:Resistance [Physiologic Function]
   770   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   770   C1579433:Insulin [Pharmacologic Substance]
   770   C3161035:Model [Intellectual Product]
   715 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]

Phrase: "restored"

Phrase: "normal insulin sensitivity"
Meta Candidates (Total=16; Excluded=4; Pruned=0; Remaining=12)
   901   C0858301:normal insulin [Finding]
   901   C0920563:Insulin Sensitivity [Pathologic Function]
   827   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C0036667:Sensitivity [Quantitative Concept]
   827   C0312418:Sensitivity [Mental Process]
   827   C0427965:Sensitivity [Finding]
   827   C1511883:Sensitivity [Quantitative Concept]
   827   C1522640:Sensitivity [Qualitative Concept]
   827   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C1579433:Insulin [Pharmacologic Substance]
   827   C2346484:SENSITIVITY [Phenomenon or Process]
   827   C2349185:Sensitivity [Qualitative Concept]
   771 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   755 E C0332324:Sensitive [Functional Concept]
   755 E C1550474:sensitive [Idea or Concept]
   743 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "(61"

Phrase: ")."
Processing 00000000.tx.110: Because all three peptides are under transcriptional control of PPAR- (57,6264), any of them (and possibly other peptides yet to be identified) could mediate the Pro12Ala effect on insulin sensitivity (Fig. 2). 

Phrase: "Because"

Phrase: "all three peptides"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030956:Peptides [Amino Acid, Peptide, or Protein]

Phrase: "are under transcriptional control of PPAR-"
Meta Candidates (Total=16; Excluded=1; Pruned=0; Remaining=15)
   818   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   818   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   764   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   764   C1158770:Transcriptional Control [Genetic Function]
   742   C0040649:Transcriptional [Genetic Function]
   742   C0243148:control [Qualitative Concept]
   742   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   742   C0752063:Peroxysome [Cell Component]
   742   C1550141:Control [Substance]
   742   C1551058:Are [Quantitative Concept]
   742   C1879547:Activated [Activity]
   742   C1882979:Control [Conceptual Entity]
   742   C2587213:Control [Functional Concept]
   742   C2984308:Peroxisome [Functional Concept]
   742   C3274648:Control [Qualitative Concept]
   708 E C1515877:Activate [Functional Concept]

Phrase: "(57,"

Phrase: "6264"

Phrase: ")"

Phrase: ","

Phrase: "any of them"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C1552551:Any [Qualitative Concept]
   790   C3272371:ANY [Intellectual Product]

Phrase: "("

Phrase: "and"

Phrase: "possibly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2362652:Possibly [Qualitative Concept]

Phrase: "other peptides yet to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0030956:Peptides [Amino Acid, Peptide, or Protein]

Phrase: "be"

Phrase: "identified"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205396:Identified [Qualitative Concept]
  1000   C1550043:Identified [Finding]
  1000   C1551388:Identified [Functional Concept]

Phrase: ")"

Phrase: "could"

Phrase: "mediate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0086597:Mediate [Social Behavior]

Phrase: "the Pro12Ala effect on insulin sensitivity"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1280500:Effect [Qualitative Concept]
   753   C2348382:Effect [Qualitative Concept]

Phrase: "(Fig. 2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")."
Processing 00000000.tx.111: In humans, however, it has not been studied yet whether the Pro12Ala polymorphism influences systemic or local adipocytokine concentrations. 

Phrase: "In humans,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0086418:Humans [Human]

Phrase: "however,"

Phrase: "it"

Phrase: "has"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "been"

Phrase: "studied"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0557651:Study [Manufactured Object]
   966   C2603343:Study [Research Activity]

Phrase: "yet"

Phrase: "whether"

Phrase: "the Pro12Ala polymorphism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0032529:Polymorphism [Genetic Function]
   861   C1882417:Polymorphism [Qualitative Concept]

Phrase: "influences"

Phrase: "systemic"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205373:Systemic [Functional Concept]

Phrase: "or"

Phrase: "local adipocytokine concentrations."
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   827   C0086045:Concentrations [Mental Process]
   793 E C1446561:Concentration [Quantitative Concept]
   743 E C1880165:Concentrated [Biomedical or Dental Material]
Processing 00000000.tx.112: View larger version (44K): [in this window] [in a new window]  FIG. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(44K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  FIG."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.113: 2. 

Phrase: "2."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]
Processing 00000000.tx.114: Effect of the Pro12Ala polymorphism and other factors on PPAR- activity in adipocytes and release of mediators relevant for glucose homeostasis.  

Phrase: "Effect of the Pro12Ala polymorphism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1280500:Effect [Qualitative Concept]
   760   C2348382:Effect [Qualitative Concept]

Phrase: "and"

Phrase: "other factors on PPAR- activity"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   711   C1521761:Factor [Functional Concept]
   711   C2827422:Factor [Conceptual Entity]
   703   C2266880:Peroxisome Proliferator-activated Receptor Activity [Molecular Function]

Phrase: "in adipocytes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0206131:Adipocytes [Cell]

Phrase: "and"

Phrase: "release of mediators"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C0030685:Release [Health Care Activity]
   790   C0391871:Release [Functional Concept]
   790   C0439180:% release [Quantitative Concept]
   790   C0680255:release [Health Care Activity]
   790   C1283071:Release [Functional Concept]
   790   C1963578:Release [Therapeutic or Preventive Procedure]

Phrase: "relevant for glucose homeostasis."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C2347946:Relevant [Qualitative Concept]
Processing 00000000.tx.115: It has been difficult to explain why, paradoxically, both reduced transcriptional activity (due to heterozygous knockout or the Pro12Ala polymorphism) and pharmacological activation (by thiazolidinediones) of PPAR- results in improved insulin sensitivity (65). 

Phrase: "It"

Phrase: "has"

Phrase: "been"

Phrase: "difficult to"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0332218:Difficult [Qualitative Concept]
   789 E C1299586:Difficulty [Finding]

Phrase: "explain"

Phrase: "why,"

Phrase: "paradoxically,"

Phrase: "both reduced transcriptional activity"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   913   C0086439:Reduced Activity [Sign or Symptom]
   827   C0205177:Activity [Functional Concept]
   827   C0439167:% activity [Quantitative Concept]
   827   C0441655:Activity [Activity]
   827   C1561536:*Activity [Idea or Concept]

Phrase: "("

Phrase: "due to heterozygous knockout"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0560617:knock out [Injury or Poisoning]
   861   C1522225:Knock-out [Experimental Model of Disease]

Phrase: "or"

Phrase: "the Pro12Ala polymorphism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0032529:Polymorphism [Genetic Function]
   861   C1882417:Polymorphism [Qualitative Concept]

Phrase: ")"

Phrase: "and"

Phrase: "pharmacological activation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1879547:Activation [Activity]

Phrase: "("

Phrase: "by thiazolidinediones"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C1257987:Thiazolidinediones [Organic Chemical,Pharmacologic Substance]
   966 E C0289779:thiazolidinedione [Organic Chemical,Pharmacologic Substance]
   966 E C3537039:Thiazolidinedione [Pharmacologic Substance]

Phrase: ")"

Phrase: "of PPAR- results"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   771   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   771   C1274040:Result [Functional Concept]
   771   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   771   C1546471:Result [Idea or Concept]
   771   C2825142:Result [Finding]

Phrase: "in improved insulin sensitivity"
Meta Candidates (Total=15; Excluded=4; Pruned=0; Remaining=11)
   901   C0920563:Insulin Sensitivity [Pathologic Function]
   827   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C0036667:Sensitivity [Quantitative Concept]
   827   C0312418:Sensitivity [Mental Process]
   827   C0427965:Sensitivity [Finding]
   827   C1511883:Sensitivity [Quantitative Concept]
   827   C1522640:Sensitivity [Qualitative Concept]
   827   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C1579433:Insulin [Pharmacologic Substance]
   827   C2346484:SENSITIVITY [Phenomenon or Process]
   827   C2349185:Sensitivity [Qualitative Concept]
   771 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   755 E C0332324:Sensitive [Functional Concept]
   755 E C1550474:sensitive [Idea or Concept]
   743 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "(65"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450385:65 [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.116: Recent studies in heterozygous PPAR--deficient mice, however, have contributed to unraveling this problem. 

Phrase: "Recent studies in heterozygous PPAR"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   744   C0947630:studies [Laboratory Procedure]
   711 E C0557651:Study [Manufactured Object]
   711 E C2603343:Study [Research Activity]

Phrase: "--"

Phrase: "deficient mice,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0025914:Mice [Mammal]
   861   C0025929:mice [Mammal]
   861   C0026809:Mice [Mammal]

Phrase: "however,"

Phrase: "have"

Phrase: "contributed to unraveling"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   756   C1880177:Contribute [Activity]

Phrase: "this problem."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033213:Problem [Finding]
Processing 00000000.tx.117: Alterations in white adipose tissue triglycerides, hepatic triglycerides, hepatic energy consumption, and muscle energy metabolism were markedly different between the two levels of PPAR- activation (63), indicating that entirely different metabolic pathways must be mediating the insulin-sensitizing effect of supraphysiological stimulation (thiazolidinediones) and moderate reduction (heterozygous knockout or Pro12Ala) of PPAR- activity. 

Phrase: "Alterations in white adipose tissue triglycerides,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   719   C1515926:Alteration [Idea or Concept]

Phrase: "hepatic triglycerides,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0041004:Triglycerides [Biologically Active Substance,Lipid]

Phrase: "hepatic energy consumption,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0009830:Consumption [Activity]
   827   C1947907:Consumption [Physiologic Function]

Phrase: "and"

Phrase: "muscle energy metabolism"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   913   C0596984:muscle metabolism [Organ or Tissue Function]
   901   C0014272:Energy Metabolism [Physiologic Function]
   901   C1562466:Muscle Energy [Therapeutic or Preventive Procedure]
   827   C0025519:Metabolism [Organism Function]
   827   C0025520:metabolism [Functional Concept]
   827   C0424589:Energy [Finding]
   827   C0542479:Energy [Natural Phenomenon or Process]
   827   C1442080:Energy [Quantitative Concept]

Phrase: "were"

Phrase: "markedly different between the two levels of PPAR- activation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   736   C1705242:Different [Qualitative Concept]

Phrase: "(63"

Phrase: ")"

Phrase: ","

Phrase: "indicating"

Phrase: "that entirely different metabolic pathways"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C1291081:Metabolic Pathways [Functional Concept]
   812   C0311400:Metabolic [Functional Concept]
   812   C1524026:Metabolic [Cell Function]
   812   C1704259:Pathways [Molecular Function]
   812   C1705987:Pathways [Conceptual Entity]
   812   C2707259:Metabolic [Clinical Attribute]

Phrase: "must"

Phrase: "be"

Phrase: "mediating"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0086597:Mediating [Social Behavior]

Phrase: "the insulin-sensitizing effect of supraphysiological stimulation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C1280500:Effect [Qualitative Concept]
   748   C2348382:Effect [Qualitative Concept]

Phrase: "(thiazolidinediones"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C1257987:Thiazolidinediones [Organic Chemical,Pharmacologic Substance]
   966 E C0289779:thiazolidinedione [Organic Chemical,Pharmacologic Substance]
   966 E C3537039:Thiazolidinedione [Pharmacologic Substance]

Phrase: ")"

Phrase: "and"

Phrase: "moderate reduction"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0301630:Reduction [Natural Phenomenon or Process]
   861   C0392756:Reduction [Qualitative Concept]
   861   C0441610:Reduction [Therapeutic or Preventive Procedure]

Phrase: "(heterozygous knockout"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0560617:knock out [Injury or Poisoning]
   861   C1522225:Knock-out [Experimental Model of Disease]

Phrase: "or"

Phrase: "Pro12Ala"

Phrase: ")"

Phrase: "of PPAR- activity."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
  1000   C2266880:Peroxisome Proliferator-activated Receptor Activity [Molecular Function]
   840   C1152633:receptor activity [Molecular Function]
   804   C0205177:Activity [Functional Concept]
   804   C0439167:% activity [Quantitative Concept]
   804   C0441655:Activity [Activity]
   804   C1561536:*Activity [Idea or Concept]
   771   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   771   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
Processing 00000000.tx.118: Comparison with other naturally occurring variants in PPAR- may be useful for elucidating the molecular mechanisms. 

Phrase: "Comparison with other naturally occurring variants"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1707455:Comparison [Activity]

Phrase: "in PPAR-"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
  1000   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   861   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C0752063:Peroxysome [Cell Component]
   812   C1879547:Activated [Activity]
   812   C2984308:Peroxisome [Functional Concept]
   779 E C1515877:Activate [Functional Concept]
   741 E C3546463:peroxisomal [Cell Component]

Phrase: "may"

Phrase: "be"

Phrase: "useful for elucidating"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   718   C0042153:use [Functional Concept]
   718   C0457083:Use [Functional Concept]
   718   C1947944:Use [Intellectual Product]

Phrase: "the molecular mechanisms."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0441712:Mechanisms [Functional Concept]
   827 E C1706376:Mechanism [Manufactured Object]
Processing 00000000.tx.119: The Val290Met and Pro467Leu mutations drastically reduced transcriptional activity of PPAR- in a dominant-negative fashion in vitro and resulted in a severely insulin resistant though lean phenotype in vivo (9). 

Phrase: "The Val290Met"

Phrase: "and"

Phrase: "Pro467Leu mutations drastically"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0026882:Mutations [Genetic Function]
   793 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "reduced"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0392756:Reduced [Qualitative Concept]

Phrase: "transcriptional activity of PPAR-"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   879   C2266880:Peroxisome Proliferator-activated Receptor Activity [Molecular Function]
   774   C1152633:receptor activity [Molecular Function]
   748   C0205177:Activity [Functional Concept]
   748   C0439167:% activity [Quantitative Concept]
   748   C0441655:Activity [Activity]
   748   C1561536:*Activity [Idea or Concept]

Phrase: "in a dominant-negative fashion"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   734   C1512032:Dominant Negative [Cell or Molecular Dysfunction]

Phrase: "in vitro"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0021135:In Vitro [Intellectual Product]
  1000   C1533691:in vitro [Qualitative Concept]
           vitro
  1000   C2827718:In Vitro [Functional Concept]

Phrase: "and"

Phrase: "resulted in a severely insulin"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   760   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C0205082:Severely [Qualitative Concept]
   760   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C1579433:Insulin [Pharmacologic Substance]
   726   C1274040:Result [Functional Concept]
   726   C1546471:Result [Idea or Concept]
   726   C2825142:Result [Finding]
   704 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]

Phrase: "resistant"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332325:Resistant [Functional Concept]
  1000   C2827757:RESISTANT [Laboratory or Test Result]

Phrase: "though"

Phrase: "lean phenotype"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0031437:Phenotype [Organism Attribute]
   861   C1285572:Phenotype [Laboratory Procedure]

Phrase: "in vivo"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1515655:In Vivo [Spatial Concept]
           vivo

Phrase: "(9"

Phrase: ")."
Processing 00000000.tx.120: Structure-function simulations suggested that these mutations affect the orientation of helix 12 of PPAR-, which is important for the interaction with ligands and coactivators (9). 

Phrase: "Structure-function simulations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0679083:simulations [Research Activity]
   743 E C0284447:simulated [Biomedical or Dental Material]

Phrase: "suggested"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "that"

Phrase: "these mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0026882:Mutations [Genetic Function]
   966 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "affect"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001721:Affect [Mental Process]

Phrase: "the orientation of helix 12 of PPAR-,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   739   C0029266:Orientation [Mental Process]
   739   C1704322:orientation [Spatial Concept]
   739   C1704972:Orientation [Spatial Concept]
   739   C3539923:Orientation [Intellectual Product]

Phrase: "which"

Phrase: "is"

Phrase: "important for the interaction"

Phrase: "with ligands"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0023688:Ligands [Chemical]

Phrase: "and"

Phrase: "coactivators"

Phrase: "(9"

Phrase: ")."
Processing 00000000.tx.121: On the other hand, these mutations are less likely to affect ligand-independent transcriptional activity, a process strongly controlled by the NH2 terminus (66), the domain that harbors codon 12. 

Phrase: "On the"

Phrase: "other hand,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0018563:Hand [Body Part, Organ, or Organ Component]
  1000   C1281583:Hand [Body Part, Organ, or Organ Component]
  1000   C1552914:hand [Quantitative Concept]
   944 E C0024763:Manual [Intellectual Product,Manufactured Object]
   944 E C0175674:Manual [Functional Concept]

Phrase: "these mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0026882:Mutations [Genetic Function]
   966 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "are"

Phrase: "less likely to"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0332148:Likely [Qualitative Concept]
   827   C0439092:less [Intellectual Product]
   827   C0547044:Less [Qualitative Concept]
   827   C0750492:Likely [Idea or Concept]

Phrase: "affect"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001721:Affect [Mental Process]

Phrase: "ligand-independent transcriptional activity,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   812   C0205177:Activity [Functional Concept]
   812   C0439167:% activity [Quantitative Concept]
   812   C0441655:Activity [Activity]
   812   C1561536:*Activity [Idea or Concept]

Phrase: "a process strongly"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1184743:Process [Body Part, Organ, or Organ Component]
   861   C1522240:Process [Phenomenon or Process]

Phrase: "controlled by the NH2 terminus"
Meta Candidates (Total=8; Excluded=4; Pruned=0; Remaining=4)
   806   C0332298:Controlled by [Functional Concept]
   760   C0002508:NH2 [Organic Chemical]
   760   C0025033:NH2 [Hazardous or Poisonous Substance,Organic Chemical,Pharmacologic Substance]
   760   C2587213:Controlled [Functional Concept]
   726 E C0243148:control [Qualitative Concept]
   726 E C1550141:Control [Substance]
   726 E C1882979:Control [Conceptual Entity]
   726 E C3274648:Control [Qualitative Concept]

Phrase: "(66"

Phrase: ")"

Phrase: ","

Phrase: "the domain"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1880389:Domain [Functional Concept]
  1000   C1883221:Domain [Conceptual Entity]
  1000   C3541951:Domain [Intellectual Product]

Phrase: "that harbors codon 12."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0009221:Codon [Nucleotide Sequence]
   827   C1095825:Codon [Plant]
   793   C0475311:Harbor [Manufactured Object]
Processing 00000000.tx.122: Thus, the net result of an amino acid exchange that decreases transcriptional activity of PPAR- critically depends on the localization within the PPAR- molecule. 

Phrase: "Thus,"

Phrase: "the net result of an amino acid"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C1274040:Result [Functional Concept]
   748   C1546471:Result [Idea or Concept]
   748   C2825142:Result [Finding]

Phrase: "exchange"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0678640:exchange [Social Behavior]

Phrase: "that"

Phrase: "decreases"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0392756:Decrease [Qualitative Concept]
  1000   C0547047:Decrease [Quantitative Concept]

Phrase: "transcriptional activity of PPAR- critically"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   855   C2266880:Peroxisome Proliferator-activated Receptor Activity [Molecular Function]
   767   C1152633:receptor activity [Molecular Function]
   744   C0205177:Activity [Functional Concept]
   744   C0439167:% activity [Quantitative Concept]
   744   C0441655:Activity [Activity]
   744   C1561536:*Activity [Idea or Concept]

Phrase: "depends on the localization"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0475264:Localisation [Functional Concept]
   770   C0725813:depend [Medical Device]
   770   C1744691:localisation [Biologic Function]

Phrase: "within the PPAR- molecule."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   804   C0567416:Molecule [Substance]
   771   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   771   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   733 E C1521991:Molecular [Qualitative Concept]
Processing 00000000.tx.123: In support of this concept, antidiabetic properties of PPAR- antagonists (67) or PPAR- modulators (6870) have been demonstrated. 

Phrase: "In support"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0183683:Support [Medical Device]
  1000   C1521721:Support [Conceptual Entity]

Phrase: "of this concept,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0178566:concept [Idea or Concept]

Phrase: "antidiabetic properties of PPAR- antagonists"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   744   C0871161:properties [Qualitative Concept]
   744   C1292721:properties [Functional Concept]
   711 E C1882134:Property [Conceptual Entity]
   711 E C2347695:Property [Entity]

Phrase: "(67"

Phrase: ")"

Phrase: "or"

Phrase: "PPAR- modulators"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   771   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   771   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   771   C1709060:Modulator [Manufactured Object]

Phrase: "(6870"

Phrase: ")"

Phrase: "have"

Phrase: "been"

Phrase: "demonstrated."
Processing 00000000.tx.124: Finally, it is necessary to point out that the CCA-to-GCA missense mutation in PPAR- (which causes the Pro12Ala exchange) need not necessarily be the functionally relevant mutation, but rather in linkage disequilibrium with it. 

Phrase: "Finally,"

Phrase: "it"

Phrase: "is"

Phrase: "necessary to"

Phrase: "point"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1552961:Point [Quantitative Concept]
  1000   C2347617:point [Quantitative Concept]

Phrase: "out"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439787:Out [Spatial Concept]
  1000   C0849355:Out [Qualitative Concept]

Phrase: "that"

Phrase: "the CCA-to-GCA missense mutation"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   840   C0599155:Missense Mutation [Genetic Function]
   804   C0026882:Mutation [Genetic Function]
   804   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "in PPAR-"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
  1000   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   861   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C0752063:Peroxysome [Cell Component]
   812   C1879547:Activated [Activity]
   812   C2984308:Peroxisome [Functional Concept]
   779 E C1515877:Activate [Functional Concept]
   741 E C3546463:peroxisomal [Cell Component]

Phrase: "("

Phrase: "which"

Phrase: "causes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0015127:cause [Functional Concept]
  1000   C1314792:Causes [Functional Concept]
  1000   C1524003:Cause [Conceptual Entity]

Phrase: "the Pro12Ala exchange"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0678640:exchange [Social Behavior]

Phrase: ")"

Phrase: "need"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0027552:Need [Qualitative Concept]
  1000   C0686904:need [Functional Concept]

Phrase: "not necessarily"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1518422:Not [Functional Concept]

Phrase: "be"

Phrase: "the functionally relevant mutation,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0026882:Mutation [Genetic Function]
   827   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "but"

Phrase: "rather in linkage disequilibrium"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   833   C0023746:Linkage Disequilibrium [Quantitative Concept]
   770   C0023745:linkage [Molecular Function]
   770   C0281825:Disequilibrium [Finding]
   770   C0394006:Disequilibrium [Disease or Syndrome]

Phrase: "with it."
Processing 00000000.tx.125: For example, the functional mutation could reside in the promoter region of the PPAR- gene and result in reduced expression of PPAR- protein. 

Phrase: "For example,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707959:Example [Conceptual Entity]

Phrase: "the functional mutation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0026882:Mutation [Genetic Function]
   861   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "could"

Phrase: "reside in the promoter region of the PPAR- gene"
Meta Candidates (Total=16; Excluded=1; Pruned=0; Remaining=15)
   790   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   790   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   753   C0033413:Region, Promoter [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   753   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   753   C1335671:Receptor Gene [Gene or Genome]
   751   C0314621:Promoter gene [Gene or Genome]
   736   C0017337:Gene [Gene or Genome]
   736   C0017446:Region [Geographic Area]
   736   C0086860:Promoter [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   736   C0205147:Region [Spatial Concept]
   736   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   736   C0752063:Peroxysome [Cell Component]
   736   C1879547:Activated [Activity]
   736   C2982691:Reside [Activity]
   736   C2984308:Peroxisome [Functional Concept]
   703 E C1515877:Activate [Functional Concept]

Phrase: "and"

Phrase: "result in reduced expression of PPAR- protein."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   739   C1274040:Result [Functional Concept]
   739   C1546471:Result [Idea or Concept]
   739   C2825142:Result [Finding]
Processing 00000000.tx.126: The Pro12Ala polymorphism would then merely represent a genetic marker for the relevant mutation. 

Phrase: "The Pro12Ala polymorphism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0032529:Polymorphism [Genetic Function]
   861   C1882417:Polymorphism [Qualitative Concept]

Phrase: "would"

Phrase: "then merely"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1883708:Then [Temporal Concept]

Phrase: "represent"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882932:Represent [Activity]

Phrase: "a genetic marker for the relevant mutation."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   778   C0017393:Marker, Genetic [Genetic Function]
   778   C0600223:genetic marker [Laboratory Procedure]
   774   C0026882:Genetic mutation [Genetic Function]
   748   C0005516:Marker [Clinical Attribute]
   748   C0017296:GENETIC [Therapeutic or Preventive Procedure]
   748   C0314603:Genetic [Functional Concept]
Processing 00000000.tx.127: However, the demonstrated reduction in transcriptional activity argues against such a scenario (11,49). 

Phrase: "However,"

Phrase: "the demonstrated reduction in transcriptional activity"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   783   C2267000:Reduction Activity [Molecular Function]
   753   C0301630:Reduction [Natural Phenomenon or Process]
   753   C0392756:Reduction [Qualitative Concept]
   753   C0441610:Reduction [Therapeutic or Preventive Procedure]

Phrase: "argues against such"

Phrase: "a scenario"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0683579:scenario [Functional Concept]

Phrase: "(11,"

Phrase: "49"

Phrase: ")."
Processing 00000000.tx.128: In addition, a systematic screening of 70 diabetic individuals failed to reveal additional missense mutations elsewhere in the PPAR- gene or its promoter (19). 

Phrase: "In addition,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1883712:Addition [Functional Concept]
   928 E C1524062:Additional [Functional Concept]

Phrase: "a systematic screening of 70 diabetic individuals"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   748   C0220908:Screening [Health Care Activity]
   748   C0220909:screening [Functional Concept]
   748   C1698960:screening [Intellectual Product]
   748   C1710031:Screening [Diagnostic Procedure]
   748   C1710477:SCREENING [Research Activity]

Phrase: "failed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0231175:Failed [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "reveal"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0443289:reveal [Qualitative Concept]

Phrase: "additional missense mutations elsewhere in the PPAR- gene"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   756   C0599155:Mutations, Missense [Genetic Function]
   754   C0596611:gene mutations [Genetic Function]
   738   C0026882:Mutations [Genetic Function]
   704 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "or"

Phrase: "its promoter"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0086860:Promoter [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "(19"

Phrase: ")."
Processing 00000000.tx.129: All in all, a strong case exists for Pro12Ala itself being the etiologic exchange.  

Phrase: "All in all,"

Phrase: "a strong case"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0868928:Case [Functional Concept]
   861   C1706255:CASE [Medical Device]
   861   C1706256:Case [Conceptual Entity]

Phrase: "exists for Pro12Ala"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C2987476:Exist [Conceptual Entity]

Phrase: "itself"

Phrase: "being"

Phrase: "the etiologic exchange."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0678640:exchange [Social Behavior]
Processing 00000000.tx.130: SUMMARY AND CONCLUSIONS TOP ABSTRACT INTRODUCTION ASSOCIATION WITH TYPE 2... 

Phrase: "SUMMARY"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1552616:summary [Intellectual Product]
  1000   C1706244:Summary [Intellectual Product]

Phrase: "AND"

Phrase: "CONCLUSIONS TOP ABSTRACT INTRODUCTION ASSOCIATION WITH TYPE 2..."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   767   C3645563:Association type [Intellectual Product]
   744   C0004083:Association [Mental Process]
   744   C0439849:Association [Qualitative Concept]
   744   C0596306:Association [Phenomenon or Process]
   744   C0699792:association [Social Behavior]
Processing 00000000.tx.131: EFFECT ON INSULIN SENSITIVITY EFFECT ON INSULIN SECRETION EFFECT ON OBESITY CELLULAR MECHANISM SUMMARY AND CONCLUSIONS REFERENCES  The transcription factor PPAR- is a master regulator of the relationships between nutrients, susceptibility to obesity, control of peptides released from adipocytes, and insulin sensitivity. 

Phrase: "EFFECT ON INSULIN SENSITIVITY EFFECT"

Phrase: "ON INSULIN SECRETION EFFECT"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C1280500:Effect [Qualitative Concept]
   827   C2348382:Effect [Qualitative Concept]
   734   C1256369:insulin secretion [Cell Function]

Phrase: "ON OBESITY CELLULAR MECHANISM SUMMARY"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C1552616:summary [Intellectual Product]
   812   C1706244:Summary [Intellectual Product]

Phrase: "AND"

Phrase: "CONCLUSIONS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707478:Conclusions [Idea or Concept]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "The transcription factor PPAR-"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   901   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   901   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   827   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   799   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   799   C0752063:Peroxysome [Cell Component]
   799   C1879547:Activated [Activity]
   799   C2984308:Peroxisome [Functional Concept]
   766 E C1515877:Activate [Functional Concept]
   727 E C3546463:peroxisomal [Cell Component]

Phrase: "is"

Phrase: "a master regulator of the relationships"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0182953:REGULATOR [Medical Device]
   753   C1704734:Regulator [Medical Device]
   753   C1704735:Regulator [Conceptual Entity]

Phrase: "between nutrients,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0678695:Nutrients [Food]
   966 E C2347375:Nutrient [Conceptual Entity]

Phrase: "susceptibility to obesity,"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   790   C0012655:Susceptibility [Clinical Attribute]
   790   C0220898:Susceptibility [Organism Attribute]
   790   C1264642:Susceptibility [Functional Concept]
   790   C1547045:*Susceptibility [Quantitative Concept]
   718 E C0231204:Susceptible [Functional Concept]
   718 E C2827758:SUSCEPTIBLE [Laboratory or Test Result]

Phrase: "control of peptides"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   790   C0243148:control [Qualitative Concept]
   790   C1550141:Control [Substance]
   790   C1882979:Control [Conceptual Entity]
   790   C2587213:Control [Functional Concept]
   790   C3274648:Control [Qualitative Concept]

Phrase: "released from adipocytes,"
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
   790   C0206131:Adipocytes [Cell]
   790   C0391871:Released [Functional Concept]
   790   C1283071:Released [Functional Concept]
   756 E C0030685:Release [Health Care Activity]
   756 E C0439180:% release [Quantitative Concept]
   756 E C0680255:release [Health Care Activity]
   756 E C1963578:Release [Therapeutic or Preventive Procedure]

Phrase: "and"

Phrase: "insulin sensitivity."
Meta Candidates (Total=15; Excluded=4; Pruned=0; Remaining=11)
  1000   C0920563:Insulin Sensitivity [Pathologic Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036667:Sensitivity [Quantitative Concept]
   861   C0312418:Sensitivity [Mental Process]
   861   C0427965:Sensitivity [Finding]
   861   C1511883:Sensitivity [Quantitative Concept]
   861   C1522640:Sensitivity [Qualitative Concept]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   861   C2346484:SENSITIVITY [Phenomenon or Process]
   861   C2349185:Sensitivity [Qualitative Concept]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   789 E C0332324:Sensitive [Functional Concept]
   789 E C1550474:sensitive [Idea or Concept]
   777 E C3537244:Insulins [Pharmacologic Substance]
Processing 00000000.tx.132: The alanine allele of the common Pro12Ala polymorphisms in the isoform PPAR-2 is associated with a 25% reduced risk for type 2 diabetes. 

Phrase: "The alanine allele of the common Pro12Ala polymorphisms"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0002085:Allele [Gene or Genome]

Phrase: "in the isoform PPAR-2"
Meta Candidates (Total=10; Excluded=2; Pruned=0; Remaining=8)
   901   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   901   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   827   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   799   C0597298:Isoform [Amino Acid, Peptide, or Protein]
   799   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   799   C0752063:Peroxysome [Cell Component]
   799   C1879547:Activated [Activity]
   799   C2984308:Peroxisome [Functional Concept]
   766 E C1515877:Activate [Functional Concept]
   727 E C3546463:peroxisomal [Cell Component]

Phrase: "is"

Phrase: "associated with a 25% reduced risk"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   790   C0332281:Associated with [Qualitative Concept]
           Associated
   753   C0035647:Risk [Qualitative Concept]
   753   C0392756:Reduced [Qualitative Concept]
   719 E C0750490:Associate [Idea or Concept]
   719 E C1706221:Associate [Professional or Occupational Group]

Phrase: "for type 2 diabetes."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0011860:Type 2 Diabetes [Disease or Syndrome]
   913   C1320657:type diabetes [Finding]
   901   C0441730:Type 2 [Classification]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]
Processing 00000000.tx.133: It thus represents the first genetic variant with a broad impact on the risk of common type 2 diabetes. 

Phrase: "It thus"

Phrase: "represents"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882932:Represent [Activity]

Phrase: "the first genetic variant with a broad impact"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0205419:Variant [Qualitative Concept]

Phrase: "on the risk"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0035647:Risk [Qualitative Concept]

Phrase: "of common type 2 diabetes."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   923   C0011860:Type 2 Diabetes [Disease or Syndrome]
   875   C1320657:type diabetes [Finding]
   861   C0441730:Type 2 [Classification]
   812   C0011847:Diabetes [Disease or Syndrome]
   812   C0011849:Diabetes [Disease or Syndrome]
   812   C0332307:Type [Qualitative Concept]
   812   C1547052:*Type [Quantitative Concept]
Processing 00000000.tx.134: The effect of this polymorphism is probably mediated by increased insulin sensitivity, which may be secondary to more efficient suppression of FFA release from fat tissue, where the isoform PPAR-2 is exclusively expressed. 

Phrase: "The effect of this polymorphism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1280500:Effect [Qualitative Concept]
   760   C2348382:Effect [Qualitative Concept]

Phrase: "is"

Phrase: "probably"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750492:Probably [Idea or Concept]

Phrase: "mediated by increased insulin sensitivity,"
Meta Candidates (Total=19; Excluded=1; Pruned=0; Remaining=18)
   806   C0020459:increased insulin [Disease or Syndrome]
   806   C0920563:Insulin Sensitivity [Pathologic Function]
   797   C1881189:INCREASED SENSITIVITY [Phenomenon or Process]
   797   C2346484:INCREASED SENSITIVITY [Phenomenon or Process]
           SENSITIVITY
   760   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C0036667:Sensitivity [Quantitative Concept]
   760   C0086597:mediated [Social Behavior]
   760   C0127400:Mediated [Organic Chemical,Pharmacologic Substance]
   760   C0205217:Increased [Quantitative Concept]
   760   C0312418:Sensitivity [Mental Process]
   760   C0427965:Sensitivity [Finding]
   760   C0442805:Increased [Functional Concept]
   760   C1511883:Sensitivity [Quantitative Concept]
   760   C1522640:Sensitivity [Qualitative Concept]
   760   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C1579433:Insulin [Pharmacologic Substance]
   760   C2349185:Sensitivity [Qualitative Concept]
   704 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]

Phrase: "which"

Phrase: "may"

Phrase: "be"

Phrase: "secondary to more efficient suppression of FFA release"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   739   C0221103:Suppression [Pathologic Function]
   739   C0301625:Suppression [Organism Function]
   739   C0439181:% suppression [Quantitative Concept]
   739   C0728721:suppression [Mental Process]

Phrase: "from fat tissue,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0001527:Fat Tissue [Tissue]
   861   C0040300:Tissue [Tissue]
   861   C1547928:Tissue [Intellectual Product]

Phrase: "where"

Phrase: "the isoform PPAR-2"
Meta Candidates (Total=10; Excluded=2; Pruned=0; Remaining=8)
   901   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   901   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   827   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   799   C0597298:Isoform [Amino Acid, Peptide, or Protein]
   799   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   799   C0752063:Peroxysome [Cell Component]
   799   C1879547:Activated [Activity]
   799   C2984308:Peroxisome [Functional Concept]
   766 E C1515877:Activate [Functional Concept]
   727 E C3546463:peroxisomal [Cell Component]

Phrase: "is"

Phrase: "exclusively"

Phrase: "expressed."
Processing 00000000.tx.135: Modulation of expression and release of adipocytokines that influence insulin sensitivity are likely also to be involved, but this remains to be demonstrated in humans. 

Phrase: "Modulation of expression"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0443264:Modulation [Spatial Concept]

Phrase: "and"

Phrase: "release of adipocytokines"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C0030685:Release [Health Care Activity]
   790   C0391871:Release [Functional Concept]
   790   C0439180:% release [Quantitative Concept]
   790   C0680255:release [Health Care Activity]
   790   C1283071:Release [Functional Concept]
   790   C1963578:Release [Therapeutic or Preventive Procedure]

Phrase: "that"

Phrase: "influence"

Phrase: "insulin sensitivity"
Meta Candidates (Total=15; Excluded=4; Pruned=0; Remaining=11)
  1000   C0920563:Insulin Sensitivity [Pathologic Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036667:Sensitivity [Quantitative Concept]
   861   C0312418:Sensitivity [Mental Process]
   861   C0427965:Sensitivity [Finding]
   861   C1511883:Sensitivity [Quantitative Concept]
   861   C1522640:Sensitivity [Qualitative Concept]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   861   C2346484:SENSITIVITY [Phenomenon or Process]
   861   C2349185:Sensitivity [Qualitative Concept]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   789 E C0332324:Sensitive [Functional Concept]
   789 E C1550474:sensitive [Idea or Concept]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "are"

Phrase: "likely also to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0332148:Likely [Qualitative Concept]
   827   C0750492:Likely [Idea or Concept]

Phrase: "be"

Phrase: "involved"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1314939:Involved [Functional Concept]

Phrase: ","

Phrase: "but"

Phrase: "this remains to"

Phrase: "be"

Phrase: "demonstrated in humans."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0086418:Humans [Human]
Processing 00000000.tx.136: The effects on muscle, liver, and possibly other tissues ultimately influencing glucose homeostasis are secondary. 

Phrase: "The effects on muscle,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   783   C2945629:muscular effects [Organ or Tissue Function]
   770   C1280500:effects [Qualitative Concept]
   737 E C2348382:Effect [Qualitative Concept]

Phrase: "liver,"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0023884:Liver [Body Part, Organ, or Organ Component]
  1000   C0736268:LIVER [Body Part, Organ, or Organ Component]
  1000   C1278929:Liver [Body Part, Organ, or Organ Component]
  1000   C2346688:LIVER [Food]
   944 E C0205054:Hepatic [Body Location or Region]

Phrase: "and"

Phrase: "possibly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2362652:Possibly [Qualitative Concept]

Phrase: "other tissues ultimately"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0040300:Tissues [Tissue]
   827 E C1547928:Tissue [Intellectual Product]

Phrase: "influencing"

Phrase: "glucose homeostasis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1326961:glucose homeostasis [Physiologic Function]
   861   C0019868:Homeostasis [Biologic Function]

Phrase: "are"

Phrase: "secondary."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0027627:secondary [Neoplastic Process]
  1000   C0175668:Secondary [Temporal Concept]
  1000   C0205436:Secondary [Quantitative Concept]
Processing 00000000.tx.137: The underlying molecular mechanism of this polymorphism is a moderate reduction of the ligand-independent activity of PPAR-. 

Phrase: "The underlying molecular mechanism of this polymorphism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0441712:Mechanism [Functional Concept]
   748   C1706376:Mechanism [Manufactured Object]

Phrase: "is"

Phrase: "a moderate reduction of the ligand-independent activity"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   767   C2267000:Reduction Activity [Molecular Function]
   744   C0301630:Reduction [Natural Phenomenon or Process]
   744   C0392756:Reduction [Qualitative Concept]
   744   C0441610:Reduction [Therapeutic or Preventive Procedure]

Phrase: "of PPAR-."
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
  1000   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   861   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C0752063:Peroxysome [Cell Component]
   812   C1879547:Activated [Activity]
   812   C2984308:Peroxisome [Functional Concept]
   779 E C1515877:Activate [Functional Concept]
   741 E C3546463:peroxisomal [Cell Component]
Processing 00000000.tx.138: Some findings for the Pro12Ala variant differed depending on superimposition of environmental factors. 

Phrase: "Some findings for the Pro12Ala variant"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   753   C2607943:findings [Functional Concept]
   753   C2926606:Findings [Clinical Attribute]
   753   C3539655:Findings [Intellectual Product]
   719 E C0037088:Finding [Sign or Symptom]
   719 E C0243095:Finding [Finding]
   719 E C2825141:Finding [Finding]

Phrase: "differed"

Phrase: "depending on superimposition of environmental factors."
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   790   C1516998:Environmental Factors [Functional Concept]
   773 E C0686732:Environmental Factor [Qualitative Concept]
   753   C0014406:Environmental [Spatial Concept]
   753   C0429562:Superimposition [Finding]
   719   C0725813:depend [Medical Device]
   719   C1521761:Factor [Functional Concept]
   719   C2827422:Factor [Conceptual Entity]
Processing 00000000.tx.139: This clearly suggests that so-called "gene-environment interaction" may well hinge on genetic variations, such as those occurring in the transcription factor PPAR-. 

Phrase: "This clearly"

Phrase: "suggests"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that so-called ""gene-environment interaction"""
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   884   C0596609:Gene-Environment Interaction [Genetic Function]
   853   C0596610:gene interaction [Genetic Function]
   804   C0014406:Environment [Spatial Concept]
   804   C0017337:Gene [Gene or Genome]
   804   C1704675:Interaction [Functional Concept]

Phrase: "may"

Phrase: "well"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205170:Well [Qualitative Concept]
  1000   C3146287:Well [Manufactured Object]

Phrase: "hinge on genetic variations,"
Meta Candidates (Total=13; Excluded=7; Pruned=0; Remaining=6)
   833   C0042333:Variations, Genetic [Natural Phenomenon or Process]
   770   C0017296:GENETIC [Therapeutic or Preventive Procedure]
   770   C0205419:variations [Qualitative Concept]
   770   C0314603:Genetic [Functional Concept]
   770   C0457406:Hinge [Medical Device]
   770   C1706053:Hinge [Medical Device]
   715 E C0005615:Birth [Organism Function]
   715 E C0035150:Reproduction [Organism Function]
   715 E C0079946:origin [Classification]
   715 E C0439659:Origin [Temporal Concept]
   715 E C1550512:origin [Intellectual Product]
   715 E C1550722:birth [Idea or Concept]
   715 E C3245487:birth [Intellectual Product]

Phrase: "such as those occurring"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C1709305:Occur [Activity]
   966   C2745955:OCCUR [Temporal Concept]

Phrase: "in the transcription factor PPAR-."
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   901   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   901   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   827   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   799   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   799   C0752063:Peroxysome [Cell Component]
   799   C1879547:Activated [Activity]
   799   C2984308:Peroxisome [Functional Concept]
   766 E C1515877:Activate [Functional Concept]
   727 E C3546463:peroxisomal [Cell Component]
Processing 00000000.tx.140: A number of issues remain to be confirmed and further explored, including the increased vascular complications and more pronounced -cell dysfunction associated with the Ala allele once diabetes has developed. 

Phrase: "A number of issues"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0237753:*Number [Quantitative Concept]
   770   C0449788:Number [Quantitative Concept]

Phrase: "remain"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "confirmed"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0521093:confirmed [Qualitative Concept]
  1000   C0750484:Confirmed [Idea or Concept]
   966 E C1456348:Confirm [Qualitative Concept]

Phrase: "and"

Phrase: "further"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1517331:Further [Spatial Concept]
   966 E C0205108:far [Spatial Concept]

Phrase: "explored"

Phrase: ","

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "the increased vascular complications"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   827   C0009566:Complications [Pathologic Function]
   827   C1171258:complications [Pathologic Function]
   793 E C2362589:Complication [Idea or Concept]
   743 E C0231242:Complicated [Functional Concept]

Phrase: "and"

Phrase: "more"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205172:More [Functional Concept]

Phrase: "pronounced -"

Phrase: "cell dysfunction"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   861   C0031847:dysfunction [Functional Concept]
   861   C0277785:Dysfunction, NOS [Qualitative Concept]
   805 E C0231174:Malfunction [Functional Concept]
   805 E C1881681:MALFUNCTION [Phenomenon or Process]

Phrase: "associated with the Ala allele once diabetes"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   778   C0332281:Associated with [Qualitative Concept]
           Associated
   748   C0002085:Allele [Gene or Genome]
   748   C0011847:Diabetes [Disease or Syndrome]
   748   C0011849:Diabetes [Disease or Syndrome]
   714 E C0750490:Associate [Idea or Concept]
   714 E C1706221:Associate [Professional or Occupational Group]

Phrase: "has"

Phrase: "developed."
Processing 00000000.tx.141: Moreover, the likely interaction with independent modulators such as obesity, ethnicity, ratio of unsaturated to saturated fatty acids, and other common genetic polymorphisms requires further studies. 

Phrase: "Moreover,"

Phrase: "the likely interaction with independent modulators"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1704675:Interaction [Functional Concept]

Phrase: "such as obesity,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0028754:Obesity [Disease or Syndrome]
  1000   C1963185:Obesity [Finding]

Phrase: "ethnicity,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0015031:Ethnicity [Population Group]
  1000   C0243103:ethnicity [Qualitative Concept]
   928 E C0680174:ethnic [Finding]

Phrase: "ratio of unsaturated"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0456603:Ratio [Quantitative Concept]
   790   C1547037:Ratio [Intellectual Product]

Phrase: "to saturated fatty acids,"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0597423:Fatty Acids, Saturated [Biologically Active Substance,Food,Lipid]
   901   C0015684:Fatty Acids [Lipid]
   827   C0001128:Acids [Chemical]
   827   C0522534:Saturated [Phenomenon or Process]
   827   C1705188:SATURATED [Quantitative Concept]
   793 E C0202406:Acid [Laboratory Procedure]

Phrase: "and"

Phrase: "other common genetic polymorphisms"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   901   C0032529:Genetic Polymorphisms [Genetic Function]
           polymorphisms
   793 E C1882417:Polymorphism [Qualitative Concept]

Phrase: "requires"

Phrase: "further studies."
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0947630:studies [Laboratory Procedure]
   827 E C0557651:Study [Manufactured Object]
   827 E C2603343:Study [Research Activity]
Processing 00000000.tx.142: The understanding of how specific modulation of PPAR- influences metabolism in humans may accelerate the development of novel pharmacological agents useful for preventing or treating type 2 diabetes and related disorders.  

Phrase: "The understanding of how specific modulation of PPAR-"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   738   C0162340:Understanding [Mental Process]

Phrase: "influences"

Phrase: "metabolism in humans"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0025519:Metabolism [Organism Function]
   790   C0025520:metabolism [Functional Concept]

Phrase: "may"

Phrase: "accelerate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0521110:accelerate [Functional Concept]

Phrase: "the development of novel pharmacological agents"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0243107:development [Physiologic Function]
   753   C0678723:Development [Organism Function]
   753   C1527148:Development [Functional Concept]

Phrase: "useful for preventing"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   718   C0042153:use [Functional Concept]
   718   C0457083:Use [Functional Concept]
   718   C1947944:Use [Intellectual Product]

Phrase: "or"

Phrase: "treating type 2 diabetes"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   923   C0011860:Type 2 Diabetes [Disease or Syndrome]
   875   C1320657:type diabetes [Finding]
   861   C0441730:Type 2 [Classification]
   812   C0011847:Diabetes [Disease or Syndrome]
   812   C0011849:Diabetes [Disease or Syndrome]
   812   C0332307:Type [Qualitative Concept]
   812   C1547052:*Type [Quantitative Concept]

Phrase: "and"

Phrase: "related disorders."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0012634:Disorders [Disease or Syndrome]
Processing 00000000.tx.143: ACKNOWLEDGMENTS  Dr. 

Phrase: "ACKNOWLEDGMENTS  Dr."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0031831:DR [Professional or Occupational Group]
   861   C1707664:DR [Biomedical or Dental Material]
   861   C2348314:Dr. [Conceptual Entity]
   861   C3540849:DR [Idea or Concept]
Processing 00000000.tx.144: Stumvoll is currently supported by a Heisenberg Grant of the Deutsche Forschungsgemeinschaft.  

Phrase: "Stumvoll"

Phrase: "is"

Phrase: "currently"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0521116:Currently [Temporal Concept]

Phrase: "supported by a Heisenberg Grant of the Deutsche Forschungsgemeinschaft."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   742   C0018173:Grant [Quantitative Concept]
   742   C1521721:Supported [Conceptual Entity]
   742   C1548284:Grant [Idea or Concept]
   708 E C0183683:Support [Medical Device]
Processing 00000000.tx.145: FOOTNOTES  Address correspondence and reprint requests to Dr. 

Phrase: "FOOTNOTES  Address correspondence"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0282413:Correspondence [Intellectual Product]

Phrase: "and"

Phrase: "reprint"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3273171:Reprint [Intellectual Product]

Phrase: "requests to Dr."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   790   C0031831:DR [Professional or Occupational Group]
   790   C0686900:request [Functional Concept]
   790   C1272683:Request [Functional Concept]
   790   C1522634:Request [Intellectual Product]
   790   C1707664:DR [Biomedical or Dental Material]
   790   C2348314:Dr. [Conceptual Entity]
   790   C3540849:DR [Idea or Concept]
Processing 00000000.tx.146: Michael Stumvoll, Medizinische Universittsklinik, Otfried-Mller-Str. 

Phrase: "Michael Stumvoll,"

Phrase: "Medizinische Universittsklinik,"

Phrase: "Otfried-Mller-Str."
Processing 00000000.tx.147: 10, D-72076, Tbingen, Germany. 

Phrase: "10,"

Phrase: "D-"

Phrase: "72076,"

Phrase: "Tbingen,"

Phrase: "Germany."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017480:Germany [Geographic Area]
Processing 00000000.tx.148: E-mail: michael.stumvoll{at}med.uni-tuebingen.de . Received for publication 20 December 2001 and accepted in revised form 12 February 2002. 

Phrase: "E-mail"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0013849:E-Mail [Intellectual Product]
  1000   C1705961:E-mail [Intellectual Product]
   861   C0024492:Mail [Manufactured Object]
   861   C1538057:MAIL [Gene or Genome]
   861   C1547565:Mail [Idea or Concept]

Phrase: ":"

Phrase: "michael.stumvoll{at}med.uni-tuebingen.de ."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   795   C0011198:DE [Geographic Area]
   795   C0017480:DE [Geographic Area]
   795   C3541240:DE [Idea or Concept]

Phrase: "Received for publication 20 December 2001"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0034036:Publication [Intellectual Product,Manufactured Object]
   753   C0034037:Publication [Occupational Activity]
   753   C1514756:Received [Qualitative Concept]
   753   C1704324:Publication [Intellectual Product]

Phrase: "and"

Phrase: "accepted in revised form 12 February 2002."
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   748   C0348078:Form [Qualitative Concept]
   748   C0376315:Form [Manufactured Object]
   748   C1272684:Accepted [Qualitative Concept]
   748   C1522492:Form [Functional Concept]
   748   C1527075:Revised [Therapeutic or Preventive Procedure]
   748   C1548435:Accepted [Idea or Concept]
   714 E C1548601:Accept [Idea or Concept]
Processing 00000000.tx.149: FFA, free fatty acid; 

Phrase: "FFA,"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
  1000   C0015688:free fatty acid [Lipid]
  1000   C2698488:Free Fatty Acid [Laboratory Procedure]
   901   C0015684:Fatty acid [Lipid]
   827   C0001128:Acid [Chemical]
   827   C0202406:Acid [Laboratory Procedure]
   827   C0332296:free [Functional Concept]
   827   C1880497:Free [Qualitative Concept]
   827   C1996904:Free [Qualitative Concept]

Phrase: "free fatty acid"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
  1000   C0015688:free fatty acid [Lipid]
  1000   C2698488:Free Fatty Acid [Laboratory Procedure]
   901   C0015684:Fatty acid [Lipid]
   827   C0001128:Acid [Chemical]
   827   C0202406:Acid [Laboratory Procedure]
   827   C0332296:free [Functional Concept]
   827   C1880497:Free [Qualitative Concept]
   827   C1996904:Free [Qualitative Concept]

Phrase: ";"
Processing 00000000.tx.150: PPAR, peroxisome proliferator-activated receptor; 

Phrase: "PPAR,"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
  1000   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   861   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C0752063:Peroxysome [Cell Component]
   812   C1879547:Activated [Activity]
   812   C2984308:Peroxisome [Functional Concept]
   779 E C1515877:Activate [Functional Concept]
   741 E C3546463:peroxisomal [Cell Component]

Phrase: "peroxisome proliferator-activated receptor"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
  1000   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   861   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C0752063:Peroxysome [Cell Component]
   812   C1879547:Activated [Activity]
   812   C2984308:Peroxisome [Functional Concept]
   779 E C1515877:Activate [Functional Concept]
   741 E C3546463:peroxisomal [Cell Component]

Phrase: ";"
Processing 00000000.tx.151: TNF-, tumor necrosis factor-.  

Phrase: "TNF-"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
  1000   C0041368:tumor necrosis factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C1323304:tumor necrosis factor [Molecular Function]
  1000   C1456820:Tumour necrosis factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   901   C0333516:Tumor necrosis [Neoplastic Process]
   827   C0027540:Necrosis [Organ or Tissue Function]
   827   C0027651:Tumor [Neoplastic Process]
   827   C1334928:Necrosis [Finding]
   827   C1521761:Factor [Functional Concept]
   827   C1578706:Tumor [Intellectual Product]
   827   C2827422:Factor [Conceptual Entity]
   827   C3273930:Tumor [Finding]

Phrase: ","

Phrase: "tumor necrosis factor-."
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
  1000   C0041368:tumor necrosis factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C1323304:tumor necrosis factor [Molecular Function]
  1000   C1456820:Tumour necrosis factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   901   C0333516:Tumor necrosis [Neoplastic Process]
   827   C0027540:Necrosis [Organ or Tissue Function]
   827   C0027651:Tumor [Neoplastic Process]
   827   C1334928:Necrosis [Finding]
   827   C1521761:Factor [Functional Concept]
   827   C1578706:Tumor [Intellectual Product]
   827   C2827422:Factor [Conceptual Entity]
   827   C3273930:Tumor [Finding]
Processing 00000000.tx.152: REFERENCES TOP ABSTRACT INTRODUCTION ASSOCIATION WITH TYPE 2... 

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "TOP ABSTRACT INTRODUCTION ASSOCIATION WITH TYPE 2..."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   774   C3645563:Association type [Intellectual Product]
   748   C0004083:Association [Mental Process]
   748   C0439849:Association [Qualitative Concept]
   748   C0596306:Association [Phenomenon or Process]
   748   C0699792:association [Social Behavior]
Processing 00000000.tx.153: EFFECT ON INSULIN SENSITIVITY EFFECT ON INSULIN SECRETION EFFECT ON OBESITY CELLULAR MECHANISM SUMMARY AND CONCLUSIONS REFERENCES  Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. 

Phrase: "EFFECT ON INSULIN SENSITIVITY EFFECT"

Phrase: "ON INSULIN SECRETION EFFECT"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C1280500:Effect [Qualitative Concept]
   827   C2348382:Effect [Qualitative Concept]
   734   C1256369:insulin secretion [Cell Function]

Phrase: "ON OBESITY CELLULAR MECHANISM SUMMARY"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C1552616:summary [Intellectual Product]
   812   C1706244:Summary [Intellectual Product]

Phrase: "AND"

Phrase: "CONCLUSIONS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707478:Conclusions [Idea or Concept]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Desvergne B,"

Phrase: "Wahli W"

Phrase: ":"

Phrase: "Peroxisome proliferator-activated receptors"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
  1000   C0166418:Peroxisome Proliferator-Activated Receptors [Amino Acid, Peptide, or Protein,Receptor]
   988 E C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   861   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   812   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   812   C0752063:Peroxysome [Cell Component]
   812   C1879547:Activated [Activity]
   812   C2984308:Peroxisome [Functional Concept]
   779 E C1515877:Activate [Functional Concept]
   741 E C3546463:peroxisomal [Cell Component]

Phrase: ":"

Phrase: "nuclear control of metabolism."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0243148:control [Qualitative Concept]
   770   C1550141:Control [Substance]
   770   C1882979:Control [Conceptual Entity]
   770   C2587213:Control [Functional Concept]
   770   C3274648:Control [Qualitative Concept]
Processing 00000000.tx.154: Endocr Rev20 :649 688,1999[Abstract/Free FullText] Olefsky JM: Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. 

Phrase: "Endocr Rev20"

Phrase: ":"

Phrase: "649 688,"

Phrase: "1999"

Phrase: "[Abstract/Free FullText"

Phrase: "] Olefsky JM"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0022337:JM [Geographic Area]

Phrase: ":"

Phrase: "Treatment of insulin resistance"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   819   C0745343:insulin treatment [Therapeutic or Preventive Procedure]
   770   C0039798:treatment [Functional Concept]
   770   C0087111:Treatment [Therapeutic or Preventive Procedure]
   770   C1522326:Treatment [Functional Concept]
   770   C1533734:Treatment [Therapeutic or Preventive Procedure]
   770   C1705169:Treatment [Conceptual Entity]
   770   C3538994:TREATMENT [Research Activity]

Phrase: "with peroxisome proliferator-activated receptor gamma agonists."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
  1000   C2916798:Peroxisome Proliferator-activated Receptor gamma Agonists [Molecular Function]
   920   C2917405:Peroxisome Proliferator Receptor gamma Agonist [Pharmacologic Substance]
   799   C0243192:agonists [Pharmacologic Substance]
   799   C2987634:agonists [Pharmacologic Substance]
   780   C0166417:Peroxisome Proliferator-Activated Receptor gamma [Amino Acid, Peptide, or Protein,Receptor]
   780   C1335238:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA [Gene or Genome]
   734   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   734   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
Processing 00000000.tx.155: J Clin Invest106 :467 472,2000[Free FullText] Schoonjans K, Auwerx J: Thiazolidinediones: an update. 

Phrase: "J Clin Invest106"

Phrase: ":"

Phrase: "467 472,"

Phrase: "2000"

Phrase: "[Free FullText"

Phrase: "] Schoonjans K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Auwerx J"

Phrase: ":"

Phrase: "Thiazolidinediones"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C1257987:Thiazolidinediones [Organic Chemical,Pharmacologic Substance]
   966 E C0289779:thiazolidinedione [Organic Chemical,Pharmacologic Substance]
   966 E C3537039:Thiazolidinedione [Pharmacologic Substance]

Phrase: ":"

Phrase: "an update."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1519814:Update [Temporal Concept]
Processing 00000000.tx.156: Lancet355 :1008 1010,2000[Medline] Saltiel AR, Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and type II diabetes (Review). 

Phrase: "Lancet355"

Phrase: ":"

Phrase: "1008 1010,"

Phrase: "2000"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Saltiel AR,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2986463:AR+ [Finding]

Phrase: "Olefsky JM"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0022337:JM [Geographic Area]

Phrase: ":"

Phrase: "Thiazolidinediones in the treatment of insulin resistance"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   748   C1257987:Thiazolidinediones [Organic Chemical,Pharmacologic Substance]
   714 E C0289779:thiazolidinedione [Organic Chemical,Pharmacologic Substance]
   714 E C3537039:Thiazolidinedione [Pharmacologic Substance]

Phrase: "and"

Phrase: "type II diabetes"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0011860:Type 2 Diabetes [Disease or Syndrome]
   913   C1320657:type diabetes [Finding]
   901   C0441730:Type II [Classification]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]

Phrase: "(Review"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0282443:Review [Intellectual Product]
  1000   C1552617:Review [Idea or Concept]

Phrase: ")."
Processing 00000000.tx.157: Diabetes45 :1661 1669,1996[Abstract] Spiegelman BM: PPAR-gamma: adipogenic regulator and thiazolidinedione receptor (Review). 

Phrase: "Diabetes45"

Phrase: ":"

Phrase: "1661 1669,"

Phrase: "1996"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Spiegelman BM"

Phrase: ":"

Phrase: "PPAR-gamma"
Meta Candidates (Total=14; Excluded=2; Pruned=0; Remaining=12)
  1000   C0166417:Peroxisome Proliferator-Activated Receptor gamma [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1335238:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA [Gene or Genome]
   937   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   937   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   840   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   804   C0017011:Gamma [Natural Phenomenon or Process]
   804   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   804   C0752063:Peroxysome [Cell Component]
   804   C1552644:Gamma [Intellectual Product]
   804   C1879547:Activated [Activity]
   804   C2349976:Gamma [Quantitative Concept]
   804   C2984308:Peroxisome [Functional Concept]
   771 E C1515877:Activate [Functional Concept]
   733 E C3546463:peroxisomal [Cell Component]

Phrase: ":"

Phrase: "adipogenic regulator"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0182953:REGULATOR [Medical Device]
   861   C1704734:Regulator [Medical Device]
   861   C1704735:Regulator [Conceptual Entity]

Phrase: "and"

Phrase: "thiazolidinedione receptor"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0166417:Thiazolidinedione Receptor [Amino Acid, Peptide, or Protein,Receptor]
   861   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "(Review"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0282443:Review [Intellectual Product]
  1000   C1552617:Review [Idea or Concept]

Phrase: ")."
Processing 00000000.tx.158: Diabetes47 :507 514,1998[Abstract] Auwerx J: PPARgamma, the ultimate thrifty gene. 

Phrase: "Diabetes47"

Phrase: ":"

Phrase: "507 514,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0450381:507 [Intellectual Product]

Phrase: "1998"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Auwerx J"

Phrase: ":"

Phrase: "PPARgamma,"
Meta Candidates (Total=14; Excluded=2; Pruned=0; Remaining=12)
  1000   C0166417:Peroxisome Proliferator-Activated Receptor gamma [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1335238:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA [Gene or Genome]
   937   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   937   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   840   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   804   C0017011:Gamma [Natural Phenomenon or Process]
   804   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   804   C0752063:Peroxysome [Cell Component]
   804   C1552644:Gamma [Intellectual Product]
   804   C1879547:Activated [Activity]
   804   C2349976:Gamma [Quantitative Concept]
   804   C2984308:Peroxisome [Functional Concept]
   771 E C1515877:Activate [Functional Concept]
   733 E C3546463:peroxisomal [Cell Component]

Phrase: "the ultimate thrifty gene."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0017337:Gene [Gene or Genome]
Processing 00000000.tx.159: Diabetologia42 :1033 1049,1999[Medline] Beamer BA, Negri C, Yen CJ, Gavrilova O, Rumberger JM, Durcan MJ, Yarnall DP, Hawkins AL, Griffin CA, Burns DK, Roth J, Reitman M, Shuldiner AR: Chromosomal localization and partial genomic structure of the human peroxisome proliferator activated receptor-gamma (hPPAR gamma) gene. 

Phrase: "Diabetologia42"

Phrase: ":"

Phrase: "1033 1049,"

Phrase: "1999"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Beamer BA,"

Phrase: "Negri C,"

Phrase: "Yen CJ,"

Phrase: "Gavrilova O,"

Phrase: "Rumberger JM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0022337:JM [Geographic Area]

Phrase: "Durcan MJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439254:MJ [Medical Device]

Phrase: "Yarnall DP,"

Phrase: "Hawkins AL,"

Phrase: "Griffin CA,"

Phrase: "Burns"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0006434:Burn [Injury or Poisoning]
  1000   C1550619:Burn [Substance]

Phrase: "DK,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0011318:DK [Geographic Area]

Phrase: "Roth J,"

Phrase: "Reitman M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Shuldiner AR"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2986463:AR+ [Finding]

Phrase: ":"

Phrase: "Chromosomal localization"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   964   C1657114:chromosome localisation [Biologic Function]
   861   C0475264:Localisation [Functional Concept]
   861   C1744691:localisation [Biologic Function]

Phrase: "and"

Phrase: "partial genomic structure of the human peroxisome proliferator activated receptor-gamma (hPPAR gamma) gene."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   751   C1517495:Gene Structure [Gene or Genome]
   742   C0314607:Human structural gene [Gene or Genome]
   736   C0678594:Structure [Spatial Concept]
   715 E C0017366:Structural gene [Gene or Genome]
Processing 00000000.tx.160: Biochem Biophys Res Commun233 :756 759,1997[Medline] Ristow M, Muller Wieland D, Pfeiffer A, Krone W, Kahn CR: Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. 

Phrase: "Biochem Biophys Res Commun233"

Phrase: ":"

Phrase: "756 759,"

Phrase: "1997"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Ristow M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Muller Wieland D,"

Phrase: "Pfeiffer A,"

Phrase: "Krone W,"

Phrase: "Kahn CR"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0201975:Cr [Laboratory Procedure]
   861   C3539604:CR [Gene or Genome]

Phrase: ":"

Phrase: "Obesity"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0028754:Obesity [Disease or Syndrome]
  1000   C1963185:Obesity [Finding]

Phrase: "associated with a mutation"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   833   C0332281:Associated with [Qualitative Concept]
           Associated
   770   C0026882:Mutation [Genetic Function]
   770   C1705285:Mutation [Cell or Molecular Dysfunction]
   737 E C0750490:Associate [Idea or Concept]
   737 E C1706221:Associate [Professional or Occupational Group]

Phrase: "in a genetic regulator"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0182953:REGULATOR [Medical Device]
   861   C1704734:Regulator [Medical Device]
   861   C1704735:Regulator [Conceptual Entity]

Phrase: "of adipocyte differentiation."
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C1159884:adipocyte differentiation [Cell Function]
   861   C0007589:Differentiation [Cell Function]
   861   C1511938:Differentiation [Clinical Attribute]
   861   C2945687:Differentiation [Functional Concept]
   789 E C0205615:Differentiated [Qualitative Concept]
Processing 00000000.tx.161: N Engl J Med339 :953 959,1998[Abstract/Free FullText] Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, ORahilly S: Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. 

Phrase: "N Engl J Med339"

Phrase: ":"

Phrase: "953 959,"

Phrase: "1998"

Phrase: "[Abstract/Free FullText"

Phrase: "] Barroso I,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Gurnell M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Crowley VE,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0042469:VE [Geographic Area]

Phrase: "Agostini M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Schwabe JW,"

Phrase: "Soos MA,"

Phrase: "Maslen GL,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0018229:GL [Geographic Area]
   861   C1423073:GL [Gene or Genome]
   861   C1427674:GL [Gene or Genome]

Phrase: "Williams TD,"

Phrase: "Lewis H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Schafer AJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0230613:AJ [Cell Component]

Phrase: "Chatterjee VK,"

Phrase: "ORahilly S"

Phrase: ":"

Phrase: "Dominant negative mutations in human PPARgamma"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   765   C1512032:Dominant-Negative Mutation [Cell or Molecular Dysfunction]
   739   C0026882:Mutations [Genetic Function]
   706 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "associated with severe insulin resistance,"
Meta Candidates (Total=13; Excluded=3; Pruned=0; Remaining=10)
   806   C0021655:Insulin Resistance [Pathologic Function]
   806   C0332281:Associated with [Qualitative Concept]
           Associated
   806   C2700570:INSULIN RESISTANCE [Gene or Genome]
   760   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C0205082:Severe [Qualitative Concept]
   760   C0237834:Resistance [Mental Process]
   760   C1514892:Resistance [Physiologic Function]
   760   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C1579433:Insulin [Pharmacologic Substance]
   726 E C0750490:Associate [Idea or Concept]
   726 E C1706221:Associate [Professional or Occupational Group]
   704 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]

Phrase: "diabetes mellitus"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0011849:Diabetes Mellitus [Disease or Syndrome]
           Diabetes
   861   C0011847:Diabetes [Disease or Syndrome]

Phrase: "and"

Phrase: "hypertension."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0020538:Hypertension [Disease or Syndrome]
  1000   C1963138:Hypertension [Finding]
Processing 00000000.tx.162: Nature402 :880 883,1999[Medline] Valve R, Sivenius K, Miettinen R, Pihlajamaki J, Rissanen A, Deeb SS, Auwerx J, Uusitupa M, Laakso M: Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. 

Phrase: "Nature402"

Phrase: ":"

Phrase: "880 883,"

Phrase: "1999"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Valve R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Sivenius K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Miettinen R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Pihlajamaki J,"

Phrase: "Rissanen A,"

Phrase: "Deeb SS,"

Phrase: "Auwerx J,"

Phrase: "Uusitupa M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Laakso M"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: ":"

Phrase: "Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   757   C0678951:gene polymorphisms [Genetic Function]
   739   C0032529:polymorphisms [Genetic Function]
   706 E C1882417:Polymorphism [Qualitative Concept]

Phrase: "are"

Phrase: "associated with severe overweight"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   833   C0332281:Associated with [Qualitative Concept]
           Associated
   770   C0205082:Severe [Qualitative Concept]
   770   C0497406:OVER WEIGHT [Sign or Symptom]
   737 E C0750490:Associate [Idea or Concept]
   737 E C1706221:Associate [Professional or Occupational Group]

Phrase: "among obese women."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0043210:Women [Population Group]
Processing 00000000.tx.163: J Clin Endocrinol Metab84 :3708 3712,1999[Abstract/Free FullText] Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J: A Pro12Ala substitution in PPARg2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. 

Phrase: "J Clin Endocrinol Metab84"

Phrase: ":"

Phrase: "3708 3712,"

Phrase: "1999"

Phrase: "[Abstract/Free FullText"

Phrase: "] Deeb SS,"

Phrase: "Fajas L,"

Phrase: "Nemoto M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Pihlajamaki J,"

Phrase: "Mykkanen L,"

Phrase: "Kuusisto J,"

Phrase: "Laakso M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Fujimoto W,"

Phrase: "Auwerx J"

Phrase: ":"

Phrase: "A Pro12Ala substitution in PPARg2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1555721:Substitution [Idea or Concept]
   760   C1706204:Substitution [Activity]

Phrase: "associated with decreased receptor activity,"
Meta Candidates (Total=15; Excluded=3; Pruned=0; Remaining=12)
   806   C0332281:Associated with [Qualitative Concept]
           Associated
   806   C1152633:receptor activity [Molecular Function]
   797   C0086439:Decreased activity [Sign or Symptom]
   760   C0205177:Activity [Functional Concept]
   760   C0205216:Decreased [Quantitative Concept]
   760   C0392756:Decreased [Qualitative Concept]
   760   C0439167:% activity [Quantitative Concept]
   760   C0441655:Activity [Activity]
   760   C0442797:decreased [Qualitative Concept]
   760   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   760   C1561536:*Activity [Idea or Concept]
   726 E C0547047:Decrease [Quantitative Concept]
   726 E C0750490:Associate [Idea or Concept]
   726 E C1706221:Associate [Professional or Occupational Group]

Phrase: "lower"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0441994:Lower [Spatial Concept]
  1000   C1548802:Lower [Body Location or Region]
  1000   C2003888:Lower [Activity]

Phrase: "body mass index"
Meta Candidates (Total=13; Excluded=1; Pruned=0; Remaining=12)
  1000   C0005893:Body Mass Index [Diagnostic Procedure]
  1000   C1305855:Body mass index [Clinical Attribute]
   901   C0518010:body mass [Finding]
   827   C0242821:body [Human]
   827   C0460148:Body [Anatomical Structure]
   827   C0577559:Mass [Finding]
   827   C0918012:Index [Intellectual Product]
   827   C1268086:Body [Anatomical Structure]
   827   C1306372:*Mass [Quantitative Concept]
   827   C1552854:index [Idea or Concept]
   827   C1637833:% index [Quantitative Concept]
   827   C3152252:Mass [Quantitative Concept]
   743 E C1995017:Bodies [Cell Component]

Phrase: "and"

Phrase: "improved insulin sensitivity."
Meta Candidates (Total=15; Excluded=4; Pruned=0; Remaining=11)
   901   C0920563:Insulin Sensitivity [Pathologic Function]
   827   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C0036667:Sensitivity [Quantitative Concept]
   827   C0312418:Sensitivity [Mental Process]
   827   C0427965:Sensitivity [Finding]
   827   C1511883:Sensitivity [Quantitative Concept]
   827   C1522640:Sensitivity [Qualitative Concept]
   827   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C1579433:Insulin [Pharmacologic Substance]
   827   C2346484:SENSITIVITY [Phenomenon or Process]
   827   C2349185:Sensitivity [Qualitative Concept]
   771 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   755 E C0332324:Sensitive [Functional Concept]
   755 E C1550474:sensitive [Idea or Concept]
   743 E C3537244:Insulins [Pharmacologic Substance]
Processing 00000000.tx.164: Nat Genet20 :284 287,1998[Medline] Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Lebel P, Dallongeville J, Deeb S, Auwerx J, Amouyel P: A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans. 

Phrase: "Nat Genet20"

Phrase: ":"

Phrase: "284 287,"

Phrase: "1998"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Meirhaeghe A,"

Phrase: "Fajas L,"

Phrase: "Helbecque N,"

Phrase: "Cottel D,"

Phrase: "Lebel P,"

Phrase: "Dallongeville J,"

Phrase: "Deeb S,"

Phrase: "Auwerx J,"

Phrase: "Amouyel P"

Phrase: ":"

Phrase: "A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   756   C0032529:Genetic Polymorphism [Genetic Function]
           Polymorphism
   754   C0678951:gene polymorphism [Genetic Function]
   738   C0017296:GENETIC [Therapeutic or Preventive Procedure]
   738   C0314603:Genetic [Functional Concept]
   738   C1882417:Polymorphism [Qualitative Concept]

Phrase: "influences"

Phrase: "plasma leptin levels in obese humans."
Meta Candidates (Total=10; Excluded=3; Pruned=0; Remaining=7)
   767   C0544357:Human plasma [Pharmacologic Substance]
   767   C3535635:LEPTIN HUMAN [Pharmacologic Substance]
   753   C0032105:Plasma [Body Substance]
   753   C0299583:Leptin [Amino Acid, Peptide, or Protein,Hormone]
   753   C0441889:Levels [Qualitative Concept]
   753   C1416825:LEPTIN [Gene or Genome]
   753   C1550098:Plasma, NOS (not otherwise specified) [Body Substance]
   719 E C0456079:Level [Classification]
   719 E C1547707:Level [Geographic Area]
   719 E C2946261:Level [Pharmacologic Substance]
Processing 00000000.tx.165: Hum Mol Genet7 :435 440,1998[Abstract/Free FullText] Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, Burns DK, Roth J, Shuldiner AR: Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. 

Phrase: "Hum Mol Genet7"

Phrase: ":"

Phrase: "435 440,"

Phrase: "1998"

Phrase: "[Abstract/Free FullText"

Phrase: "] Yen CJ,"

Phrase: "Beamer BA,"

Phrase: "Negri C,"

Phrase: "Silver K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Brown KA,"

Phrase: "Yarnall DP,"

Phrase: "Burns"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0006434:Burn [Injury or Poisoning]
  1000   C1550619:Burn [Substance]

Phrase: "DK,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0011318:DK [Geographic Area]

Phrase: "Roth J,"

Phrase: "Shuldiner AR"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2986463:AR+ [Finding]

Phrase: ":"

Phrase: "Molecular scanning of the human peroxisome proliferator activated receptor gamma"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   739   C0034606:Scanning [Diagnostic Procedure]
   739   C0441633:Scanning [Diagnostic Procedure]

Phrase: "(hPPAR gamma"
Meta Candidates (Total=14; Excluded=2; Pruned=0; Remaining=12)
   947   C0166417:Peroxisome Proliferator-Activated Receptor gamma [Amino Acid, Peptide, or Protein,Receptor]
   947   C1335238:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA [Gene or Genome]
   901   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   901   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   827   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   799   C0017011:Gamma [Natural Phenomenon or Process]
   799   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   799   C0752063:Peroxysome [Cell Component]
   799   C1552644:Gamma [Intellectual Product]
   799   C1879547:Activated [Activity]
   799   C2349976:Gamma [Quantitative Concept]
   799   C2984308:Peroxisome [Functional Concept]
   766 E C1515877:Activate [Functional Concept]
   727 E C3546463:peroxisomal [Cell Component]

Phrase: ")"

Phrase: "gene in diabetic Caucasians"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0017337:Gene [Gene or Genome]

Phrase: ":"

Phrase: "identification of a Pro12Ala PPAR gamma 2 missense mutation."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   736   C0020792:Identification [Mental Process]
   736   C0205396:Identification [Qualitative Concept]
Processing 00000000.tx.166: Biochem Biophys Res Commun241 :270 274,1997[Medline] Vigouroux C, Fajas L, Khallouf E, Meier M, Gyapay G, Lascols O, Auwerx J, Weissenbach J, Capeau J, Magre J: Human peroxisome proliferator-activated receptor-gamma2: genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes. 

Phrase: "Biochem Biophys Res Commun241"

Phrase: ":"

Phrase: "270 274,"

Phrase: "1997"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Vigouroux C,"

Phrase: "Fajas L,"

Phrase: "Khallouf E,"

Phrase: "Meier M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Gyapay G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Lascols O,"

Phrase: "Auwerx J,"

Phrase: "Weissenbach J,"

Phrase: "Capeau J,"

Phrase: "Magre J"

Phrase: ":"

Phrase: "Human peroxisome proliferator-activated receptor-gamma2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   734   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   734   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: ":"

Phrase: "genetic mapping,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0008630:genetic mapping [Laboratory Procedure,Molecular Biology Research Technique]
   861   C1283195:Mapping [Activity]

Phrase: "identification of a variant"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0020792:Identification [Mental Process]
   770   C0205396:Identification [Qualitative Concept]

Phrase: "in the coding sequence,"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
  1000   C0079941:Coding Sequence [Gene or Genome]
   861   C0004793:Sequence [Nucleotide Sequence]
   861   C0009219:Coding [Occupational Activity]
   861   C0162326:Sequence [Nucleotide Sequence]
   861   C0162327:Sequence [Nucleotide Sequence]
   861   C1519249:Sequence [Functional Concept]
   827 E C0805701:Code [Intellectual Product]
   789 E C1548958:Sequential [Idea or Concept]
   789 E C1705294:Sequential [Qualitative Concept]

Phrase: "and"

Phrase: "exclusion as the gene"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0680251:EXCLUSION [Functional Concept]
   770   C2828389:Exclusion [Activity]

Phrase: "responsible for lipoatrophic diabetes."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1273518:Responsible [Finding]
Processing 00000000.tx.167: Diabetes47 :490 492,1998[Free FullText] Mori H, Ikegami H, Kawaguchi Y, Seino S, Yokoi N, Takeda J, Inoue I, Seino Y, Yasuda K, Hanafusa T, Yamagata K, Awata T, Kadowaki T, Hara K, Yamada N, Gotoda T, Iwasaki N, Iwamoto Y, Sanke T, Nanjo K, Oka Y, Matsutani A, Maeda E, Kasuga M: The Pro12 Ala substitution in PPAR- is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. 

Phrase: "Diabetes47"

Phrase: ":"

Phrase: "490 492,"

Phrase: "1998"

Phrase: "[Free FullText"

Phrase: "] Mori H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Ikegami H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Kawaguchi Y,"

Phrase: "Seino S,"

Phrase: "Yokoi N,"

Phrase: "Takeda J,"

Phrase: "Inoue I,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Seino Y,"

Phrase: "Yasuda K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Hanafusa T,"

Phrase: "Yamagata K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Awata T,"

Phrase: "Kadowaki T,"

Phrase: "Hara K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Yamada N,"

Phrase: "Gotoda T,"

Phrase: "Iwasaki N,"

Phrase: "Iwamoto Y,"

Phrase: "Sanke T,"

Phrase: "Nanjo K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Oka Y,"

Phrase: "Matsutani A,"

Phrase: "Maeda E,"

Phrase: "Kasuga M"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: ":"

Phrase: "The Pro12 Ala substitution in PPAR-"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   742   C1555721:Substitution [Idea or Concept]
   742   C1706204:Substitution [Activity]

Phrase: "is"

Phrase: "associated with resistance"
Meta Candidates (Total=9; Excluded=5; Pruned=0; Remaining=4)
   882   C0332281:Associated with [Qualitative Concept]
           Associated
   790   C0237834:Resistance [Mental Process]
   790   C1514892:Resistance [Physiologic Function]
   756 E C0750490:Associate [Idea or Concept]
   756 E C1706221:Associate [Professional or Occupational Group]
   718 E C0332325:Resistant [Functional Concept]
   718 E C1550464:resistent [Idea or Concept]
   718 E C2827757:RESISTANT [Laboratory or Test Result]

Phrase: "to development"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0243107:development [Physiologic Function]
  1000   C0678723:Development [Organism Function]
  1000   C1527148:Development [Functional Concept]
   928 E C0458003:Developmental [Qualitative Concept]

Phrase: "of diabetes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0011847:Diabetes [Disease or Syndrome]
  1000   C0011849:Diabetes [Disease or Syndrome]

Phrase: "in the general population"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0683971:General Population [Population Group]
   861   C0032659:Population [Quantitative Concept]
   861   C1257890:Population [Population Group]

Phrase: ":"

Phrase: "possible involvement in impairment of insulin secretion"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1314939:Involvement [Functional Concept]

Phrase: "in individuals"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0027361:Individual [Population Group]
   966   C0237401:Individual [Human]

Phrase: "with type 2 diabetes."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0011860:Type 2 Diabetes [Disease or Syndrome]
   913   C1320657:type diabetes [Finding]
   901   C0441730:Type 2 [Classification]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]
Processing 00000000.tx.168: Diabetes50 :891 894,2001[Abstract/Free FullText] Medici F, Hawa M, Pyke DA, Leslie RD: Concordance rate for type II diabetes mellitus in monozygotic twins: actuarial analysis. 

Phrase: "Diabetes50"

Phrase: ":"

Phrase: "891 894,"

Phrase: "2001"

Phrase: "[Abstract/Free FullText"

Phrase: "] Medici F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Hawa M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Pyke DA,"

Phrase: "Leslie RD"

Phrase: ":"

Phrase: "Concordance rate for type II diabetes mellitus"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0680240:concordance [Social Behavior]
   748   C0871208:Rate [Activity]
   748   C1521828:Rate [Quantitative Concept]

Phrase: "in monozygotic twins"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0041432:Monozygotic twins [Family Group]
   861   C0041427:Twins [Family Group]
   827 E C0205173:Twin [Functional Concept]

Phrase: ":"

Phrase: "actuarial analysis."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0001296:Actuarial Analysis [Occupational Activity]
   861   C0002778:Analysis [Laboratory Procedure]
   861   C0936012:Analysis [Research Activity]
   861   C1524024:analysis [Functional Concept]
Processing 00000000.tx.169: Diabetologia42 :146 150,1999[Medline] Poulsen P, Kyvik KO, Vaag A, Beck Nielsen H: Heritability of type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance-a population-based twin study. 

Phrase: "Diabetologia42"

Phrase: ":"

Phrase: "146 150,"

Phrase: "1999"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Poulsen P,"

Phrase: "Kyvik KO,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1416746:KO [Gene or Genome]
   861   C1862225:Ko [Body System]

Phrase: "Vaag A,"

Phrase: "Beck Nielsen H"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0033727:H+ [Element, Ion, or Isotope]
   827   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0441932:H+ [Classification]
   827   C0564385:/h [Quantitative Concept]

Phrase: ":"

Phrase: "Heritability of type II"

Phrase: "(non-insulin-dependent) diabetes mellitus"
Meta Candidates (Total=17; Excluded=2; Pruned=0; Remaining=15)
  1000   C0011860:Diabetes Mellitus, Non-Insulin-Dependent [Disease or Syndrome]
           Non-Insulin Dependent Diabetes
  1000   C2697407:DIABETES MELLITUS, NONINSULIN-DEPENDENT [Gene or Genome]
   937   C0011854:Diabetes Mellitus, Insulin-Dependent [Disease or Syndrome]
           Insulin Dependent Diabetes
   840   C0011849:Diabetes Mellitus [Disease or Syndrome]
           Diabetes
   804   C0011847:Diabetes [Disease or Syndrome]
   804   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   804   C0851827:Dependent [Qualitative Concept]
   804   C1518422:Non [Functional Concept]
   804   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   804   C1579433:Insulin [Pharmacologic Substance]
   804   C1701901:Dependent [Qualitative Concept]
   804   C3244310:dependent [Functional Concept]
   748 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   721 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "and"

Phrase: "abnormal glucose tolerance-"
Meta Candidates (Total=14; Excluded=2; Pruned=0; Remaining=12)
  1000   C0235401:Abnormal glucose tolerance [Finding]
   901   C0178665:Glucose tolerance [Physiologic Function]
   901   C0580546:Abnormal glucose [Finding]
   827   C0013220:Tolerance [Finding]
   827   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   827   C0020963:Tolerance [Pathologic Function]
   827   C0205161:Abnormal [Qualitative Concept]
   827   C0220929:tolerance [Mental Process]
   827   C0231197:Tolerance [Physiologic Function]
   827   C1704410:Tolerance [Qualitative Concept]
   827   C2347472:% Abnormal [Quantitative Concept]
   827   C2699333:ABNORMAL [Intellectual Product]
   771 E C0680282:toleration [Social Behavior]
   755 E C0231198:Tolerant [Functional Concept]

Phrase: "a population-based twin study."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   923   C1709599:Population Based Study [Research Activity]
   902   C0681876:Population Study [Research Activity]
   861   C0282476:twin study [Research Activity]
   861   C1096782:Twin Study [Intellectual Product]
   812   C0557651:Study [Manufactured Object]
   812   C2603343:Study [Research Activity]
Processing 00000000.tx.170: Diabetologia42 :139 145,1999[Medline] Lehtovirta M, Kaprio J, Forsblom C, Eriksson J, Tuomilehto J, Groop L: Insulin sensitivity and insulin secretion in monozygotic and dizygotic twins. 

Phrase: "Diabetologia42"

Phrase: ":"

Phrase: "139 145,"

Phrase: "1999"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Lehtovirta M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Kaprio J,"

Phrase: "Forsblom C,"

Phrase: "Eriksson J,"

Phrase: "Tuomilehto J,"

Phrase: "Groop L"

Phrase: ":"

Phrase: "Insulin sensitivity"
Meta Candidates (Total=15; Excluded=4; Pruned=0; Remaining=11)
  1000   C0920563:Insulin Sensitivity [Pathologic Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036667:Sensitivity [Quantitative Concept]
   861   C0312418:Sensitivity [Mental Process]
   861   C0427965:Sensitivity [Finding]
   861   C1511883:Sensitivity [Quantitative Concept]
   861   C1522640:Sensitivity [Qualitative Concept]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   861   C2346484:SENSITIVITY [Phenomenon or Process]
   861   C2349185:Sensitivity [Qualitative Concept]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   789 E C0332324:Sensitive [Functional Concept]
   789 E C1550474:sensitive [Idea or Concept]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "and"

Phrase: "insulin secretion in monozygotic"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   833   C1256369:insulin secretion [Cell Function]
   770   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   770   C0036536:secretion [Biologic Function]
   770   C0036537:Secretion [Body Substance]
   770   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   770   C1579433:Insulin [Pharmacologic Substance]
   715 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]

Phrase: "and"

Phrase: "dizygotic twins."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0041429:Twins, Dizygotic [Family Group]
  1000   C0220761:Dizygotic twins [Finding]
   861   C0041427:Twins [Family Group]
   827 E C0205173:Twin [Functional Concept]
Processing 00000000.tx.171: Diabetologia43 :285 293,2000[Medline] Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl M-C, Nemesh J, Lane CD, Schaffner SF, Bolk A, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES: The common PPARg Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. 

Phrase: "Diabetologia43"

Phrase: ":"

Phrase: "285 293,"

Phrase: "2000"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Altshuler D,"

Phrase: "Hirschhorn JN,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1428813:JN [Gene or Genome]

Phrase: "Klannemark M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Lindgren CM,"

Phrase: "Vohl M-C,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0441923:M+ [Intellectual Product]

Phrase: "Nemesh J,"

Phrase: "Lane CD,"

Phrase: "Schaffner SF,"

Phrase: "Bolk A,"

Phrase: "Brewer C,"

Phrase: "Tuomi T,"

Phrase: "Gaudet D,"

Phrase: "Hudson TJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0039247:TJ [Geographic Area]

Phrase: "Daly M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Groop L,"

Phrase: "Lander ES"

Phrase: ":"

Phrase: "The common PPARg Pro12Ala polymorphism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   793   C0032529:Polymorphism [Genetic Function]
   793   C1882417:Polymorphism [Qualitative Concept]

Phrase: "is"

Phrase: "associated with decreased risk of type 2 diabetes."
Meta Candidates (Total=17; Excluded=3; Pruned=0; Remaining=14)
   800   C0011860:Type 2 Diabetes [Disease or Syndrome]
   770   C0332281:Associated with [Qualitative Concept]
           Associated
   770   C0441730:Type 2 [Classification]
   767   C1171304:diabetes risk [Quantitative Concept]
   767   C1320657:Diabetes type [Finding]
   744   C0011847:Diabetes [Disease or Syndrome]
   744   C0011849:Diabetes [Disease or Syndrome]
   744   C0035647:Risk [Qualitative Concept]
   744   C0205216:Decreased [Quantitative Concept]
   744   C0332307:Type [Qualitative Concept]
   744   C0392756:Decreased [Qualitative Concept]
   744   C0442797:decreased [Qualitative Concept]
   744   C1547052:*Type [Quantitative Concept]
   711 E C0547047:Decrease [Quantitative Concept]
   711 E C0750490:Associate [Idea or Concept]
   711 E C1706221:Associate [Professional or Occupational Group]
Processing 00000000.tx.172: Nat Gen26 :76 80,2000[Medline] Douglas JA, Erdos MR, Watanabe RM, Braun A, Johnston CL, Oeth P, Mohlke KL, Valle TT, Ehnholm C, Buchanan TA, Bergman RN, Collins FS, Boehnke M, Tuomilehto J: The peroxisome proliferator-activated receptor-2 Pro12A1a variant: association with type 2 diabetes and trait differences. 

Phrase: "Nat Gen26"

Phrase: ":"

Phrase: "76 80,"

Phrase: "2000"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Douglas JA,"

Phrase: "Erdos MR,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2347167:Mr. [Conceptual Entity]

Phrase: "Watanabe RM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2951520:RM [Body Location or Region]

Phrase: "Braun A,"

Phrase: "Johnston CL,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0596019:Cl - [Element, Ion, or Isotope]

Phrase: "Oeth P,"

Phrase: "Mohlke KL,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1366480:KL [Gene or Genome]
   861   C1416656:KL [Gene or Genome]

Phrase: "Valle TT,"

Phrase: "Ehnholm C,"

Phrase: "Buchanan TA,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1506978:Ta [Immunologic Factor]
   861   C1705538:TA [Idea or Concept]

Phrase: "Bergman RN,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3540639:RN [Gene or Genome]

Phrase: "Collins FS,"

Phrase: "Boehnke M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Tuomilehto J"

Phrase: ":"

Phrase: "The peroxisome proliferator-activated receptor-2 Pro12A1a variant"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   795   C0205419:Variant [Qualitative Concept]
   710   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   710   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: ":"

Phrase: "association with type 2 diabetes"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   797   C3645563:Association type [Intellectual Product]
   760   C0004083:Association [Mental Process]
   760   C0439849:Association [Qualitative Concept]
   760   C0596306:Association [Phenomenon or Process]
   760   C0699792:association [Social Behavior]

Phrase: "and"

Phrase: "trait differences."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C1705241:*Difference [Quantitative Concept]
   827   C1705242:Difference [Qualitative Concept]
   777 E C0443199:Differential [Qualitative Concept]
Processing 00000000.tx.173: Diabetes50 :886 890,2001[Abstract/Free FullText] Clement K, Hercberg S, Passinge B, Galan P, Varroud-Vial M, Shuldiner AR, Beamer BA, Charpentier G, Guy-Grand B, Froguel P, Vaisse C: The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes. 

Phrase: "Diabetes50"

Phrase: ":"

Phrase: "886 890,"

Phrase: "2001"

Phrase: "[Abstract/Free FullText"

Phrase: "] Clement K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Hercberg S,"

Phrase: "Passinge B,"

Phrase: "Galan P,"

Phrase: "Varroud-Vial M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0441923:M+ [Intellectual Product]

Phrase: "Shuldiner AR,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2986463:AR+ [Finding]

Phrase: "Beamer BA,"

Phrase: "Charpentier G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Guy-Grand B,"

Phrase: "Froguel P,"

Phrase: "Vaisse C"

Phrase: ":"

Phrase: "The Pro115Gln"

Phrase: "and"

Phrase: "Pro12Ala PPAR gamma gene mutations in obesity"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   760   C0596611:gene mutations [Genetic Function]
   757   C1335671:Receptor Gene [Gene or Genome]
   739   C0017337:Gene [Gene or Genome]
   739   C0026882:Mutations [Genetic Function]
   706 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "and"

Phrase: "type 2 diabetes."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0011860:Type 2 Diabetes [Disease or Syndrome]
   913   C1320657:type diabetes [Finding]
   901   C0441730:Type 2 [Classification]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]
Processing 00000000.tx.174: Int J Obes Relat Metab Disord24 :391 393,2000[Medline] Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H, Hagura R, Akanuma Y, Kimura S, Ito C, Kadowaki T: The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. 

Phrase: "Int J Obes Relat Metab Disord24"

Phrase: ":"

Phrase: "391 393,"

Phrase: "2000"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Hara K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Okada T,"

Phrase: "Tobe K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Yasuda K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Mori Y,"

Phrase: "Kadowaki H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Hagura R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Akanuma Y,"

Phrase: "Kimura S,"

Phrase: "Ito C,"

Phrase: "Kadowaki T"

Phrase: ":"

Phrase: "The Pro12Ala polymorphism in PPAR gamma2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   742   C0032529:Polymorphism [Genetic Function]
   742   C1882417:Polymorphism [Qualitative Concept]

Phrase: "may"

Phrase: "confer"

Phrase: "resistance to type 2 diabetes."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0332325:Resistant to [Functional Concept]
   760   C0237834:Resistance [Mental Process]
   760   C1514892:Resistance [Physiologic Function]
Processing 00000000.tx.175: Biochem Biophys Res Commun271 :212 216,2000[Medline] Mancini FP, Vaccaro O, Sabatino L, Tufano A, Rivellese AA, Riccardi G, Colantuoni V: Pro12Ala substitution in the peroxisome proliferator-activated receptor-2 is not associated with type 2 diabetes. 

Phrase: "Biochem Biophys Res Commun271"

Phrase: ":"

Phrase: "212 216,"

Phrase: "2000"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Mancini FP,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C1419068:FP [Gene or Genome]
   861   C1419906:FP [Gene or Genome]
   861   C3541238:Fp [Amino Acid, Peptide, or Protein,Enzyme]
   861   C3541412:FP [Gene or Genome]

Phrase: "Vaccaro O,"

Phrase: "Sabatino L,"

Phrase: "Tufano A,"

Phrase: "Rivellese AA,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1235746:Aa [Plant]
   861   C1882141:aa [Qualitative Concept]

Phrase: "Riccardi G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Colantuoni V"

Phrase: ":"

Phrase: "Pro12Ala substitution in the peroxisome proliferator-activated receptor-2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   742   C1555721:Substitution [Idea or Concept]
   742   C1706204:Substitution [Activity]

Phrase: "is"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "associated with type 2 diabetes."
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
   862   C0011860:Type 2 Diabetes [Disease or Syndrome]
   806   C0332281:Associated with [Qualitative Concept]
           Associated
   806   C0441730:Type 2 [Classification]
   797   C1320657:Diabetes type [Finding]
   760   C0011847:Diabetes [Disease or Syndrome]
   760   C0011849:Diabetes [Disease or Syndrome]
   760   C0332307:Type [Qualitative Concept]
   760   C1547052:*Type [Quantitative Concept]
   726 E C0750490:Associate [Idea or Concept]
   726 E C1706221:Associate [Professional or Occupational Group]
Processing 00000000.tx.176: Diabetes48 :1466 1468,1999[Abstract] Ringel J, Engeli S, Distler A, Sharma AM: Pro12Ala missense mutation of the peroxisome proliferator activated receptor gamma and diabetes mellitus. 

Phrase: "Diabetes48"

Phrase: ":"

Phrase: "1466 1468,"

Phrase: "1999"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Ringel J,"

Phrase: "Engeli S,"

Phrase: "Distler A,"

Phrase: "Sharma"

Phrase: "AM"

Phrase: ":"

Phrase: "Pro12Ala missense mutation of the peroxisome proliferator activated receptor gamma"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0599155:Missense Mutation [Genetic Function]
   739   C0026882:Mutation [Genetic Function]
   739   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "and"

Phrase: "diabetes mellitus."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0011849:Diabetes Mellitus [Disease or Syndrome]
           Diabetes
   861   C0011847:Diabetes [Disease or Syndrome]
Processing 00000000.tx.177: Biochem Biophys Res Commun254 :450 453,1999[Medline] Bell GI, Polonsky KS: Diabetes mellitus and genetically programmed defects in beta-cell function. 

Phrase: "Biochem Biophys Res Commun254"

Phrase: ":"

Phrase: "450 453,"

Phrase: "1999"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Bell GI,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3539617:GI [Idea or Concept]

Phrase: "Polonsky KS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3541894:ks [Quantitative Concept]

Phrase: ":"

Phrase: "Diabetes mellitus"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0011849:Diabetes Mellitus [Disease or Syndrome]
           Diabetes
   861   C0011847:Diabetes [Disease or Syndrome]

Phrase: "and"

Phrase: "genetically programmed defects in beta-cell function."
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   748   C0243067:defects [Functional Concept]
   714 E C1457869:Defect [Functional Concept]
   714 E C1861101:DEFECT [Disease or Syndrome]
Processing 00000000.tx.178: Nature414 :788 791,2001[Medline] Jacob S, Stumvoll M, Becker R, Koch M, Nielsen M, Lblein K, Maerker E, Volk A, Renn W, Balletshofer B, Machicao F, Rett K, Hring HU: The PPARgamma2 polymorphism Pro12Ala is associated with better insulin sensitivity in the offspring of type 2 diabetic patients. 

Phrase: "Nature414"

Phrase: ":"

Phrase: "788 791,"

Phrase: "2001"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Jacob S,"

Phrase: "Stumvoll M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Becker R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Koch M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Nielsen M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Lblein K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Maerker E,"

Phrase: "Volk A,"

Phrase: "Renn W,"

Phrase: "Balletshofer B,"

Phrase: "Machicao F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Rett K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Hring HU"

Phrase: ":"

Phrase: "The PPARgamma2 polymorphism Pro12Ala"

Phrase: "is"

Phrase: "associated with better insulin sensitivity"
Meta Candidates (Total=17; Excluded=3; Pruned=0; Remaining=14)
   806   C0332281:Associated with [Qualitative Concept]
           Associated
   806   C0920563:Insulin Sensitivity [Pathologic Function]
   760   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C0036667:Sensitivity [Quantitative Concept]
   760   C0312418:Sensitivity [Mental Process]
   760   C0332272:Better [Qualitative Concept]
   760   C0427965:Sensitivity [Finding]
   760   C1511883:Sensitivity [Quantitative Concept]
   760   C1522640:Sensitivity [Qualitative Concept]
   760   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C1579433:Insulin [Pharmacologic Substance]
   760   C2346484:SENSITIVITY [Phenomenon or Process]
   760   C2349185:Sensitivity [Qualitative Concept]
   726 E C0750490:Associate [Idea or Concept]
   726 E C1706221:Associate [Professional or Occupational Group]
   704 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]

Phrase: "in the offspring"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0680063:Offspring [Family Group]

Phrase: "of type 2 diabetic patients."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0030705:Patients [Patient or Disabled Group]
Processing 00000000.tx.179: Horm Metab Res32 :413 416,2000[Medline] Ek J, Andersen G, Urhammer SA, Hansen L, Carstensen B, Borch-Johnson K, Drivsholm T, Berglund L, Hansen T, Lithell H, Pedersen O: Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-g2 (PPAR-g2) gene in relation to insulin sensitivity among glucose tolerant Caucasians. 

Phrase: "Horm Metab Res32"

Phrase: ":"

Phrase: "413 416,"

Phrase: "2000"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Ek J,"

Phrase: "Andersen G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Urhammer SA,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0036243:SA [Geographic Area]
   861   C1539696:SA [Gene or Genome]
   861   C1825840:SA [Gene or Genome]
   861   C3539736:Sa [Spatial Concept]

Phrase: "Hansen L,"

Phrase: "Carstensen B,"

Phrase: "Borch-Johnson K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   827   C1708601:K' [Quantitative Concept]

Phrase: "Drivsholm T,"

Phrase: "Berglund L,"

Phrase: "Hansen T,"

Phrase: "Lithell H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Pedersen O"

Phrase: ":"

Phrase: "Studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0947630:studies [Laboratory Procedure]
   966 E C0557651:Study [Manufactured Object]
   966 E C2603343:Study [Research Activity]

Phrase: "of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-g2 (PPAR-g2) gene"
Meta Candidates (Total=14; Excluded=2; Pruned=0; Remaining=12)
   827   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   827   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   807   C1335671:Receptor Gene [Gene or Genome]
   799   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   787   C0017337:Gene [Gene or Genome]
   787   C0032529:Polymorphism [Genetic Function]
   787   C0332285:Of [Spatial Concept]
   787   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   787   C0752063:Peroxysome [Cell Component]
   787   C1879547:Activated [Activity]
   787   C1882417:Polymorphism [Qualitative Concept]
   787   C2984308:Peroxisome [Functional Concept]
   754 E C1515877:Activate [Functional Concept]
   716 E C3546463:peroxisomal [Cell Component]

Phrase: "in relation to insulin sensitivity"
Meta Candidates (Total=15; Excluded=4; Pruned=0; Remaining=11)
  1000   C0920563:Insulin Sensitivity [Pathologic Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036667:Sensitivity [Quantitative Concept]
   861   C0312418:Sensitivity [Mental Process]
   861   C0427965:Sensitivity [Finding]
   861   C1511883:Sensitivity [Quantitative Concept]
   861   C1522640:Sensitivity [Qualitative Concept]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   861   C2346484:SENSITIVITY [Phenomenon or Process]
   861   C2349185:Sensitivity [Qualitative Concept]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   789 E C0332324:Sensitive [Functional Concept]
   789 E C1550474:sensitive [Idea or Concept]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "among glucose tolerant Caucasians."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0007457:Caucasians [Population Group]
   827   C0043157:Caucasians [Population Group]
Processing 00000000.tx.180: Diabetologia44 :1170 1176,2001[Medline] Chuang L-M, Hsueh W, Chen Y-DI, Ho LT, Sheu WHH, Pei D, Nakatsuka CH, Cox D, Pratley RE, Lei HH, Tai TY: Sibling-based association study of the PPARg 2 Pro12Ala polymorphism and metabolic variables in Chinese and Japanese hypertension families: a SAPPHIRr study. 

Phrase: "Diabetologia44"

Phrase: ":"

Phrase: "1170 1176,"

Phrase: "2001"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Chuang L-M, Hsueh W,"

Phrase: "Chen Y-DI,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C3538902:DI [Gene or Genome]
   827   C3541881:DI [Idea or Concept]

Phrase: "Ho LT,"

Phrase: "Sheu WHH,"

Phrase: "Pei D,"

Phrase: "Nakatsuka CH,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0558269:Ch. [Professional or Occupational Group]
   861   C1552984:[Ch] [Quantitative Concept]

Phrase: "Cox D,"

Phrase: "Pratley RE,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2986904:RE [Idea or Concept]

Phrase: "Lei HH,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0062941:HH [Organic Chemical,Pharmacologic Substance]
   861   C1384665:HH [Gene or Genome]
   861   C1414862:Hh [Gene or Genome]

Phrase: "Tai TY"

Phrase: ":"

Phrase: "Sibling-based association study"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0557651:Study [Manufactured Object]
   812   C2603343:Study [Research Activity]

Phrase: "of the PPARg 2 Pro12Ala polymorphism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   793   C0032529:Polymorphism [Genetic Function]
   793   C1882417:Polymorphism [Qualitative Concept]

Phrase: "and"

Phrase: "metabolic variables in Chinese"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0439828:variables [Qualitative Concept]

Phrase: "and"

Phrase: "Japanese hypertension families"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C0015576:Families [Family Group]
   827   C1704727:Family [Conceptual Entity]
   743 E C0241888:Familial [Functional Concept]

Phrase: ":"

Phrase: "a SAPPHIRr study."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0557651:Study [Manufactured Object]
   861   C2603343:Study [Research Activity]
Processing 00000000.tx.181: J Mol Med79 :656 664. 

Phrase: "J Mol Med79"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   734   C2346604:J/mol [Quantitative Concept]

Phrase: ":"

Phrase: "656 664."
Processing 00000000.tx.182: 2002 Stumvoll M, Stefan N, Fritsche A, Madaus A, Tschritter O, Koch M, Machicao F, Hring H: Interaction effect between common polymorphisms in PPARg2 (Pro12Ala) and IRS-1 (Gly972Arg) on insulin sensitivity. 

Phrase: "2002 Stumvoll M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0441923:M+ [Intellectual Product]

Phrase: "Stefan N,"

Phrase: "Fritsche A,"

Phrase: "Madaus"

Phrase: "A,"

Phrase: "Tschritter O,"

Phrase: "Koch M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Machicao F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Hring H"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: ":"

Phrase: "Interaction effect between common polymorphisms"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C1280500:Effect [Qualitative Concept]
   760   C1704675:Interaction [Functional Concept]
   760   C2348382:Effect [Qualitative Concept]

Phrase: "in PPARg2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0166417:PPARG2 [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1335238:PPARG2 [Gene or Genome]
  1000   C1706243:PPARG2 [Gene or Genome]

Phrase: "(Pro12Ala"

Phrase: ")"

Phrase: "and"

Phrase: "IRS-1"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0123658:IRS-1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "(Gly972Arg"

Phrase: ")"

Phrase: "on insulin sensitivity."
Meta Candidates (Total=15; Excluded=4; Pruned=0; Remaining=11)
  1000   C0920563:Insulin Sensitivity [Pathologic Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036667:Sensitivity [Quantitative Concept]
   861   C0312418:Sensitivity [Mental Process]
   861   C0427965:Sensitivity [Finding]
   861   C1511883:Sensitivity [Quantitative Concept]
   861   C1522640:Sensitivity [Qualitative Concept]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   861   C2346484:SENSITIVITY [Phenomenon or Process]
   861   C2349185:Sensitivity [Qualitative Concept]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   789 E C0332324:Sensitive [Functional Concept]
   789 E C1550474:sensitive [Idea or Concept]
   777 E C3537244:Insulins [Pharmacologic Substance]
Processing 00000000.tx.183: J Mol Med80 :33 38,2002[Medline] Koch M, Rett K, Maerker E, Volk A, Haist K, Deninger M, Renn W, Hring HU: The PPARgamma2 amino acid polymorphism Pro 12 Ala is prevalent in offspring of type II diabetic patients and is associated to increased insulin sensitivity in a subgroup of obese subjects. 

Phrase: "J Mol Med80"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   734   C2346604:J/mol [Quantitative Concept]

Phrase: ":"

Phrase: "33 38,"

Phrase: "2002"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Koch M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Rett K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Maerker E,"

Phrase: "Volk A,"

Phrase: "Haist K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Deninger M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Renn W,"

Phrase: "Hring HU"

Phrase: ":"

Phrase: "The PPARgamma2 amino acid polymorphism Pro 12 Ala"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   724   C0702172:Alar [Hazardous or Poisonous Substance,Organic Chemical]
   703 E C0043189:Wing [Body Part, Organ, or Organ Component]

Phrase: "is"

Phrase: "prevalent in offspring of type II diabetic patients"

Phrase: "and"

Phrase: "is"

Phrase: "associated to increased insulin sensitivity"
Meta Candidates (Total=21; Excluded=3; Pruned=0; Remaining=18)
   806   C0020459:increased insulin [Disease or Syndrome]
   806   C0920563:Insulin Sensitivity [Pathologic Function]
   797   C1881189:INCREASED SENSITIVITY [Phenomenon or Process]
   797   C2346484:INCREASED SENSITIVITY [Phenomenon or Process]
           SENSITIVITY
   762   C0332324:Sensitive to [Functional Concept]
   760   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C0036667:Sensitivity [Quantitative Concept]
   760   C0205217:Increased [Quantitative Concept]
   760   C0312418:Sensitivity [Mental Process]
   760   C0332281:Associated [Qualitative Concept]
   760   C0427965:Sensitivity [Finding]
   760   C0442805:Increased [Functional Concept]
   760   C1511883:Sensitivity [Quantitative Concept]
   760   C1522640:Sensitivity [Qualitative Concept]
   760   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C1579433:Insulin [Pharmacologic Substance]
   760   C2349185:Sensitivity [Qualitative Concept]
   726 E C0750490:Associate [Idea or Concept]
   726 E C1706221:Associate [Professional or Occupational Group]
   704 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]

Phrase: "in a subgroup"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1079230:subgroup [Virus]
  1000   C1515021:Subgroup [Classification]

Phrase: "of obese subjects."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   827   C0681850:Subject [Group]
   827   C1550501:{Subject} [Idea or Concept]
   827   C1706203:Subject [Idea or Concept]
   827   C2349001:Subject [Human]
   827   C2697811:Subject [Functional Concept]
Processing 00000000.tx.184: Diabetologia42 :758 762,1999[Medline] Globerman H, Zauberman Y, Makarov T, Beamer BA, Yen CJ, Shuldiner AR, Harel C, Karnieli E: Analysis of the peroxisome proliferator activated receptor gamma (PPARgamma) gene in HAIRAN syndrome with obesity. 

Phrase: "Diabetologia42"

Phrase: ":"

Phrase: "758 762,"

Phrase: "1999"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Globerman H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Zauberman Y,"

Phrase: "Makarov T,"

Phrase: "Beamer BA,"

Phrase: "Yen CJ,"

Phrase: "Shuldiner AR,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2986463:AR+ [Finding]

Phrase: "Harel C,"

Phrase: "Karnieli E"

Phrase: ":"

Phrase: "Analysis of the peroxisome proliferator activated receptor gamma (PPARgamma) gene"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   742   C0002778:Analysis [Laboratory Procedure]
   742   C0936012:Analysis [Research Activity]
   742   C1524024:analysis [Functional Concept]

Phrase: "in HAIRAN syndrome"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1963745:HAIR-AN syndrome [Disease or Syndrome]
   861   C0039082:Syndrome [Disease or Syndrome]

Phrase: "with obesity."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0028754:Obesity [Disease or Syndrome]
  1000   C1963185:Obesity [Finding]
Processing 00000000.tx.185: Clin Endocrinol (Oxf)52 :479 485,2000[Medline] Stumvoll M, Wahl HG, Lblein K, Becker R, Machicao F, Jacob S, Hring H: The Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-2 gene is associated with increased antilipolytic insulin sensitivity. 

Phrase: "Clin Endocrinol"

Phrase: "(Oxf"

Phrase: ")"

Phrase: "52"

Phrase: ":"

Phrase: "479 485,"

Phrase: "2000"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Stumvoll M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Wahl HG,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0025424:Hg [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   861   C2347108:Hg+ [Element, Ion, or Isotope]
   861   C2347109:Hg++ [Element, Ion, or Isotope]
   861   C2348272:Hg [Element, Ion, or Isotope]

Phrase: "Lblein K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Becker R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Machicao F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Jacob S,"

Phrase: "Hring H"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: ":"

Phrase: "The Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-2 gene"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   754   C0678951:gene polymorphism [Genetic Function]
   738   C0032529:Polymorphism [Genetic Function]
   738   C1882417:Polymorphism [Qualitative Concept]

Phrase: "is"

Phrase: "associated with increased antilipolytic insulin sensitivity."
Meta Candidates (Total=20; Excluded=2; Pruned=0; Remaining=18)
   790   C0332281:Associated with [Qualitative Concept]
           Associated
   790   C0920563:Insulin Sensitivity [Pathologic Function]
   783   C0020459:increased insulin [Disease or Syndrome]
   783   C1881189:INCREASED SENSITIVITY [Phenomenon or Process]
   783   C2346484:INCREASED SENSITIVITY [Phenomenon or Process]
           SENSITIVITY
   753   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   753   C0036667:Sensitivity [Quantitative Concept]
   753   C0205217:Increased [Quantitative Concept]
   753   C0312418:Sensitivity [Mental Process]
   753   C0427965:Sensitivity [Finding]
   753   C0442805:Increased [Functional Concept]
   753   C1511883:Sensitivity [Quantitative Concept]
   753   C1522640:Sensitivity [Qualitative Concept]
   753   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   753   C1579433:Insulin [Pharmacologic Substance]
   753   C2349185:Sensitivity [Qualitative Concept]
   719 E C0750490:Associate [Idea or Concept]
   719 E C1706221:Associate [Professional or Occupational Group]
Processing 00000000.tx.186: Diabetes50 :876 881,2001[Abstract/Free FullText] Stumvoll M, Hring H: Reduced lipolysis as possible cause for greater weight gain in subjects with the Pro12Ala polymorphism in PPAR2. 

Phrase: "Diabetes50"

Phrase: ":"

Phrase: "876 881,"

Phrase: "2001"

Phrase: "[Abstract/Free FullText"

Phrase: "] Stumvoll M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Hring H"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: ":"

Phrase: "Reduced lipolysis as possible cause"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0023796:Lipolysis [Organism Function]

Phrase: "for greater weight gain"
Meta Candidates (Total=15; Excluded=8; Pruned=0; Remaining=7)
   901   C0043094:Weight Gain [Finding]
   901   C2911647:Weight gain [Finding]
   859 E C0231246:weight gaining [Sign or Symptom]
   827   C0005910:weight [Organism Attribute]
   827   C0043100:Weight [Quantitative Concept]
   827   C1305866:weight [Diagnostic Procedure]
   827   C1517378:Gain [Quantitative Concept]
   827   C1705104:Weight [Idea or Concept]
   771 E C0205217:Increased [Quantitative Concept]
   771 E C0439661:Acquired [Temporal Concept]
   771 E C0442805:Increase [Functional Concept]
   771 E C0442808:Increasing [Functional Concept]
   771 E C1301820:Obtain [Functional Concept]
   771 E C1706701:Acquire [Activity]
   771 E C3245488:acquired [Intellectual Product]

Phrase: "in subjects"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   966   C0681850:Subject [Group]
   966   C1550501:{Subject} [Idea or Concept]
   966   C1706203:Subject [Idea or Concept]
   966   C2349001:Subject [Human]
   966   C2697811:Subject [Functional Concept]

Phrase: "with the Pro12Ala polymorphism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0032529:Polymorphism [Genetic Function]
   861   C1882417:Polymorphism [Qualitative Concept]

Phrase: "in PPAR2."
Processing 00000000.tx.187: Diabetologia45 :152 153,2001 Boden G: Role of fatty acids in the pathogenesis of insulin resistance and NIDDM (Review). 

Phrase: "Diabetologia45"

Phrase: ":"

Phrase: "152 153,"

Phrase: "2001 Boden G"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0439267:g% [Quantitative Concept]

Phrase: ":"

Phrase: "Role of fatty acids"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0035820:Role [Social Behavior]
   770   C1705810:Role [Conceptual Entity]

Phrase: "in the pathogenesis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0543483:pathogenesis [Functional Concept]
  1000   C0699748:Pathogenesis [Pathologic Function]

Phrase: "of insulin resistance"
Meta Candidates (Total=12; Excluded=5; Pruned=0; Remaining=7)
  1000   C0021655:Insulin Resistance [Pathologic Function]
  1000   C2700570:INSULIN RESISTANCE [Gene or Genome]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0237834:Resistance [Mental Process]
   861   C1514892:Resistance [Physiologic Function]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   789 E C0332325:Resistant [Functional Concept]
   789 E C1550464:resistent [Idea or Concept]
   789 E C2827757:RESISTANT [Laboratory or Test Result]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "and"

Phrase: "NIDDM (Review"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0282443:Review [Intellectual Product]
   861   C1552617:Review [Idea or Concept]

Phrase: ")."
Processing 00000000.tx.188: Diabetes46 :3 10,1997[Abstract] Stefan N, Fritsche A, Hring H, Stumvoll M: Effect of experimental elevation of free fatty acids on insulin secretion and insulin sensitivity in healthy carriers of the Pro12Ala polymorphism of peroxisome-proliferator-activated receptor-2 gene. 

Phrase: "Diabetes46"

Phrase: ":"

Phrase: "3 10,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0439086:<3 [Quantitative Concept]
   861   C2827736:3+ [Quantitative Concept]
   861   C2981702:3+ [Classification]

Phrase: "1997"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Stefan N,"

Phrase: "Fritsche A,"

Phrase: "Hring H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Stumvoll M"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: ":"

Phrase: "Effect of experimental elevation of free fatty acids"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C1280500:Effect [Qualitative Concept]
   744   C2348382:Effect [Qualitative Concept]

Phrase: "on insulin secretion"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C1256369:insulin secretion [Cell Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036536:secretion [Biologic Function]
   861   C0036537:Secretion [Body Substance]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "and"

Phrase: "insulin sensitivity in healthy carriers of the Pro12Ala polymorphism"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   764   C0920563:Insulin Sensitivity [Pathologic Function]
   742   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   742   C0036667:Sensitivity [Quantitative Concept]
   742   C0312418:Sensitivity [Mental Process]
   742   C0427965:Sensitivity [Finding]
   742   C1511883:Sensitivity [Quantitative Concept]
   742   C1522640:Sensitivity [Qualitative Concept]
   742   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   742   C1579433:Insulin [Pharmacologic Substance]
   742   C2346484:SENSITIVITY [Phenomenon or Process]
   742   C2349185:Sensitivity [Qualitative Concept]

Phrase: "of peroxisome-proliferator-activated receptor-2 gene."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   839   C1335671:Receptor Gene [Gene or Genome]
   799   C0017337:Gene [Gene or Genome]
   734   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   734   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
Processing 00000000.tx.189: Diabetes50 :1143 1148,2001[Abstract/Free FullText] Dubois M, Pattou F, Kerr-Conte J, Gmyr V, Vanderwalle B, Desreumaux P, Auwerx J, Schoonjans K, Lefebvre J: Expression of peroxisome proliferator-activated receptor gamma (PPAR gamma) in normal human pancreatic islet cells. 

Phrase: "Diabetes50"

Phrase: ":"

Phrase: "1143 1148,"

Phrase: "2001"

Phrase: "[Abstract/Free FullText"

Phrase: "] Dubois M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Pattou F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Kerr-Conte J,"

Phrase: "Gmyr V,"

Phrase: "Vanderwalle B,"

Phrase: "Desreumaux P,"

Phrase: "Auwerx J,"

Phrase: "Schoonjans K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Lefebvre J"

Phrase: ":"

Phrase: "Expression of peroxisome proliferator-activated receptor gamma (PPAR gamma)"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   774   C0597360:receptor expression [Genetic Function]
   748   C0185117:Expression [Therapeutic or Preventive Procedure]
   731   C0166417:Peroxisome Proliferator-Activated Receptor gamma [Amino Acid, Peptide, or Protein,Receptor]
   731   C1335238:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA [Gene or Genome]

Phrase: "in normal human pancreatic islet cells."
Meta Candidates (Total=11; Excluded=4; Pruned=0; Remaining=7)
   881   C0007634:Normal cell [Cell]
           Cells
   881   C1268443:Normal cell [Cell]
   875   C0427861:Human cells [Laboratory or Test Result]
   867   C0734999:Pancreatic islet cell [Cell]
   840   C0022131:Islet Cells [Body Part, Organ, or Organ Component]
   806 E C1522529:Islet Cell [Cell]
   804   C3282337:Cells [Cell]
   771 E C1269647:Cell [Cell]
   771 E C1704653:Cell [Medical Device]
   771 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.190: Diabetologia43 :1165 1169,2000[Medline] Norman RA, Thompson DB, Foroud T, Garvey WT, Bennett PH, Bogardus C, Ravussin E: Genomewide search for genes influencing percent body fat in Pima Indians: suggestive linkage at chromosome 11q21-q22: Pima Diabetes Gene Group. 

Phrase: "Diabetologia43"

Phrase: ":"

Phrase: "1165 1169,"

Phrase: "2000"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Norman RA,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3538806:Ra [Spatial Concept]

Phrase: "Thompson DB,"

Phrase: "Foroud T,"

Phrase: "Garvey WT,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2700323:WT [Fish]

Phrase: "Bennett PH,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0020283:[pH] [Quantitative Concept]
   861   C0450407:ph+ [Finding]
   861   C0450408:ph++ [Finding]
   861   C0450409:ph+++ [Finding]

Phrase: "Bogardus C,"

Phrase: "Ravussin E"

Phrase: ":"

Phrase: "Genomewide search for genes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1552603:search [Intellectual Product]
   770   C1706202:Search [Activity]

Phrase: "influencing"

Phrase: "percent body fat in Pima Indians"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   790   C0001527:Body Fat [Tissue]
   790   C0015665:body fat [Body Part, Organ, or Organ Component]
   790   C0344335:Body Fat [Clinical Attribute]
   783 E C0935625:Fat body [Tissue]
   753   C0242821:body [Human]
   753   C0424612:FAT [Organism Attribute]
   753   C0439165:Percent [Quantitative Concept]
   753   C0460148:Body [Anatomical Structure]
   753   C1268086:Body [Anatomical Structure]

Phrase: ":"

Phrase: "suggestive linkage at chromosome 11q21-q22"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0023745:linkage [Molecular Function]

Phrase: ":"

Phrase: "Pima Diabetes Gene Group."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   812   C0441833:Group [Idea or Concept]
   812   C0687744:group [Population Group]
   812   C1257890:Group [Population Group]
   812   C1552516:Group [Health Care Related Organization]
   812   C1705428:Group [Conceptual Entity]
   812   C1705429:Group [Population Group]
Processing 00000000.tx.191: Am J Hum Genet60 :166 173,1997[Medline] Swarbrick MM, Chapman CM, McQuillan BM, Hung J, Thompson PL, Beilby JP: A Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor-gamma 2 is associated with combined hyperlipidaemia in obesity. 

Phrase: "Am"

Phrase: "J Hum Genet60"

Phrase: ":"

Phrase: "166 173,"

Phrase: "1997"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Swarbrick MM,"

Phrase: "Chapman CM,"

Phrase: "McQuillan BM,"

Phrase: "Hung"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0544691:hang [Injury or Poisoning]
   966   C1823998:HANG [Gene or Genome]

Phrase: "J,"

Phrase: "Thompson PL,"

Phrase: "Beilby JP"

Phrase: ":"

Phrase: "A Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor-gamma 2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   736   C0032529:Polymorphism [Genetic Function]
   736   C1882417:Polymorphism [Qualitative Concept]

Phrase: "is"

Phrase: "associated with combined hyperlipidaemia"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   833   C0332281:Associated with [Qualitative Concept]
           Associated
   833   C2712907:Combined hyperlipidemia NOS [Disease or Syndrome]
   770   C0020473:Hyperlipidaemia [Disease or Syndrome]
   770   C0205195:Combined [Qualitative Concept]
   737 E C0336789:Combine [Manufactured Object]
   737 E C0750490:Associate [Idea or Concept]
   737 E C1706221:Associate [Professional or Occupational Group]

Phrase: "in obesity."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0028754:Obesity [Disease or Syndrome]
  1000   C1963185:Obesity [Finding]
Processing 00000000.tx.192: Eur J Endocrinol144 :277 282,2001[Medline] Oh EY, Min KM, Chung JH, Min YK, Lee MS, Kim KW, Lee MK: Significance of Pro12Ala mutation in peroxisome proliferator-activated receptor-gamma2 in Korean diabetic and obese subjects. 

Phrase: "Eur J Endocrinol144"

Phrase: ":"

Phrase: "277 282,"

Phrase: "2001"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Oh EY,"

Phrase: "Min KM,"

Phrase: "Chung JH,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0268060:JH [Disease or Syndrome]
   861   C1415529:JH [Gene or Genome]

Phrase: "Min YK,"

Phrase: "Lee MS,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039676:MS [Amino Acid, Peptide, or Protein,Enzyme]
   861   C2349943:Ms. [Conceptual Entity]
   861   C3539704:MS [Gene or Genome]

Phrase: "Kim KW,"

Phrase: "Lee MK"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3539059:MK [Idea or Concept]

Phrase: ":"

Phrase: "Significance of Pro12Ala mutation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0237881:Significance [Quantitative Concept]
   770   C0750502:Significance [Idea or Concept]

Phrase: "in peroxisome proliferator-activated receptor-gamma2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   771   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   771   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "in Korean"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1556095:Korean [Population Group]

Phrase: "diabetic"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0241863:DIABETIC [Finding]

Phrase: "and"

Phrase: "obese subjects."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   827   C0681850:Subject [Group]
   827   C1550501:{Subject} [Idea or Concept]
   827   C1706203:Subject [Idea or Concept]
   827   C2349001:Subject [Human]
   827   C2697811:Subject [Functional Concept]
Processing 00000000.tx.193: J Clin Endocrinol Metab85 :1801 1804,2000[Abstract/Free FullText] Cole SA, Mitchell BD, Hsueh WC, Pineda P, Beamer BA, Shuldiner AR, Comuzzie AG, Blangero J, Hixson JE: The Pro12Ala variant of peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) is associated with measures of obesity in Mexican Americans. 

Phrase: "J Clin Endocrinol Metab85"

Phrase: ":"

Phrase: "1801 1804,"

Phrase: "2000"

Phrase: "[Abstract/Free FullText"

Phrase: "] Cole SA,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0036243:SA [Geographic Area]
   861   C1539696:SA [Gene or Genome]
   861   C1825840:SA [Gene or Genome]
   861   C3539736:Sa [Spatial Concept]

Phrase: "Mitchell BD,"

Phrase: "Hsueh WC,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0013123:WC [Organism Function]
   861   C2825512:WC [Quantitative Concept]

Phrase: "Pineda P,"

Phrase: "Beamer BA,"

Phrase: "Shuldiner AR,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2986463:AR+ [Finding]

Phrase: "Comuzzie AG,"

Phrase: "Blangero J,"

Phrase: "Hixson JE"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0454673:JE [Geographic Area]
   861   C1550752:JE [Temporal Concept]

Phrase: ":"

Phrase: "The Pro12Ala variant of peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2)"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C0205419:Variant [Qualitative Concept]

Phrase: "is"

Phrase: "associated with measures of obesity"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   806   C0332281:Associated with [Qualitative Concept]
           Associated
   760   C0028754:Obesity [Disease or Syndrome]
   760   C0079809:Measures [Quantitative Concept]
   760   C1879489:Measures [Functional Concept]
   760   C1963185:Obesity [Finding]
   726 E C0242485:Measure [Functional Concept]
   726 E C0750490:Associate [Idea or Concept]
   726 E C1706221:Associate [Professional or Occupational Group]

Phrase: "in Mexican Americans."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0025884:Mexican Americans [Population Group]
   861   C0596070:americans [Population Group]
Processing 00000000.tx.194: Int J Obes Relat Metab Disord24 :522 524,2000[Medline] Beamer BA, Yen CJ, Andersen RE, Muller D, Elahi D, Cheskin LJ, Andres R, Roth J, Shuldiner AR: Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-2 gene with obesity in two Caucasian populations. 

Phrase: "Int J Obes Relat Metab Disord24"

Phrase: ":"

Phrase: "522 524,"

Phrase: "2000"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Beamer BA,"

Phrase: "Yen CJ,"

Phrase: "Andersen RE,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2986904:RE [Idea or Concept]

Phrase: "Muller D,"

Phrase: "Elahi D,"

Phrase: "Cheskin LJ,"

Phrase: "Andres R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Roth J,"

Phrase: "Shuldiner AR"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2986463:AR+ [Finding]

Phrase: ":"

Phrase: "Association of the Pro12Ala variant"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0004083:Association [Mental Process]
   760   C0439849:Association [Qualitative Concept]
   760   C0596306:Association [Phenomenon or Process]
   760   C0699792:association [Social Behavior]

Phrase: "in the peroxisome proliferator-activated receptor-2 gene"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   839   C1335671:Receptor Gene [Gene or Genome]
   799   C0017337:Gene [Gene or Genome]
   734   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   734   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "with obesity"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0028754:Obesity [Disease or Syndrome]
  1000   C1963185:Obesity [Finding]

Phrase: "in two Caucasian populations."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0032659:Population [Quantitative Concept]
   827   C1257890:Population [Population Group]
Processing 00000000.tx.195: Diabetes47 :1806 1808,1998[Free FullText] Lindi V, Sivenius K, Niskanen L, Laakso M, Uusitupa MI: Effect of the Pro12Ala polymorphism of the PPAR-2 gene on long-term weight change in Finnish non-diabetic subjects. 

Phrase: "Diabetes47"

Phrase: ":"

Phrase: "1806 1808,"

Phrase: "1998"

Phrase: "[Free FullText"

Phrase: "] Lindi V,"

Phrase: "Sivenius K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Niskanen L,"

Phrase: "Laakso M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Uusitupa MI"

Phrase: ":"

Phrase: "Effect of the Pro12Ala polymorphism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1280500:Effect [Qualitative Concept]
   760   C2348382:Effect [Qualitative Concept]

Phrase: "of the PPAR-2 gene"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   839   C1335671:Receptor Gene [Gene or Genome]
   799   C0017337:Gene [Gene or Genome]
   734   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   734   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "on long-term weight change"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0005911:Weight change [Finding]
   812   C0392747:Change [Functional Concept]
   812   C0443172:change [Quantitative Concept]
   812   C1705241:Change [Quantitative Concept]

Phrase: "in Finnish non-diabetic subjects."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   779   C0681850:Subject [Group]
   779   C1550501:{Subject} [Idea or Concept]
   779   C1706203:Subject [Idea or Concept]
   779   C2349001:Subject [Human]
   779   C2697811:Subject [Functional Concept]
Processing 00000000.tx.196: Diabetologia44 :925 926,2001[Medline] Nicklas BJ, van Rossum EF, Berman DM, Ryan AS, Dennis KE, Shuldiner AR: Genetic variation in the peroxisome proliferator-activated receptor-2 gene (Pro12Ala) affects metabolic responses to weight loss and subsequent weight regain. 

Phrase: "Diabetologia44"

Phrase: ":"

Phrase: "925 926,"

Phrase: "2001"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Nicklas BJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0005005:BJ [Geographic Area]

Phrase: "van Rossum EF,"

Phrase: "Berman DM,"

Phrase: "Ryan AS,"

Phrase: "Dennis KE,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0022558:KE [Geographic Area]

Phrase: "Shuldiner AR"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2986463:AR+ [Finding]

Phrase: ":"

Phrase: "Genetic variation in the peroxisome proliferator-activated receptor-2 gene"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0042333:Genetic Variation [Natural Phenomenon or Process]
   739   C0205419:Variation [Qualitative Concept]

Phrase: "(Pro12Ala"

Phrase: ")"

Phrase: "affects"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001721:Affect [Mental Process]

Phrase: "metabolic responses to weight loss"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   760   C0871261:responses [Organism Attribute]
   726 E C1704632:Response [Finding]
   726 E C1706817:Response [Intellectual Product]
   726 E C2911692:Response [Mental Process]

Phrase: "and"

Phrase: "subsequent weight"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0005910:weight [Organism Attribute]
   861   C0043100:Weight [Quantitative Concept]
   861   C1305866:weight [Diagnostic Procedure]
   861   C1705104:Weight [Idea or Concept]

Phrase: "regain."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1875723:REGAIN [Food]
Processing 00000000.tx.197: Diabetes50 :2172 2176,2001[Abstract/Free FullText] Swinburn BA, Nyomba BL, Saad MF, Zurlo F, Raz I, Knowler WC, Lillioja S, Bogardus C, Ravussin E: Insulin resistance associated with lower rates of weight gain in Pima Indians. 

Phrase: "Diabetes50"

Phrase: ":"

Phrase: "2172 2176,"

Phrase: "2001"

Phrase: "[Abstract/Free FullText"

Phrase: "] Swinburn BA,"

Phrase: "Nyomba BL,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0006413:BL [Neoplastic Process]
   861   C1552663:BL [Idea or Concept]
   861   C2827109:BL [Geographic Area]

Phrase: "Saad MF,"

Phrase: "Zurlo F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Raz I,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Knowler WC,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0013123:WC [Organism Function]
   861   C2825512:WC [Quantitative Concept]

Phrase: "Lillioja S,"

Phrase: "Bogardus C,"

Phrase: "Ravussin E"

Phrase: ":"

Phrase: "Insulin resistance"
Meta Candidates (Total=12; Excluded=5; Pruned=0; Remaining=7)
  1000   C0021655:Insulin Resistance [Pathologic Function]
  1000   C2700570:INSULIN RESISTANCE [Gene or Genome]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0237834:Resistance [Mental Process]
   861   C1514892:Resistance [Physiologic Function]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   789 E C0332325:Resistant [Functional Concept]
   789 E C1550464:resistent [Idea or Concept]
   789 E C2827757:RESISTANT [Laboratory or Test Result]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "associated with lower rates of weight gain"
Meta Candidates (Total=17; Excluded=3; Pruned=0; Remaining=14)
   778   C0043094:Weight Gain [Finding]
   778   C0332281:Associated with [Qualitative Concept]
           Associated
   778   C2911647:Weight gain [Finding]
   748   C0005910:weight [Organism Attribute]
   748   C0043100:Weight [Quantitative Concept]
   748   C0441994:Lower [Spatial Concept]
   748   C1305866:weight [Diagnostic Procedure]
   748   C1517378:Gain [Quantitative Concept]
   748   C1548802:Lower [Body Location or Region]
   748   C1705104:Weight [Idea or Concept]
   748   C2003888:Lower [Activity]
   737 E C0231246:weight gaining [Sign or Symptom]
   714 E C0750490:Associate [Idea or Concept]
   714   C0871208:Rate [Activity]
   714   C1521828:Rate [Quantitative Concept]
   714 E C1706221:Associate [Professional or Occupational Group]

Phrase: "in Pima Indians."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   966   C1551488:Pima Indian [Population Group]
           Pima
   861   C1524069:Indians [Population Group]
   805 E C0032831:Potassium Iodide [Inorganic Chemical,Pharmacologic Substance]
Processing 00000000.tx.198: J Clin Invest88 :168 173,1991[Medline] Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, Satoh S, Nakano R, Ishii C, Sugiyama T, Eto K, Tsubamoto Y, Okuno A, Murakami K, Sekihara H, Hasegawa G, Naito M, Toyoshima Y, Tanaka S, Shiota K, Kitamura T, Fujita T, Ezaki O, Aizawa S, Nagai R, Tobe K, Kimura S, Kadowaki T: PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. 

Phrase: "J Clin Invest88"

Phrase: ":"

Phrase: "168 173,"

Phrase: "1991"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Kubota N,"

Phrase: "Terauchi Y,"

Phrase: "Miki H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Tamemoto H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Yamauchi T,"

Phrase: "Komeda K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Satoh S,"

Phrase: "Nakano R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Ishii C,"

Phrase: "Sugiyama T,"

Phrase: "Eto K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Tsubamoto Y,"

Phrase: "Okuno A,"

Phrase: "Murakami K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Sekihara H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Hasegawa G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Naito M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Toyoshima Y,"

Phrase: "Tanaka S,"

Phrase: "Shiota K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Kitamura T,"

Phrase: "Fujita T,"

Phrase: "Ezaki O,"

Phrase: "Aizawa S,"

Phrase: "Nagai R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Tobe K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Kimura S,"

Phrase: "Kadowaki T"

Phrase: ":"

Phrase: "PPAR gamma"
Meta Candidates (Total=14; Excluded=2; Pruned=0; Remaining=12)
  1000   C0166417:Peroxisome Proliferator-Activated Receptor gamma [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1335238:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA [Gene or Genome]
   937   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   937   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   840   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   804   C0017011:Gamma [Natural Phenomenon or Process]
   804   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   804   C0752063:Peroxysome [Cell Component]
   804   C1552644:Gamma [Intellectual Product]
   804   C1879547:Activated [Activity]
   804   C2349976:Gamma [Quantitative Concept]
   804   C2984308:Peroxisome [Functional Concept]
   771 E C1515877:Activate [Functional Concept]
   733 E C3546463:peroxisomal [Cell Component]

Phrase: "mediates"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0086597:Mediate [Social Behavior]

Phrase: "high-fat diet-induced adipocyte hypertrophy"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   876   C0406602:Fat hypertrophy [Pathologic Function]
   799   C0020564:Hypertrophy [Pathologic Function]
   727 E C0333959:Hypertrophic [Functional Concept]

Phrase: "and"

Phrase: "insulin resistance."
Meta Candidates (Total=12; Excluded=5; Pruned=0; Remaining=7)
  1000   C0021655:Insulin Resistance [Pathologic Function]
  1000   C2700570:INSULIN RESISTANCE [Gene or Genome]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0237834:Resistance [Mental Process]
   861   C1514892:Resistance [Physiologic Function]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   789 E C0332325:Resistant [Functional Concept]
   789 E C1550464:resistent [Idea or Concept]
   789 E C2827757:RESISTANT [Laboratory or Test Result]
   777 E C3537244:Insulins [Pharmacologic Substance]
Processing 00000000.tx.199: Mol Cell4 :597 609,1999[Medline] Allison DB, Heo M, Faith MS, Pietrobelli A: Meta-analysis of the association of the Trp64Arg polymorphism in the beta3 adrenergic receptor with body mass index. 

Phrase: "Mol Cell4"

Phrase: ":"

Phrase: "597 609,"

Phrase: "1999"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Allison DB,"

Phrase: "Heo M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Faith MS,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039676:MS [Amino Acid, Peptide, or Protein,Enzyme]
   861   C2349943:Ms. [Conceptual Entity]
   861   C3539704:MS [Gene or Genome]

Phrase: "Pietrobelli A"

Phrase: ":"

Phrase: "Meta-analysis of the association of the Trp64Arg polymorphism"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   764   C0282458:Meta-Analysis [Intellectual Product]
   764   C0920317:Meta-Analysis [Research Activity]
   762   C0796451:polymorphism analysis [Diagnostic Procedure]
   742   C0002778:Analysis [Laboratory Procedure]
   742   C0936012:Analysis [Research Activity]
   742   C1042496:Meta [Eukaryote]
   742   C1524024:analysis [Functional Concept]

Phrase: "in the beta3 adrenergic receptor"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0034783:Adrenergic Receptor [Amino Acid, Peptide, or Protein,Receptor]
   827   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   827   C0599756:adrenergic [Functional Concept]

Phrase: "with body mass index."
Meta Candidates (Total=13; Excluded=1; Pruned=0; Remaining=12)
  1000   C0005893:Body Mass Index [Diagnostic Procedure]
  1000   C1305855:Body mass index [Clinical Attribute]
   901   C0518010:body mass [Finding]
   827   C0242821:body [Human]
   827   C0460148:Body [Anatomical Structure]
   827   C0577559:Mass [Finding]
   827   C0918012:Index [Intellectual Product]
   827   C1268086:Body [Anatomical Structure]
   827   C1306372:*Mass [Quantitative Concept]
   827   C1552854:index [Idea or Concept]
   827   C1637833:% index [Quantitative Concept]
   827   C3152252:Mass [Quantitative Concept]
   743 E C1995017:Bodies [Cell Component]
Processing 00000000.tx.200: Int J Obes Relat Metab Disord22 :559 566,1998[Medline] Hsueh WC, Cole SA, Shuldiner AR, Beamer BA, Blangero J, Hixson JE, MacCluer JW, Mitchell BD: Interactions between variants in the 3-adrenergic receptor and peroxisome proliferator-activated receptor-2 genes and obesity. 

Phrase: "Int J Obes Relat Metab Disord22"

Phrase: ":"

Phrase: "559 566,"

Phrase: "1998"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Hsueh WC,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0013123:WC [Organism Function]
   861   C2825512:WC [Quantitative Concept]

Phrase: "Cole SA,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0036243:SA [Geographic Area]
   861   C1539696:SA [Gene or Genome]
   861   C1825840:SA [Gene or Genome]
   861   C3539736:Sa [Spatial Concept]

Phrase: "Shuldiner AR,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2986463:AR+ [Finding]

Phrase: "Beamer BA,"

Phrase: "Blangero J,"

Phrase: "Hixson JE,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0454673:JE [Geographic Area]
   861   C1550752:JE [Temporal Concept]

Phrase: "MacCluer JW,"

Phrase: "Mitchell BD"

Phrase: ":"

Phrase: "Interactions between variants"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   756   C1704675:Interaction [Functional Concept]

Phrase: "in the 3-adrenergic receptor"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0034783:Adrenergic Receptor [Amino Acid, Peptide, or Protein,Receptor]
   827   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   827   C0599756:adrenergic [Functional Concept]

Phrase: "and"

Phrase: "peroxisome proliferator-activated receptor-2 genes"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   822   C1335671:Receptor Gene [Gene or Genome]
   799   C0017337:Genes [Gene or Genome]
   734   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   734   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "and"

Phrase: "obesity."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0028754:Obesity [Disease or Syndrome]
  1000   C1963185:Obesity [Finding]
Processing 00000000.tx.201: Diabetes Care24 :672 677,2001[Abstract/Free FullText] Luan J, Browne PO, Harding AH, Halsall DJ, ORahilly S, Chatterjee VK, Wareham NJ: Evidence for gene-nutrient interaction at the PPAR locus. 

Phrase: "Diabetes Care24"

Phrase: ":"

Phrase: "672 677,"

Phrase: "2001"

Phrase: "[Abstract/Free FullText"

Phrase: "] Luan J,"

Phrase: "Browne PO,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0442027:PO [Spatial Concept]

Phrase: "Harding AH,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1836672:AH [Disease or Syndrome]

Phrase: "Halsall DJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0012836:DJ [Geographic Area]

Phrase: "ORahilly S,"

Phrase: "Chatterjee VK,"

Phrase: "Wareham NJ"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0027971:NJ [Geographic Area]

Phrase: ":"

Phrase: "Evidence for gene-nutrient interaction"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0332120:Evidence [Functional Concept]

Phrase: "at the PPAR locus."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   804   C1708726:Locus [Gene or Genome]
   771   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   771   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
Processing 00000000.tx.202: Diabetes50 :686 689,2001[Abstract/Free FullText] Masugi J, Tamori Y, Mori H, Koike T, Kasuga M: Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. 

Phrase: "Diabetes50"

Phrase: ":"

Phrase: "686 689,"

Phrase: "2001"

Phrase: "[Abstract/Free FullText"

Phrase: "] Masugi J,"

Phrase: "Tamori Y,"

Phrase: "Mori H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Koike T,"

Phrase: "Kasuga M"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: ":"

Phrase: "Inhibitory effect of a proline-to-alanine substitution"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   767   C0680963:substitution effect [Functional Concept]
   744   C1280500:Effect [Qualitative Concept]
   744   C2348382:Effect [Qualitative Concept]

Phrase: "at codon 12"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0009221:Codon [Nucleotide Sequence]
   861   C1095825:Codon [Plant]

Phrase: "of peroxisome proliferator-activated receptor-gamma 2"
Meta Candidates (Total=14; Excluded=2; Pruned=0; Remaining=12)
   947   C0166417:Peroxisome Proliferator-Activated Receptor gamma [Amino Acid, Peptide, or Protein,Receptor]
   947   C1335238:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA [Gene or Genome]
   901   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   901   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   827   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   799   C0017011:Gamma [Natural Phenomenon or Process]
   799   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   799   C0752063:Peroxysome [Cell Component]
   799   C1552644:Gamma [Intellectual Product]
   799   C1879547:Activated [Activity]
   799   C2349976:Gamma [Quantitative Concept]
   799   C2984308:Peroxisome [Functional Concept]
   766 E C1515877:Activate [Functional Concept]
   727 E C3546463:peroxisomal [Cell Component]

Phrase: "on thiazolidinedione-induced adipogenesis."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0596843:Adipogenesis [Molecular Function]
Processing 00000000.tx.203: Biochem Biophys Res Commun268 :178 182,2000[Medline] Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y, Kadowaki T: Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. 

Phrase: "Biochem Biophys Res Commun268"

Phrase: ":"

Phrase: "178 182,"

Phrase: "2000"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Okuno A,"

Phrase: "Tamemoto H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Tobe K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Ueki K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Mori Y,"

Phrase: "Iwamoto K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Umesono K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Akanuma Y,"

Phrase: "Fujiwara T,"

Phrase: "Horikoshi H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Yazaki Y,"

Phrase: "Kadowaki T"

Phrase: ":"

Phrase: "Troglitazone"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0245514:troglitazone [Organic Chemical,Pharmacologic Substance]

Phrase: "increases"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "the number of small adipocytes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0237753:*Number [Quantitative Concept]
   760   C0449788:Number [Quantitative Concept]

Phrase: "without the change"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0392747:Change [Functional Concept]
  1000   C0443172:change [Quantitative Concept]
  1000   C1705241:Change [Quantitative Concept]

Phrase: "of white adipose tissue mass"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   812   C0577559:Mass [Finding]
   812   C1306372:*Mass [Quantitative Concept]
   812   C3152252:Mass [Quantitative Concept]
   756   C1704223:White Adipose Tissue [Tissue]

Phrase: "in obese Zucker rats."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C0034719:Rats, Zucker [Mammal]
   827   C0028754:Obese [Disease or Syndrome]
   827   C0034693:rats [Mammal]
   827   C0034721:Rats [Mammal]
   827   C2700303:Zucker [Mammal]
Processing 00000000.tx.204: J Clin Invest101 :1354 1361,1998[Abstract/Free FullText] Abbott WG, Foley JE: Comparison of body composition, adipocyte size, and glucose and insulin concentrations in Pima Indian and Caucasian children. 

Phrase: "J Clin Invest101"

Phrase: ":"

Phrase: "1354 1361,"

Phrase: "1998"

Phrase: "[Abstract/Free FullText"

Phrase: "] Abbott WG,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0043092:WG [Disease or Syndrome]

Phrase: "Foley JE"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0454673:JE [Geographic Area]
   861   C1550752:JE [Temporal Concept]

Phrase: ":"

Phrase: "Comparison of body composition,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1707455:Comparison [Activity]

Phrase: "adipocyte size,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0456389:size [Spatial Concept]

Phrase: "and"

Phrase: "glucose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "and"

Phrase: "insulin concentrations in Pima Indian"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C0086045:Concentrations [Mental Process]
   726 E C1446561:Concentration [Quantitative Concept]

Phrase: "and"

Phrase: "Caucasian children."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0008059:Children [Age Group]
   861   C0680063:Children [Family Group]
Processing 00000000.tx.205: Metabolism36 :576 579,1987[Medline] Adams M, Montague CT, Prins JB, Holder JC, Smith SA, Sanders L, Digby JE, Sewter CP, Lazar MA, Chatterjee VK, ORahilly S: Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. 

Phrase: "Metabolism36"

Phrase: ":"

Phrase: "576 579,"

Phrase: "1987"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Adams M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Montague CT,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3540513:CT [Gene or Genome]

Phrase: "Prins JB,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1550751:JB [Temporal Concept]

Phrase: "Holder JC,"

Phrase: "Smith SA,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0036243:SA [Geographic Area]
   861   C1539696:SA [Gene or Genome]
   861   C1825840:SA [Gene or Genome]
   861   C3539736:Sa [Spatial Concept]

Phrase: "Sanders L,"

Phrase: "Digby JE,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0454673:JE [Geographic Area]
   861   C1550752:JE [Temporal Concept]

Phrase: "Sewter CP,"

Phrase: "Lazar MA,"

Phrase: "Chatterjee VK,"

Phrase: "ORahilly S"

Phrase: ":"

Phrase: "Activators of peroxisome proliferator-activated receptor gamma"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   731   C0166417:Peroxisome Proliferator-Activated Receptor gamma [Amino Acid, Peptide, or Protein,Receptor]
   731   C1335238:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA [Gene or Genome]

Phrase: "have"

Phrase: "depot-specific effects on human preadipocyte differentiation."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   748   C1280500:effects [Qualitative Concept]
   714 E C2348382:Effect [Qualitative Concept]
Processing 00000000.tx.206: J Clin Invest100 :3149 3153,1997[Abstract/Free FullText] Lefebvre AM, Laville M, Vega N, Riou JP, van Gaal L, Auwerx J, Vidal H: Depot-specific differences in adipose tissue gene expression in lean and obese subjects. 

Phrase: "J Clin Invest100"

Phrase: ":"

Phrase: "3149 3153,"

Phrase: "1997"

Phrase: "[Abstract/Free FullText"

Phrase: "] Lefebvre"

Phrase: "AM"

Phrase: ","

Phrase: "Laville M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Vega N,"

Phrase: "Riou JP,"

Phrase: "van Gaal L,"

Phrase: "Auwerx J,"

Phrase: "Vidal H"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: ":"

Phrase: "Depot-specific differences in adipose tissue gene expression"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   821   C1519516:Tissue-Specific Differential Gene Expression [Genetic Function]
           Differential Gene Expression
   711   C1705241:*Difference [Quantitative Concept]
   711   C1705242:Difference [Qualitative Concept]

Phrase: "in lean"

Phrase: "and"

Phrase: "obese subjects."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   827   C0681850:Subject [Group]
   827   C1550501:{Subject} [Idea or Concept]
   827   C1706203:Subject [Idea or Concept]
   827   C2349001:Subject [Human]
   827   C2697811:Subject [Functional Concept]
Processing 00000000.tx.207: Diabetes47 :98 103,1998[Abstract] Montague CT, ORahilly S: The perils of portliness: causes and consequences of visceral adiposity. 

Phrase: "Diabetes47"

Phrase: ":"

Phrase: "98 103,"

Phrase: "1998"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Montague CT,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3540513:CT [Gene or Genome]

Phrase: "ORahilly S"

Phrase: ":"

Phrase: "The perils of portliness"

Phrase: ":"

Phrase: "causes"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0015127:causes [Functional Concept]
  1000   C1314792:Causes [Functional Concept]
   966 E C1524003:Cause [Conceptual Entity]

Phrase: "and"

Phrase: "consequences of visceral adiposity."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   816   C0686907:Consequence of [Functional Concept]
           consequences
Processing 00000000.tx.208: Diabetes49 :883 888,2000[Abstract] Miles PD, Barak Y, He W, Evans RM, Olefsky JM: Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. 

Phrase: "Diabetes49"

Phrase: ":"

Phrase: "883 888,"

Phrase: "2000"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Miles PD,"

Phrase: "Barak Y,"

Phrase: "He W,"

Phrase: "Evans RM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2951520:RM [Body Location or Region]

Phrase: "Olefsky JM"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0022337:JM [Geographic Area]

Phrase: ":"

Phrase: "Improved insulin-sensitivity in mice"
Meta Candidates (Total=12; Excluded=1; Pruned=0; Remaining=11)
   806   C0920563:Insulin Sensitivity [Pathologic Function]
   760   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C0036667:Sensitivity [Quantitative Concept]
   760   C0312418:Sensitivity [Mental Process]
   760   C0427965:Sensitivity [Finding]
   760   C1511883:Sensitivity [Quantitative Concept]
   760   C1522640:Sensitivity [Qualitative Concept]
   760   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C1579433:Insulin [Pharmacologic Substance]
   760   C2346484:SENSITIVITY [Phenomenon or Process]
   760   C2349185:Sensitivity [Qualitative Concept]
   704 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]

Phrase: "heterozygous for PPAR-gamma deficiency."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   744   C0019425:Heterozygous [Organism Attribute]
   703   C0166417:Peroxisome Proliferator-Activated Receptor gamma [Amino Acid, Peptide, or Protein,Receptor]
   703   C1335238:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA [Gene or Genome]
Processing 00000000.tx.209: J Clin Invest105 :287 292,2000[Abstract/Free FullText] Kroder G, Bossenmaier B, Kellerer M, Capp E, Stoyanov B, Muhlhofer A, Berti L, Horikoshi H, Ullrich A, Haring H: Tumor necrosis factor-alpha- and hyperglycemia-induced insulin resistance: evidence for different mechanisms and different effects on insulin signaling. 

Phrase: "J Clin Invest105"

Phrase: ":"

Phrase: "287 292,"

Phrase: "2000"

Phrase: "[Abstract/Free FullText"

Phrase: "] Kroder G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Bossenmaier B,"

Phrase: "Kellerer M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Capp E,"

Phrase: "Stoyanov B,"

Phrase: "Muhlhofer A,"

Phrase: "Berti L,"

Phrase: "Horikoshi H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Ullrich A,"

Phrase: "Haring"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0242372:haring [Mammal]
   966 E C1425660:HARE [Gene or Genome]

Phrase: "H"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: ":"

Phrase: "Tumor necrosis factor-alpha-"
Meta Candidates (Total=17; Excluded=0; Pruned=0; Remaining=17)
  1000   C0041368:tumor necrosis factor-alpha [Amino Acid, Peptide, or Protein,Immunologic Factor]
           tumor necrosis factor
  1000   C1168005:Tumor Necrosis Factor alpha [Laboratory Procedure]
  1000   C1456820:Tumor Necrosis Factor-alpha [Amino Acid, Peptide, or Protein,Immunologic Factor]
           Tumour necrosis factor
   923   C1323304:tumor necrosis factor [Molecular Function]
   861   C0333516:Tumor necrosis [Neoplastic Process]
   812   C0027540:Necrosis [Organ or Tissue Function]
   812   C0027651:Tumor [Neoplastic Process]
   812   C0439095:Alpha [Intellectual Product]
   812   C1334928:Necrosis [Finding]
   812   C1521761:Factor [Functional Concept]
   812   C1578706:Tumor [Intellectual Product]
   812   C2003941:Alpha [Intellectual Product]
   812   C2350010:Alpha [Qualitative Concept]
   812   C2827422:Factor [Conceptual Entity]
   812   C3273930:Tumor [Finding]

Phrase: "and"

Phrase: "hyperglycemia-induced insulin resistance"
Meta Candidates (Total=12; Excluded=5; Pruned=0; Remaining=7)
   861   C0021655:Insulin Resistance [Pathologic Function]
   861   C2700570:INSULIN RESISTANCE [Gene or Genome]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0237834:Resistance [Mental Process]
   812   C1514892:Resistance [Physiologic Function]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   741 E C0332325:Resistant [Functional Concept]
   741 E C1550464:resistent [Idea or Concept]
   741 E C2827757:RESISTANT [Laboratory or Test Result]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: ":"

Phrase: "evidence for different mechanisms"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0332120:Evidence [Functional Concept]

Phrase: "and"

Phrase: "different effects on insulin signaling."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C1280500:effects [Qualitative Concept]
   726 E C2348382:Effect [Qualitative Concept]
Processing 00000000.tx.210: J Clin Invest97 :1471 1477,1996[Abstract/Free FullText] Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA: The hormone resistin links obesity to diabetes. 

Phrase: "J Clin Invest97"

Phrase: ":"

Phrase: "1471 1477,"

Phrase: "1996"

Phrase: "[Abstract/Free FullText"

Phrase: "] Steppan CM,"

Phrase: "Bailey ST,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3272372:ST [Intellectual Product]

Phrase: "Bhat S,"

Phrase: "Brown EJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1718783:Ej [Immunologic Factor]

Phrase: "Banerjee RR,"

Phrase: "Wright CM,"

Phrase: "Patel HR,"

Phrase: "Ahima RS,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3539879:RS [Idea or Concept]

Phrase: "Lazar MA"

Phrase: ":"

Phrase: "The hormone resistin"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0963992:resistin [Amino Acid, Peptide, or Protein,Hormone]
   861   C1426906:RESISTIN [Gene or Genome]

Phrase: "links"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1517892:Link [Intellectual Product]
  1000   C1704666:Link [Intellectual Product]

Phrase: "obesity to diabetes."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   858   C2945676:diabetes obesity [Finding]
   790   C0028754:Obesity [Disease or Syndrome]
   790   C1963185:Obesity [Finding]
Processing 00000000.tx.211: Nature409 :307 312,2001[Medline] Hu E, Liang P, Spiegelman BM: AdipoQ is a novel adipose-specific gene dysregulated in obesity. 

Phrase: "Nature409"

Phrase: ":"

Phrase: "307 312,"

Phrase: "2001"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Hu E,"

Phrase: "Liang P,"

Phrase: "Spiegelman BM"

Phrase: ":"

Phrase: "AdipoQ"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1540187:ADIPOQ [Gene or Genome]

Phrase: "is"

Phrase: "a novel adipose-specific gene"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0017337:Gene [Gene or Genome]

Phrase: "dysregulated in obesity."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0028754:Obesity [Disease or Syndrome]
   790   C1963185:Obesity [Finding]
Processing 00000000.tx.212: J Biol Chem271 :10697 10703,1996[Abstract/Free FullText] Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. 

Phrase: "J Biol Chem271"

Phrase: ":"

Phrase: "10697 10703,"

Phrase: "1996"

Phrase: "[Abstract/Free FullText"

Phrase: "] Weyer C,"

Phrase: "Funahashi T,"

Phrase: "Tanaka S,"

Phrase: "Hotta K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Matsuzawa Y,"

Phrase: "Pratley RE,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2986904:RE [Idea or Concept]

Phrase: "Tataranni PA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3541314:PA [Idea or Concept]

Phrase: ":"

Phrase: "Hypoadiponectinemia in obesity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C2675519:Hypoadiponectinemia [Disease or Syndrome]

Phrase: "and"

Phrase: "type 2 diabetes"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0011860:Type 2 Diabetes [Disease or Syndrome]
   913   C1320657:type diabetes [Finding]
   901   C0441730:Type 2 [Classification]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]

Phrase: ":"

Phrase: "close association with insulin resistance"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0004083:Association [Mental Process]
   760   C0439849:Association [Qualitative Concept]
   760   C0596306:Association [Phenomenon or Process]
   760   C0699792:association [Social Behavior]

Phrase: "and"

Phrase: "hyperinsulinemia."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0020459:Hyperinsulinaemia [Disease or Syndrome]
Processing 00000000.tx.213: J Clin Endocrinol Metab86 :1930 1935,2001[Abstract/Free FullText] Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, Chen CL, Tai TY, Chuang LM: Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. 

Phrase: "J Clin Endocrinol Metab86"

Phrase: ":"

Phrase: "1930 1935,"

Phrase: "2001"

Phrase: "[Abstract/Free FullText"

Phrase: "] Yang WS,"

Phrase: "Lee WJ,"

Phrase: "Funahashi T,"

Phrase: "Tanaka S,"

Phrase: "Matsuzawa Y,"

Phrase: "Chao CL,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0596019:Cl - [Element, Ion, or Isotope]

Phrase: "Chen CL,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0596019:Cl - [Element, Ion, or Isotope]

Phrase: "Tai TY,"

Phrase: "Chuang LM"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1261082:LM [Body Part, Organ, or Organ Component]
   861   C1551056:lm [Quantitative Concept]
   861   C2981682:LM [Quantitative Concept]

Phrase: ":"

Phrase: "Weight reduction"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
  1000   C0043096:Weight Reduction [Finding]
   861   C0005910:weight [Organism Attribute]
   861   C0043100:Weight [Quantitative Concept]
   861   C0301630:Reduction [Natural Phenomenon or Process]
   861   C0392756:Reduction [Qualitative Concept]
   861   C0441610:Reduction [Therapeutic or Preventive Procedure]
   861   C1305866:weight [Diagnostic Procedure]
   861   C1705104:Weight [Idea or Concept]

Phrase: "increases"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "plasma levels of an adipose-derived anti-inflammatory protein,"
Meta Candidates (Total=10; Excluded=3; Pruned=0; Remaining=7)
   762   C0032120:Plasma protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   762   C0036825:Plasma Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   762   C1168405:protein plasma [Laboratory Procedure]
   745   C0428479:Protein level [Laboratory or Test Result]
   742   C0032105:Plasma [Body Substance]
   742   C0441889:Levels [Qualitative Concept]
   742   C1550098:Plasma, NOS (not otherwise specified) [Body Substance]
   708 E C0456079:Level [Classification]
   708 E C1547707:Level [Geographic Area]
   708 E C2946261:Level [Pharmacologic Substance]

Phrase: "adiponectin."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0389071:Adiponectin [Amino Acid, Peptide, or Protein,Biologically Active Substance]
Processing 00000000.tx.214: J Clin Endocrinol Metab86 :3815 3819,2001[Abstract/Free FullText] Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. 

Phrase: "J Clin Endocrinol Metab86"

Phrase: ":"

Phrase: "3815 3819,"

Phrase: "2001"

Phrase: "[Abstract/Free FullText"

Phrase: "] Yamauchi T,"

Phrase: "Kamon J,"

Phrase: "Waki H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Terauchi Y,"

Phrase: "Kubota N,"

Phrase: "Hara K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Mori Y,"

Phrase: "Ide T,"

Phrase: "Murakami K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Tsuboyama-Kasaoka N,"

Phrase: "Ezaki O,"

Phrase: "Akanuma Y,"

Phrase: "Gavrilova O,"

Phrase: "Vinson C,"

Phrase: "Reitman ML,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439526:/mL [Quantitative Concept]

Phrase: "Kagechika H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Shudo K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Yoda M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Nakano Y,"

Phrase: "Tobe K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Nagai R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Kimura S,"

Phrase: "Tomita M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Froguel P,"

Phrase: "Kadowaki T"

Phrase: ":"

Phrase: "The fat-derived hormone adiponectin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0389071:Adiponectin [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "reverses"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1555029:Reverse [Idea or Concept]

Phrase: "insulin resistance"
Meta Candidates (Total=12; Excluded=5; Pruned=0; Remaining=7)
  1000   C0021655:Insulin Resistance [Pathologic Function]
  1000   C2700570:INSULIN RESISTANCE [Gene or Genome]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0237834:Resistance [Mental Process]
   861   C1514892:Resistance [Physiologic Function]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   789 E C0332325:Resistant [Functional Concept]
   789 E C1550464:resistent [Idea or Concept]
   789 E C2827757:RESISTANT [Laboratory or Test Result]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "associated with both lipoatrophy"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   833   C0332281:Associated with [Qualitative Concept]
           Associated
   770   C0023787:lipoatrophy [Disease or Syndrome]
   770   C1280433:Lipoatrophy [Disease or Syndrome]
   737 E C0750490:Associate [Idea or Concept]
   737 E C1706221:Associate [Professional or Occupational Group]

Phrase: "and"

Phrase: "obesity."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0028754:Obesity [Disease or Syndrome]
  1000   C1963185:Obesity [Finding]
Processing 00000000.tx.215: Nat Med7 :941 946,2001[Medline] Hofmann C, Lorenz K, Braithwaite SS, Colca JR, Palazuk BJ, Hotamisligil GS, Spiegelman BM: Altered gene expression for tumor necrosis factor-a and its receptor during drug and dietary modulation of insulin resistance. 

Phrase: "Nat Med7"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1332787:MED7 [Gene or Genome]

Phrase: ":"

Phrase: "941 946,"

Phrase: "2001"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Hofmann C,"

Phrase: "Lorenz K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Braithwaite SS,"

Phrase: "Colca JR,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1708595:Jr [Idea or Concept]
   861   C3280986:JR [Disease or Syndrome]

Phrase: "Palazuk BJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0005005:BJ [Geographic Area]

Phrase: "Hotamisligil GS,"

Phrase: "Spiegelman BM"

Phrase: ":"

Phrase: "Altered gene expression for tumor necrosis factor-"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   840   C1710304:Tumor Necrosis Factor Gene [Gene or Genome]
   778   C0017262:Gene Expression [Genetic Function]
   748   C0017337:Gene [Gene or Genome]
   748   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "a"

Phrase: "and"

Phrase: "its receptor during drug"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   819   C0034799:Drug Receptor [Amino Acid, Peptide, or Protein,Receptor]
   770   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "and"

Phrase: "dietary modulation of insulin resistance."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0443264:Modulation [Spatial Concept]
Processing 00000000.tx.216: Endocrinology134 :264 270,1994[Abstract] Yamauchi T, Kamon J, Waki H, Murakami K, Motojima K, Komeda K, Ide T, Kubota N, Terauchi Y, Tobe K, Miki H, Tsuchida A, Akanuma Y, Nagai R, Kimura S, Kadowaki T: The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. 

Phrase: "Endocrinology134"

Phrase: ":"

Phrase: "264 270,"

Phrase: "1994"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Yamauchi T,"

Phrase: "Kamon J,"

Phrase: "Waki H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Murakami K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Motojima K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Komeda K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Ide T,"

Phrase: "Kubota N,"

Phrase: "Terauchi Y,"

Phrase: "Tobe K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Miki H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Tsuchida A,"

Phrase: "Akanuma Y,"

Phrase: "Nagai R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Kimura S,"

Phrase: "Kadowaki T"

Phrase: ":"

Phrase: "The mechanisms by which"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0441712:Mechanisms [Functional Concept]
   737 E C1706376:Mechanism [Manufactured Object]

Phrase: "both heterozygous peroxisome proliferator-activated receptor gamma"
Meta Candidates (Total=14; Excluded=2; Pruned=0; Remaining=12)
   947   C0166417:Peroxisome Proliferator-Activated Receptor gamma [Amino Acid, Peptide, or Protein,Receptor]
   947   C1335238:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA [Gene or Genome]
   901   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   901   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   827   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   799   C0017011:Gamma [Natural Phenomenon or Process]
   799   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   799   C0752063:Peroxysome [Cell Component]
   799   C1552644:Gamma [Intellectual Product]
   799   C1879547:Activated [Activity]
   799   C2349976:Gamma [Quantitative Concept]
   799   C2984308:Peroxisome [Functional Concept]
   766 E C1515877:Activate [Functional Concept]
   727 E C3546463:peroxisomal [Cell Component]

Phrase: "(PPARgamma"
Meta Candidates (Total=14; Excluded=2; Pruned=0; Remaining=12)
  1000   C0166417:Peroxisome Proliferator-Activated Receptor gamma [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1335238:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA [Gene or Genome]
   937   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   937   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   840   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   804   C0017011:Gamma [Natural Phenomenon or Process]
   804   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   804   C0752063:Peroxysome [Cell Component]
   804   C1552644:Gamma [Intellectual Product]
   804   C1879547:Activated [Activity]
   804   C2349976:Gamma [Quantitative Concept]
   804   C2984308:Peroxisome [Functional Concept]
   771 E C1515877:Activate [Functional Concept]
   733 E C3546463:peroxisomal [Cell Component]

Phrase: ")"

Phrase: "deficiency"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0011155:Deficiency [Functional Concept]
  1000   C0162429:Deficiency [Disease or Syndrome]
  1000   C1623416:deficiency [Qualitative Concept]
   928 E C1636779:% deficient [Quantitative Concept]

Phrase: "and"

Phrase: "PPARgamma agonist"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   929   C2917405:Peroxisome Proliferator Receptor gamma Agonist [Pharmacologic Substance]
   799   C2987634:Agonist [Pharmacologic Substance]
   780   C0166417:Peroxisome Proliferator-Activated Receptor gamma [Amino Acid, Peptide, or Protein,Receptor]
   780   C1335238:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA [Gene or Genome]
   734   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   734   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "improve"

Phrase: "insulin resistance."
Meta Candidates (Total=12; Excluded=5; Pruned=0; Remaining=7)
  1000   C0021655:Insulin Resistance [Pathologic Function]
  1000   C2700570:INSULIN RESISTANCE [Gene or Genome]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0237834:Resistance [Mental Process]
   861   C1514892:Resistance [Physiologic Function]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   789 E C0332325:Resistant [Functional Concept]
   789 E C1550464:resistent [Idea or Concept]
   789 E C2827757:RESISTANT [Laboratory or Test Result]
   777 E C3537244:Insulins [Pharmacologic Substance]
Processing 00000000.tx.217: J Biol Chem276 :41245 41254,2001[Abstract/Free FullText] Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y: PPAR ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. 

Phrase: "J Biol Chem276"

Phrase: ":"

Phrase: "41245 41254,"

Phrase: "2001"

Phrase: "[Abstract/Free FullText"

Phrase: "] Maeda N,"

Phrase: "Takahashi M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Funahashi T,"

Phrase: "Kihara S,"

Phrase: "Nishizawa H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Kishida K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Nagaretani H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Matsuda M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Komuro R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Ouchi N,"

Phrase: "Kuriyama H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Hotta K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Nakamura T,"

Phrase: "Shimomura I,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Matsuzawa Y"

Phrase: ":"

Phrase: "PPAR ligands"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   823   C1621296:receptor ligand [Molecular Function]
   804   C0023688:Ligands [Chemical]
   771   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   771   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "increase"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "expression"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "and"

Phrase: "plasma concentrations of adiponectin,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   819   C0683150:concentrations plasma [Quantitative Concept]
   770   C0086045:Concentrations [Mental Process]
   737 E C1446561:Concentration [Quantitative Concept]

Phrase: "an adipose-derived protein."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
Processing 00000000.tx.218: Diabetes50 :2094 2099,2001[Abstract/Free FullText] Kahn CR, Chen L, Cohen SE: Unraveling the mechanism of action of thiazolidinediones. 

Phrase: "Diabetes50"

Phrase: ":"

Phrase: "2094 2099,"

Phrase: "2001"

Phrase: "[Abstract/Free FullText"

Phrase: "] Kahn CR,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0201975:Cr [Laboratory Procedure]
   861   C3539604:CR [Gene or Genome]

Phrase: "Chen L,"

Phrase: "Cohen SE"

Phrase: ":"

Phrase: "Unraveling"

Phrase: "the mechanism of action of thiazolidinediones."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   833   C0031327:mechanism of action [Physiologic Function]
   833   C1524059:mechanism of action [Functional Concept]
   753   C0441712:Mechanism [Functional Concept]
   753   C1706376:Mechanism [Manufactured Object]
Processing 00000000.tx.219: J Clin Invest106 :1305 1307,2000[Free FullText] Werman A, Hollenberg A, Solanes G, Bjorbaek C, Vidal-Puig A, Flier JS: Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor g (PPARg). 

Phrase: "J Clin Invest106"

Phrase: ":"

Phrase: "1305 1307,"

Phrase: "2000"

Phrase: "[Free FullText"

Phrase: "] Werman A,"

Phrase: "Hollenberg A,"

Phrase: "Solanes G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Bjorbaek C,"

Phrase: "Vidal-Puig A,"

Phrase: "Flier JS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1552154:Js [Body Part, Organ, or Organ Component]

Phrase: ":"

Phrase: "Ligand-independent activation domain in the N terminus"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   744   C1879547:Activation [Activity]
   744   C1880389:Domain [Functional Concept]
   744   C1883221:Domain [Conceptual Entity]
   744   C3541951:Domain [Intellectual Product]

Phrase: "of peroxisome proliferator-activated receptor g (PPARg)."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   804   C0439267:g% [Quantitative Concept]
   771   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   771   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
Processing 00000000.tx.220: J Biol Chem272 :20230 20235,2002[Abstract/Free FullText] Mukherjee R, Hoener PA, Jow L, Bilakovics J, Klausing K, Mais DE, Faulkner A, Croston GE, Paterniti JR Jr: A selective peroxisome proliferator-activated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. 

Phrase: "J Biol Chem272"

Phrase: ":"

Phrase: "20230 20235,"

Phrase: "2002"

Phrase: "[Abstract/Free FullText"

Phrase: "] Mukherjee R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Hoener PA,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3541314:PA [Idea or Concept]

Phrase: "Jow L,"

Phrase: "Bilakovics J,"

Phrase: "Klausing K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Mais DE,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0011198:DE [Geographic Area]
   861   C0017480:DE [Geographic Area]
   861   C3541240:DE [Idea or Concept]

Phrase: "Faulkner A,"

Phrase: "Croston GE,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3538705:GE [Gene or Genome]

Phrase: "Paterniti JR Jr"

Phrase: ":"

Phrase: "A selective peroxisome proliferator-activated receptor-gamma"
Meta Candidates (Total=14; Excluded=2; Pruned=0; Remaining=12)
   947   C0166417:Peroxisome Proliferator-Activated Receptor gamma [Amino Acid, Peptide, or Protein,Receptor]
   947   C1335238:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA [Gene or Genome]
   901   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   901   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   827   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   799   C0017011:Gamma [Natural Phenomenon or Process]
   799   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   799   C0752063:Peroxysome [Cell Component]
   799   C1552644:Gamma [Intellectual Product]
   799   C1879547:Activated [Activity]
   799   C2349976:Gamma [Quantitative Concept]
   799   C2984308:Peroxisome [Functional Concept]
   766 E C1515877:Activate [Functional Concept]
   727 E C3546463:peroxisomal [Cell Component]

Phrase: "(PPARgamma"
Meta Candidates (Total=14; Excluded=2; Pruned=0; Remaining=12)
  1000   C0166417:Peroxisome Proliferator-Activated Receptor gamma [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1335238:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA [Gene or Genome]
   937   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   937   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   840   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   804   C0017011:Gamma [Natural Phenomenon or Process]
   804   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   804   C0752063:Peroxysome [Cell Component]
   804   C1552644:Gamma [Intellectual Product]
   804   C1879547:Activated [Activity]
   804   C2349976:Gamma [Quantitative Concept]
   804   C2984308:Peroxisome [Functional Concept]
   771 E C1515877:Activate [Functional Concept]
   733 E C3546463:peroxisomal [Cell Component]

Phrase: ")"

Phrase: "modulator"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1709060:Modulator [Manufactured Object]

Phrase: "blocks"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0028778:Block [Pathologic Function]
  1000   C0332206:Block [Functional Concept]
  1000   C1533157:Block [Substance]
  1000   C1706084:Block [Geographic Area]
  1000   C2828370:Block [Quantitative Concept]

Phrase: "adipocyte differentiation"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C1159884:adipocyte differentiation [Cell Function]
   861   C0007589:Differentiation [Cell Function]
   861   C1511938:Differentiation [Clinical Attribute]
   861   C2945687:Differentiation [Functional Concept]
   789 E C0205615:Differentiated [Qualitative Concept]

Phrase: "but"

Phrase: "stimulates"

Phrase: "glucose uptake in 3T3-L1 adipocytes."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C1159527:glucose uptake [Cell Function]
   753   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   753   C0243144:Uptake [Physiologic Function]
   753   C0347980:% uptake [Quantitative Concept]
Processing 00000000.tx.221: Mol Endocrinol14 :1425 1433,2000[Abstract/Free FullText] Oberfield JL, Collins JL, Holmes CP, Goreham DM, Cooper JP, Cobb JE, Lenhard JM, Hull-Ryde EA, Mohr CP, Blanchard SG, Parks DJ, Moore LB, Lehmann JM, Plunket K, Miller AB, Milburn MV, Kliewer SA, Willson TM: A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. 

Phrase: "Mol Endocrinol14"

Phrase: ":"

Phrase: "1425 1433,"

Phrase: "2000"

Phrase: "[Abstract/Free FullText"

Phrase: "] Oberfield JL,"

Phrase: "Collins JL,"

Phrase: "Holmes CP,"

Phrase: "Goreham DM,"

Phrase: "Cooper JP,"

Phrase: "Cobb JE,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0454673:JE [Geographic Area]
   861   C1550752:JE [Temporal Concept]

Phrase: "Lenhard JM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0022337:JM [Geographic Area]

Phrase: "Hull-Ryde EA,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0014963:EA [Organic Chemical,Pharmacologic Substance]
   827   C1457900:EA [Quantitative Concept]

Phrase: "Mohr CP,"

Phrase: "Blanchard SG,"

Phrase: "Parks DJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0012836:DJ [Geographic Area]

Phrase: "Moore LB,"

Phrase: "Lehmann JM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0022337:JM [Geographic Area]

Phrase: "Plunket K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Miller AB,"

Phrase: "Milburn MV,"

Phrase: "Kliewer SA,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0036243:SA [Geographic Area]
   861   C1539696:SA [Gene or Genome]
   861   C1825840:SA [Gene or Genome]
   861   C3539736:Sa [Spatial Concept]

Phrase: "Willson TM"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0145779:TM [Amino Acid, Peptide, or Protein,Receptor]
   861   C3540468:TM [Gene or Genome]

Phrase: ":"

Phrase: "A peroxisome proliferator-activated receptor gamma ligand"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   839   C1621296:receptor ligand [Molecular Function]
   799   C0023688:Ligand [Chemical]
   780   C0166417:Peroxisome Proliferator-Activated Receptor gamma [Amino Acid, Peptide, or Protein,Receptor]
   780   C1335238:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA [Gene or Genome]
   734   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   734   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "inhibits"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   944   C0018790:arrested [Disease or Syndrome]
   944   C0237477:Arrest [Temporal Concept]
   944   C0392351:arrest [Governmental or Regulatory Activity]
   944   C0521111:Retarded [Qualitative Concept]
   916 E C0311403:Inhibited [Qualitative Concept]
   916 E C3463820:Inhibiting [Activity]

Phrase: "adipocyte differentiation."
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C1159884:adipocyte differentiation [Cell Function]
   861   C0007589:Differentiation [Cell Function]
   861   C1511938:Differentiation [Clinical Attribute]
   861   C2945687:Differentiation [Functional Concept]
   789 E C0205615:Differentiated [Qualitative Concept]
Processing 00000000.tx.222: Proc Natl Acad Sci U S A96 :6102 6106,1999[Abstract/Free FullText] Elbrecht A, Chen Y, Adams A, Berger J, Griffin P, Klatt T, Zhang B, Menke J, Zhou G, Smith RG, Moller DE: L-764406 is a partial agonist of human peroxisome proliferator-activated receptor gamma: the role of Cys313 in ligand binding. 

Phrase: "Proc Natl Acad Sci U S A96"

Phrase: ":"

Phrase: "6102 6106,"

Phrase: "1999"

Phrase: "[Abstract/Free FullText"

Phrase: "] Elbrecht A,"

Phrase: "Chen Y,"

Phrase: "Adams A,"

Phrase: "Berger J,"

Phrase: "Griffin P,"

Phrase: "Klatt T,"

Phrase: "Zhang B,"

Phrase: "Menke J,"

Phrase: "Zhou G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Smith RG,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1412999:RG [Gene or Genome]

Phrase: "Moller DE"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0011198:DE [Geographic Area]
   861   C0017480:DE [Geographic Area]
   861   C3541240:DE [Idea or Concept]

Phrase: ":"

Phrase: "L-764406"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0765530:L 764406 [Organic Chemical]
   861   C0439394:l's [Quantitative Concept]
   861   C1706495:L- [Intellectual Product]
   861   C3642217:/L [Quantitative Concept]

Phrase: "is"

Phrase: "a partial agonist of human peroxisome proliferator-activated receptor gamma"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   815   C2917405:Peroxisome Proliferator Receptor gamma Agonist [Pharmacologic Substance]
   739   C2987634:Agonist [Pharmacologic Substance]

Phrase: ":"

Phrase: "the role of Cys313"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0035820:Role [Social Behavior]
   770   C1705810:Role [Conceptual Entity]

Phrase: "in ligand binding."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C1517880:Ligand Binding [Molecular Function]
   861   C0023688:Ligand [Chemical]
   861   C0243122:binding [Functional Concept]
   861   C1145667:Binding [Activity]
   861   C1167622:Binding [Molecular Function]
Processing 00000000.tx.223: J Biol Chem274 :7913 7922,1999[Abstract/Free FullText] Reginato MJ, Bailey ST, Krakow SL, Minami C, Ishii S, Tanaka H, Lazar MA: A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties. 

Phrase: "J Biol Chem274"

Phrase: ":"

Phrase: "7913 7922,"

Phrase: "1999"

Phrase: "[Abstract/Free FullText"

Phrase: "] Reginato MJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439254:MJ [Medical Device]

Phrase: "Bailey ST,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3272372:ST [Intellectual Product]

Phrase: "Krakow SL,"

Phrase: "Minami C,"

Phrase: "Ishii S,"

Phrase: "Tanaka H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Lazar MA"

Phrase: ":"

Phrase: "A potent antidiabetic thiazolidinedione"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0289779:thiazolidinedione [Organic Chemical,Pharmacologic Substance]
   827   C1257987:Thiazolidinedione [Organic Chemical,Pharmacologic Substance]
   827   C3537039:Thiazolidinedione [Pharmacologic Substance]

Phrase: "with unique peroxisome proliferator-activated receptor gamma-activating properties."
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   793   C0871161:properties [Qualitative Concept]
   793   C1292721:properties [Functional Concept]
   760 E C1882134:Property [Conceptual Entity]
   760 E C2347695:Property [Entity]
   723   C0166417:Peroxisome Proliferator-Activated Receptor gamma [Amino Acid, Peptide, or Protein,Receptor]
   723   C1335238:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA [Gene or Genome]
Processing 00000000.tx.224: J Biol Chem273 :32679 32684,1998[Abstract/Free FullText]

Phrase: "J Biol Chem273"

Phrase: ":"

Phrase: "32679 32684,"

Phrase: "1998"

Phrase: "[Abstract/Free FullText"

Phrase: "]"

